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1.  The implied criticism of Hemmert et al. that on use of hydrogen peroxide with N4PyFe as
the catalyst “only 36 turnovers per hour” are obtained in the oxidation of cyclohexane to
cyclohexanol and cyclohexanone is unjustified in view of the fact that their own
tetrapyridinyl iron complex fails to display any turnover at all.
Hemmert, C.; Maestrin, A. P.; Renz, M.; Gornitzka, H.; Meunier, B. C. R. Acad. Sci.
Paris, Série IIc, Chimie: Chemistry 2000, 3, 735–741.
2.  Abbreviations are commonly used to reduce long words or frequently occurring word
combinations to a few letters. Therefore, it is pointless to abbreviate et alia or et alii to et al.
3.  The merger of different departments within a faculty, or that of separate countries into one
union, merely accentuates their internal differences.
4.  In order for organic chemists and biochemists to work together more effectively, there
should be more clarity and unity in common terminology. For example, a biochemist refers
to a metal ion as a ligand when co-ordinated to amino acids in a peptide, whereas for the
(in)organic chemist the ligand is the co-ordinating structure around the metal ion.
N.B.  Biochemists sometimes also refer to a substrate for an enzyme as a ligand.
5.  The personal findings and experiences gained during a Ph. D. study are to be found in the
unwritten chapter of the thesis.
6.  It is surprising how unpredictable exact science can be.
7.  Nothing in chemistry is straightforward.
8.  The positive effect on the motivation of a (young) researcher that stems from good
experimental results is often underestimated. But then, the opposite is equally true.
9.  The practicality of graduate research is not merely academic.
10. No matter how hard you work, there is always a machine (or machinery) fast enough to
slow you down.11. The validity of the common assumption that all postgraduate studies are equal in the fact
that they can be finished within four years should be closely examined.
12. A thesaurus provides a welcomed companion during the lonely process of writing.
13. The ability to reduce many months’ work into a few sentences is a disappointing skill.
14. In black & white photography you learn to see things not in black and white, but as different
shades of grey.
15. Photography differs from life in that a negative image can directly result in a positive
impression.
16. Nationalisme gedijt beter in het buitenland.
17. Alhoewel academici en promovendi geacht worden zich te ontwikkelen tot kritische
onderzoekers, wordt kritiek leveren niet altijd gewaardeerd.
18. De functie-omschrijving ‘Onderzoeker in opleiding’ zou beter vervangen kunnen worden
door ‘Onderzoeker door zelfstudie’.Preface
Now that this book is complete and another chapter in my life draws to a close, it is time to
reflect on the time that has passed by. On a personal level it has been by far the most difficult
period and professionally the most challenging. A problem is a challenge that can’t be met. If
one applies this definition, I have encountered only a few problems during this postgraduate
research.
It was painful to experience that hard work is not always rewarded with good results.
Although paper is patient and willing, the fumehood often proves otherwise. From that point of
view ‘paper’ or ‘black board’ chemistry is much easier and more successful than that in the
fumehood, simply because it works. Seemingly straightforward approaches on paper often do
not reveal the unforeseen and hidden flaws in a synthetic pathway that come to light in the
fumehood. And even when a reaction works, defeat during the workup procedure can still rob
you of your reward. In that respect, a profession as bricklayer would have been a lot easier:
simply by laying one brick onto another a wall can be built. There is even some room for
creativity during the assembly process. However, on reflection, this would have been for me far
less challenging, and satisfactory, than chemistry could ever be.
It is this challenging nature of organic chemistry that has led me to pursue a profession in
this area. And believe me, I have been challenged more than enough over the last few years.
This research project for example has been hampered by misfortune on many occasions. If it
wasn’t yet another futile experiment, it was a machine that failed to function properly. It is often
said that no result is still a result. Although this may sometimes be valid for some areas of
research, it is not applicable to the synthesis of a compound that continuously fails, and is
crucial to the success of the project. But then someone could rightly say that all these learnings
and experiences build character. Mine should be fully developed by now.
In all fairness, the reactions and conditions examined may not always have been the right
ones, but then this is all part of the learning process. If every Ph. D. student knew at the
beginning how to select and perform experiments, then it would actually be possible to
complete a Ph. D. study in four years. Unfortunately, reality is quite different, although some
institutions fail to acknowledge this fact.
After coming to Groningen from the Randstad, I have often been told: “Je komt hier niet
weg.” And indeed, I have often had the feeling that I was never going to leave Groningen. But
now I am and I would like to take the opportunity to thank several people who have contributed
to my research, as well as my time spent in and outside Groningen over the last few years.Firstly I would like to thank prof. dr. R. M. Kellogg and prof. dr. B. L. Feringa for allowing me to
work on this ambitious research project. Despite the difficulties I have experienced and the fact
that the goal of the project has not entirely been met, a great deal has been learnt by analysing
the problems encountered. There are still plenty of unanswered questions and challenges. I am
of the opinion that some of the suggestions presented in this thesis can provide alternative
methodologies to bring this project to a successful end. Therefore, I am pleased that dr. C. T.
Choma will continue to work on this project. Christin, thanks for introducing me to the intriguing
world of de novo design and four-helix bundles. Regrettably, I will not be the person who
constructs the real four-helix bundle with the N4Py complex incorporated into its structure. Our
active communication by email was also greatly appreciated. Good luck with the project and
please do not hesitate to contact me regarding any questions you may have. Ben, Dick, and
Christin, I am grateful to you all for your prompt and constructive amendments to the draft
version of my thesis.
I am also indebted to prof. dr. J. B. F. N. Engberts, prof. dr. D. B. Janssen, and prof. dr. J.
G. de Vries who have acted as members of the reading committee. It was interesting to see how
different errors and obscurities were spotted by different people. At the same time this also
emphasised how crucial it is to have several people review the manuscript in order to spot all of
the mistakes.
Special thanks go to Tieme van den Berg who has carried out most of the cross coupling
reactions as part of his undergraduate research. Tieme, I have been very fortunate to have you
w o r k i n g  b y  m y  s i d e  ( l i t e r a l l y ) .  Y o u  h a v e  p r o v e d  t o  b e  a  h a r d  w o r k i n g ,  m o t i v a t e d ,  a n d
enthusiastic student. Although I have been able only to summarise your work in Chapter 4, your
experiments have made a big contribution to this thesis. Your many (test) reactions have also
indicated that the newly developed tetrabromo N4Py ligand could be an interesting substrate for
further derivatisation by cross coupling reactions. Good luck with your work in the research
group of Larry Que Jr. and during your Ph. D. study in the near future. I hope you can find
some time to continue working on the tetrabromo N4Py, maybe on a Friday afternoon or so.
To my colleagues in the ‘Kellogg College’ labroom Tieme, Jan, Hans, and Lorena I would
like to say ‘bedankt’ for the pleasant and refreshing atmosphere in the lab. This also applies to
previous colleagues like Bartjan, as well as people from adjacent labrooms. I have also enjoyed
the company of Inge who has been my ‘neighbour’ for some time now. The amusement
provided by entertainers like Jan and Tieme has been a sheer delight for me, as well as many
others. It made life in front of the fumehood a lot more endurable.
I would also like to thank the current and previous members of our oxidation subgroup for
the helpful suggestions and fruitful discussions during our many meetings. Special recognition
goes to dr. Ronald Hage and dr. Scott Killeen from Unilever Research, The Netherlands, for
performing the cyclic voltammetry measurements on the iron(II) complex of tetrabromo N4Py.
I am also indebted to Margot Jeronimus-Stratingh and Annie van Dam at the Pharmacy
Department for performing the electrospray mass analyses, Albert Kiewiet for the chemical
ionisation and high resolution mass analyses, and Jan Ebels, Harm Draaier, and Jannes
Hommes for the elemental analyses. They are all kindly acknowledged for their contributions to
the structural analyses described in this thesis. Thanks also to Wim Kruizinga for performing thetemperature-dependent NMR analysis of the iron(II) complex of tetrabromo N4Py. I am also
grateful to Auke Meetsma for solving the crystal structures described in this thesis.
Marc van Gelder I want to thank not only for helping me with the many troublesome
purifications of the peptides and N4Py-peptide complexes by reversed-phase HPLC, but also for
his company during the many occasions I was in his lab.
I am grateful to prof. dr. R. M. J. Liskamp and dr. ir. J. A. W. Kruijtzer from the Medicinal
Chemistry Department of the University Utrecht for their assistance in preparing and purifying a
peptide sequence I used during my research.
Niek Buurma I would like to thank for the time he has invested in helping me to analyse the
kinetic behaviour of the ABTS oxidation by N4PyFe.
Although conversations with Ebe Schudde are regularly quite long, I would like to thank
him for his understanding and sympathy during the personal conversations we have had. Ebe,
you take up a special position in our lab that only a few truly know how to appreciate.
I have enjoyed my visit to Washington D.C. and the ICBIC99 in Minneapolis together with
Jelle Brinksma. Jelle, that visit with you to the USA has left me with many good memories.
Roos Imbos, thank you for looking after my flat during the many occasions I went to
England for a short break. I also enjoyed working together with you and José Nieuwenhuijzen
on the organisation of the workweek in 1999. In the busy programme we did not leave much
time for relaxation (it is after all a workweek), but I am convinced that it has been a very
interesting and enjoyable workweek for our group members and ourselves.
Sports and leisure activities are much more enjoyable in the presence of friends. The regular
workouts and ice-skating events with Linda Lucas, Minze Rispens, and Alette Ligtenbarg I have
always experienced as a good time that was often combined with excellent dinners. Such a
shame that all good things come to an end.
Personally, I have enjoyed assembling the photo board of our research groups and
compiling the ChemBase database. It gives me great pleasure to see that I have been able to
contribute to a more efficient method of finding chemicals in our labs that is evidently greatly
appreciated by all its users. It is therefore only fair to acknowledge Dirk Beetstra, Marco
Bouwkamp, and Wouter van Meerendonck who have constructed the actual database.
Although I originally composed the photo board in our department to assist our secretary and
the new members of our research groups in remembering the many names and faces, I am
pleased to see that these photos have also found their way to many other uses and abuses.
Many of these ‘faces’ have contributed in many ways to an enjoyable period in Groningen,
so to all those I have not thanked by name: thank you for the time that has passed by and good
luck to you all in the future.
Now that this chapter in my life has come to an end, it is time to start a new one. Firstly, I’ll do
that by fulfilling a lifelong dream by moving to England. More importantly, I’ll be spending that
time with Resh who has been my best friend for several years and will be my wife for many
years to come. A new home, a new city, a new job, and new friends, unfortunately at the
expense of sharing less time with the ones I already have. These will be interesting times indeed.A special thank you goes to my parents who have supported me in so many different ways
throughout my education. I am also grateful to my friends for the interest they have shown in
my research as well as my personal well-being. It is a shame that most of you have never been
able to understand fully what it was that I was working on. Hopefully this thesis will make things
a bit clearer. It is also unfortunate that we haven’t been able to see each other as often as I
would have liked. Admittedly, by moving to England this will become even rarer.
And finally to Resh I would like to say, thank you for being my ‘rock’ to rely upon and
confide in, and motivating me through the highs and lows. Unfortunately, we both realise that it
is far easier to give advice than to follow up on it.Contents
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Samenvatting 153“....considering the phrase, ‘How do you
know it’s not possible until you’ve tried?’ And
experiments with Hex, the University’s
thinking engine, had found that, indeed,
many things are not impossible until they
have been tried.”
“The last continent”
Terry Pratchett, A Discworld Novel1
Chapter 1
An introduction to artificial proteins
1  An introduction to artificial proteins
1.1  From native to designed proteins
Over the past several decades scientists have been trying to understand, mimic, and enhance
the tools provided by mother nature. Although considerable progress has been made to further
their understanding, the complexity and sophistication of numerous biological structures
remains bewildering. One such enigma is nature’s catalyst: the enzyme. A great deal has been
discovered about their primary, secondary, and tertiary structures, and many of the working
mechanisms have been uncovered together with their substrate ranges and limitations.
1 In
addition, genetic methods have been developed to alter the amino acid sequences in enzymes
and thereby modify their performance.
2 However, one aspect still remains a mystery: how the
primary structure determines the folded conformation of the protein, and thereby influences and
governs the function and performance of the enzyme. Although a great deal of work has already
been undertaken to unravel this puzzling and intriguing part of biochemistry,
3 there is no doubt
that future research shall lead to far deeper insights.
De novo design involves devising a peptide sequence that will give rise to a predicted
protein structure.
4–6 This requires a comprehensive understanding of the processes involved in
the translation of the amino acid sequence to the tertiary structure of a protein. Many of the
reports that have appeared so far in the literature have dealt with the design and synthesis of de
novo proteins merely as an academic exercise. With an enhanced understanding of the
complicated protein folding mechanisms, the design and synthesis of an increasing number of
functional artificial proteins has been made possible.
7 These designed structures are in general
relatively small, and are more accessible to the study and understanding of complex interactions
that are involved in larger native enzymes. Designing large globular or native-like proteins is still
a challenge waiting to be accomplished. The development of new artificial proteins will no
doubt be boosted by the application of new technology, like combinatorial approaches and
high-through-put screening. An effective rationale for the design, however, is still essential to the
successful outcome of the overall protein structure.2
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1.2  From mimic to artificial enzyme
Function can be introduced into a protein scaffold by the incorporation of a new reactive centre.
Conversely, a lot of research has been devoted to the design of small molecule catalysts
8 or
supramolecular assemblies
9 that can mimic the function of a natural enzyme. In our group we
have developed a pentadentate ligand as a model for the glycopeptide bleomycin.
10 This ligand
is called N4Py (1) and consists of four pyridine rings that are anchored to a central nitrogen
atom (Figure 1.1).
11 When its iron(II) complex, [(N4Py)Fe(MeCN)](ClO4)2 ( 2), reacts with
hydrogen peroxide, a transient low-spin iron(III) hydroperoxide species is formed, which is
capable of oxidising a wide variety of organic compounds.
12 In addition, it can also function as
an effective biomimetic DNA cleaving agent analogous to iron bleomycin.
13 The synthesis and
chemistry of N4Py and some of its derivatives will be the subject of Chapter 2.
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Figure 1.1. N4Py (1) and its iron(II) complex [(N4Py)Fe(MeCN)](ClO4)2 (2).
A popular scaffold for the introduction of function into a peptide structure is the four-helix
bundle motif, which has been used by many researchers in the field of protein design. The
design and construction of these four-helix bundles will be briefly discussed in the following
sections, as well as some examples of newly created functional protein mimics based on this
architecture.
The work presented in this thesis describes the preliminary studies as part of a larger project,
aimed at the design and synthesis of a functional mimic of a water-soluble peroxidase. The
design strategy is to embed the N4PyFe catalyst 2 inside a four-helix bundle, where it could
function as a synthetic cofactor in the protein environment.
As can be seen in Figure 1.2, the core of the four-helix bundle is well suited to host a small
catalyst like the N4PyFe complex. However, the packing of the amino acid side chains can be
disrupted by the catalyst and thereby destabilise the four-helix bundle. In the (re)design of the
peptide bundle this potential instability can be suppressed by creating a cavity to host the
N4PyFe catalyst. At the same time, this cavity can be designed to function as an active site
within a synthetic enzyme. With an appropriate selection of proximal amino acids, a local pH
can be established to influence the oxidative behaviour of the catalytic centre. The actual
binding of the catalyst will not be perturbed by altering the peptide sequences, as these are
covalently linked to the ligand. However, the sequence will affect the overall stability of the
peptide-N4PyFe structure, and might influence the binding of the substrate and the formation of
the reactive intermediate. A successful N4Py ligand modification that enabled the attachment of
two peptide chains to the N4PyFe catalyst will be presented in more detail in Chapter 2.3
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Figure 1.2. The crystal structure of N4PyFe (2) superimposed onto the backbone of
α2,
14 a dimeric four-helix bundle (left: top view, right: side view). The amino acid side
chains have been omitted for clarity.
15
The aim of this chapter is neither to present a complete overview of the literature with regard to
four-helix bundles and functional peptide structures, nor to provide a full understanding of the
underlying fundamental aspects. The examples discussed here have been chosen in the hope
that they will provide some understanding of the elegant structures that protein designers have
been able to create and the principles involved.
1.3  Four-helix bundles
Four-helix bundles (right) are commonly encountered motifs in
native enzymes like ferritin, tobacco mosaic virus, myohaemerythrin,
haemerythrin, cytochrome c’, cytochrome b562,
16 as well as in
methane mono-oxygenase.
17 These bundles consist of α-helices that
are typically fifteen to twenty-six amino acids (residues)
18 long and
display a crossing angle of about 20° with a left-handed twist.
19 This
is due to the side chain intercalation of adjacent helix’ surfaces.
20,21
Depending on the packing restrictions of these side chains, the
diameter of the core is about 1 Å and the distance between the axes
of the helices in four-helix bundles is generally 10±3 Å.
22
Although the 3D arrangement of the α-helices in a four-helix
bundle motif might be considered aesthetically pleasing, it has not been the main focus of de
novo protein design because of its architecture. Its relatively simple construction and
organisation enables modular (re)design and simulation studies of the factors that determine its
shape and stability. A great deal of knowledge has been gathered over the years about four-
helix bundles that provides to some extent an understanding of the factors that govern protein
folding and stability.
5e,23 Protein designers can now manipulate peptide sequences to introduce
function (Section 1.5),
4 and increase the stability of the peptide structure.
6c
There are many factors that can affect the stability of the α-helix, and consequently the four-
helix bundle. Over the past few years it has been suggested that a prerequisite for the formation
of an α-helix involved the incorporation of residues with a preference for α-helix formation4
Chapter 1
(helix propensity).
24 However, Hecht and co-workers demonstrated that a periodic repeat of
polar and non-polar residues in the peptide sequence can be sufficient to form an α-helix.
25 The
resulting  α-helices are amphiphilic, i.e. they have a hydrophilic and a hydrophobic surface
(Figure 1.3). In designed four-helix bundles, the carboxyl-termini (C-termini) are commonly
amidated and the amino-termini (N-termini) acylated to prevent these termini from becoming
charged, as this would lead to unfavourable interactions with the helix macrodipole.
1,26 This
macrodipole is the result of the intramolecular hydrogen bonding that orientates all the carbonyl
groups of the peptide amide bonds in the same direction (Figure 1.3). The charge build-up is
also pH-dependent due to the different pKa-values of acidic and basic side chains that might be
present in the peptide sequence.
Figure 1.3. The hydrophilic and hydrophobic surface of an amphiphilic α-helix (left)
23c
and the helix macrodipole (right).
27 The letters a–g denote the positions of the
residues in a heptad.
A prerequisite for α-helices to self-assemble into a four-helix bundle in an aqueous solution is
that they are amphiphilic. Due to the hydrophobic effect,
28 the hydrophobic side chains will be
buried inside the bundle to form a hydrophobic core, whereas the hydrophilic side chains will
be exposed to the aqueous medium.
29 The opposite is applicable to membrane proteins and ion
channels that span the cell membrane, as the non-polar residues are then exposed to the
lipophilic nature of the membrane (Section 1.5.3).
Depending on the design, these four-helix bundles can be tetrameric (A), dimeric (B), or
monomeric (C), consisting of four single α-helices, two helix-loop-helix units, or a single peptide
chain, respectively, in which the individual helices are connected by loops (Figure 1.4).
Furthermore, four-helix bundles are classified as parallel or anti-parallel bundles, depending on
the relative orientation of the macrodipoles of the individual helices. In nature four-helix
bundles are commonly encountered as anti-parallel dimeric assemblies.
5e
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ABC
Figure 1.4. Tetrameric, dimeric, and monomeric four-helix bundles.
30
Helical bundles are commonly presented as a helical wheel diagram, which illustrates the side
chain interactions within a cross-section of the bundle (Figure 1.5). The positions of the residues
over two helix turns are referred to by the letters a through to g, a so-called heptad. The
hydrophobic core consists of the residues at positions a and d of the heptad, whereas the
residues at positions b, c and f of the peptide sequence form the hydrophilic exterior. The
stability of four-helix bundles can be increased by the formation of interhelical salt bridges
between oppositely charged residues,
31 and by optional disulphide bridges between the
helices.
32,33 In addition, linking the peptides to a template or directing the assembly by
co-ordination to a metal centre will also have a favourable effect on the stability of the protein
(Section 1.4).
Figure 1.5. Helical wheel diagrams of a parallel (a) and an anti-parallel four-helix bundle
(b), viewed from the N- or the C-terminus (here Leu and Ala are represented at
positions a and d, respectively).
18,23c
Although a considerable tolerance is accepted for the exact identity and precise packing of the
side chains in the secondary structure, these factors are imperative to obtain a well-defined
tertiary structure.
5b,34 A general rule applied to protein design in order for the self-assembly of
helices to be selective, is that the side chain interactions between individual helices must favour
the desired assembly and destabilise competing conformations (i.e. negative design).
6c For good
complementary packing in the hydrophobic core of an anti-parallel four-helix bundle,6
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alternating small and large residues at positions a and d are often required (Figure 1.5b).
35 Thus,
the association into a parallel four-helix bundle would result in the small side chains occupying
the same layer in the hydrophobic core, creating a cavity that is surrounded by layers of the
larger side chains (Figure 1.5a). Also, favourable electrostatic interactions between positions c
and g, and b and e of adjacent helices in anti-parallel bundles will be absent in a parallel
orientation, and consequently disfavour the formation of a parallel four-helix bundle.
Although these rules are relatively simple to incorporate into the design, the interactions
between positions a and d one helix turn up and down the bundle also need to be taken into
account. To add to the complexity of the design, the amino acid side chains can adopt several
spatial orientations. Therefore, tight packing of the hydrophobic core is the most difficult goal to
accomplish with regard to the design of native-like de novo four-helix bundles. However, this is
equally valid for the de novo design of proteins in general. Failure to achieve a tight packing
most often results in the formation of a molten globule state; a protein folding state with a high
degree of secondary structure that lacks well-defined tertiary interactions.
6c,36
A rational and incremental approach to the de novo design of four-helix bundles was pioneered
by DeGrado and co-workers.
5e,37 This rational design tested their understanding of the factors
involved in the folding processes of the primary structure of a protein into its 3D organisation. In
1987 this research group designed the first α-helices that self-assembled in solution to form α1, a
tetramer of α-helical structures.
14 The degree of α-helicity, however, was found to be
concentration dependent, which is often the case for tetrameric assemblies. When the sequence
was shortened by four residues, crystals of α1 could be obtained that consisted of a mixture of
tetramers and hexamers.
37b By connecting two units of α1 via a short loop these helix-loop-helix
units dimerised to form an anti-parallel four-helix bundle, called α2, to neutralise the overall
macrodipole effect.
14 These peptide chains were extended even further by connecting four
copies of α1 via short loops. The resulting 74-residue, single chain peptide folded into a
monomeric four-helix bundle, called α4.
37a Its construction was the first example of a designed
single chain polypeptide that was able to adopt a globular compact structure, which displayed
properties that lay in between a native and a molten globule protein.
The design of α4 resulted in a stability that was not only higher than that of the dimer α2
and the tetramer α1, it was also found to be more stable than most natural proteins
(∆G=94.1 kJ/mol, versus 10–40 kJ/mol for natural proteins, Table 1.1, p. 11).
37a This
stability is considered to originate from the burial and close packing of the hydrophobic leucine
residues inside the core of the bundle, thus preventing their contact with water. Other helix and
four-helix bundle stabilising factors have also been included into the design.
37a
Metal-ligand interactions have also been incorporated into the design of helical bundles to
furnish more native-like structures. Handel and DeGrado introduced tetrahedral zinc(II) binding
sites into the hydrophobic core of four-helix bundles that were based on the sequence of α2
4,38a
and α4.
38b The metal binding site consisted of histidines at three corners of a tetrahedron (H3–α4),
with the fourth position vacant for catalytic activity. The binding of zinc(II) ions did not affect the
secondary structure, but it made the overall structure more ordered, causing a change from a
molten globule state to a more native-like protein (Table 1.1, p. 11). Introduction of a second7
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metal binding site (H6–α4) enhanced the stability of the protein even further, although it still
failed to adopt a native-like conformation. Similarly, Regan and Clarke also modified the
sequence of α4 to provide a tetrahedral zinc(II) binding site consisting of histidine and cysteine
residues, a chelating environment that is found in several natural metalloproteins.
39
In contrast to the hierarchical development of four-helix bundles by DeGrado et al.,
combinatorial libraries have been used by Hecht and co-workers by applying what they call a
‘binary code’ strategy.
25,40 This code only specifies the locations of polar and non-polar residues
in the sequence, and not the exact identity of the amino acids. For this purpose they constructed
a family of synthetic genes encoding the intrinsic genetic information that would introduce the
(non-)polar residues into the correct sequence positions (binary patterning). They subsequently
screened the created library for peptide chains that folded into monomeric four-helix bundles.
Without the implementation of a rational design, they obtained a 75-residue protein, called M–60,
that displayed native-like behaviour.
41
Other synthetic tetrameric four-helix bundles have been prepared by redesigning natural
proteins, like Rop
5d,34b–d,42 or the GCN4 leucine zipper,
43 or by the self-assembly of individual
α-helices.
44 There are multiple examples of helix-loop-helix polypeptides that dimerise
spontaneously into anti-parallel four-helix bundles, such as GTD–43,
45 SA–42,
46 or the
bimetallic dimer DF1.
47 Single chain, anti-parallel four-helix bundles have been constructed
using as many as nineteen of the twenty natural amino acids by Hecht et al. in the design of
Felix, a 79-residue polypeptide.
48 In contrast, Stroud and co-workers used as few as seven
different amino acids in preparation of a 108-residue four-helix bundle.
49 Chymohelizyme is an
example of a single chain, parallel four-helix bundle that was designed and synthesised in 1990
by Hahn et al. as a mimic for the serine protease chymotrypsin.
50 The four peptide chains were
connected through the carboxylic ends by amide bonds via the amino side chain group of lysine
or ornithine.
18 Construction of a four-helix bundle by connecting four α-helices via thioether
bonds has been demonstrated by Futaki et al.
51
1.4  Template-assembled synthetic proteins
The self-assembly process of individual helices via intermolecular association is concentration
dependent. In contrast, a single chain protein will fold through intramolecular interactions to
yield a concentration independent folding that is also more stable. In natural proteins, loops and
turns are used to link sequences with secondary structure. Therefore, in 1988 Mutter and
co-workers introduced the concept of using artificial templates for the attachment of peptides in
order to bypass the protein folding problem.
52 Since then extensive work has been published by
Mutter and Tuchscherer on the concept of Template-Assembled Synthetic Proteins (TASP).
53
As mentioned above, the four-helix bundle is a popular motif for the study of protein
folding and the design of novel proteins. Therefore, a large number of TASPs with a four-helix
bundle topology have been described in the literature.
23d,54 Some frequently applied scaffolds
will be briefly discussed in this section. Single α-helices, β-sheets, turns, and loops have also
been attached covalently to functionalised templates.
53,54 The reported results illustrate that by
using a template the required minimal chain length to form α-helices in four-helix bundles can
be reduced to about nine to twelve amino acids, compared to the usually observed fifteen to
twenty-six residues (vide supra).8
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Scheme 1.1. The TASP concept.
55
When the peptide chains are pre-organised onto a template, the favourable free energy of
association will be sufficient to overcome the entropic cost and will direct the peptides to
associate into the desired conformation. The template in effect constrains the mobility and
orientation of the peptides, and thus can direct the assembly towards the intended peptide
structure. The size and shape of the framework is not decisive for the formation of a four-helix
bundle on a template.
56 Even though the peptide bundles in principle can be randomly
orientated, it is common that these peptide chains come together to form helix bundles. After
all, these helix bundles were designed to incorporate a hydrophobic core, and thus the
hydrophobic surfaces of each helix will interact with the neighbouring helices due to the
hydrophobic effect. When the design of a TASP is directed towards the formation of an anti-
parallel four-helix bundle, the inverse orientation is facilitated mainly by the packing interactions
of the individual helices, and not by the helix macrodipoles.
53h Additional linkers on the
template can help to form a helix bundle if the template itself is too small. However, the length
and structure of the linker can influence the thermodynamic stability of the TASP.
56,57 For
instance, the linker might be able to form hydrogen bonds with functional groups on the
template.
57
The TASP concept enables peptide chains to be brought in close proximity in order to study
the folding mechanisms of the primary sequences. Similarly to what has been suggested for
native proteins, the folding of TASPs commences through the formation of secondary structure,
followed by the construction of a compact 3D state, like three- or four-helix bundles (Scheme
1.2).
53a
Scheme 1.2. The folding process of a TASP four-helix bundle.
53a
Numerous molecular structures can be used as a template (Figure 1.7).
58 The only requirements
for a template molecule entail stability and the ability to provide functionality (i.e. attachment9
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sites) at the periphery to obtain the appropriate spatial orientation of peptides. Also, it should be
readily accessible and provide the possibility of structural modification of the template or the
peptide linkers. Obviously, the number of functional groups defines the number of peptides that
can be attached to the template. The distance between the attachment sites can be varied by the
frame of choice, and thus makes it possible to optimise the hydrophobic interactions between
the amphiphilic peptide chains. The template then serves as a (rigid) scaffold to acquire a
maximum stability for the tertiary structure. In addition, the template can contribute to the
designed protein function, for instance by providing a cavity for the substrate, or by the use of a
metalloporphyrin for oxidative or redox activity (vide infra).
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Figure 1.6. Selectively removable protecting groups on a cyclic peptide template
(adopted from reference 53g).
18,59
If the template consists of functional groups that can be selectively addressed, different peptide
chains can be attached in a controlled manner (Regioselectively Addressable Functionalised
Templates, RAFT).
60 This can be achieved by the use of chemically different attachment sites, or
by selectively removable (orthogonal) protecting groups (Figure 1.6). Stepwise attachment of
peptide chains is also an option when equimolar amounts relative to a single functional group
are being used.
61 The obvious problem, of course, is the formation of side-products from
multiple reactions.
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Scheme 1.3. Chemoselective ligation of peptides to functionalised templates.
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Figure 1.7. Template-Assembled Synthetic Proteins. (a) cyclic peptide as a template;
53d
(b) cyclic peptide as a template with two additional co-ordinated haem groups;
62a (c)
covalently linked tetraphenylporphyrin;
63 (d) covalently linked coproporphyrin I unit;
64
(e) three bipyridine tethers co-ordinated to a Ru(II) ion;
65c (f) co-ordination of four
pyridine tethers to a Ru(II) ion;
66 (g) a D-galacto-pyranoside as a template;
67 (h) a
cavitand as a template.
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Peptides have been covalently tethered to templates by, for instance, amide,
53a,66,69–72
oxime,
73,74 disulphide,
75–77 and thioester
78 bond formation (Scheme 1.3). Also, peptide chains
with bromo- or chloro-acetylated N-termini have been linked to thiols
57,79–81 or
(thio)phenolic
57,68,82 functionalities to produce a (thio)ether bond. Other methods of
chemoselective ligation are a Michael addition
83 and reductive amination.
61  The amino acid
sequences themselves can be readily obtained and modified through Solid-Phase Peptide
Synthesis (SPPS).
84 In order to prevent unwanted side reactions, protected peptides are usually
coupled to the template. However, depending on the chosen ligation method, sometimes good
results have also been obtained using unprotected peptides that were attached to the
scaffold.
62,73,78,81
The strength of the TASP approach is that by connecting individual peptides that have a
concentration dependent secondary structure, the overall structure has a significantly increased
stability that is independent of concentration.
56,71 Another general observation is an increase in
α-helicity for template-bound helical bundles. Although the enhanced peptide helicity can also
be explained by intermolecular interactions of multiple TASP peptide chains, this effect has
been attributed to intramolecular interactions of a single TASP.
56 By tethering peptide chains to
Table 1.1. Protein denaturation and stability parameters.
a
Protein C0.5 (M) –∆G
H2O (kJmol
–1) Ref.
Native proteins: Lysozyme 4.2 37 85
α-Lactalbumin 3.6 18 85
Apocytochrome b562 n.d.
b 13 86
Ferricytochrome b562 n.d.
b 28 86
Ribonuclease 3.0 31 85
Designed four-helix bundles: (α’–SS–α’)2 (dimer) 4.8 96.2 87a
(α–l–α–SS–α–l–α) 5.2 46.9 87b
SA–42 (dimer) ∼4 53.6 88
RA–42 (dimer) ∼1 36 88
DF1 (dimer) n.d.
b 12.1 47a
Ac–α4–CONH2 6.3 64.4 38a
H6α4 3.4 10 38b
Zn
2+–H6α4 5.5 43.1 38b
M–60 ∼7 ∼17 41
TASPs: Helichrome 5.2 18 64b
Metal ion-assisted 5.5 23 66
MOP1 1.3 13.7 62a
MOP1 bis-haem 2.5 30.4 62a
Carbohydrate-based 5.1 29 67c
Cavitein 8.0 95.8 57
a The data have been acquired using the equation ∆Gunf = ∆G
H2O + mC,
89 where ∆G
H2O is the free energy
of folding in the absence of denaturant, C is the concentration of the denaturant guanidinium hydrochloride,
and  m is the co-solvation term, which is a measure of the co-operativity of the transition. C0.5 is the
concentration at which 50% of the protein is denatured. 
b n.d. = not determined.12
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the template, stronger inter-helical interactions will be induced more than in the absence of a
template. Therefore, TASPs are generally found to be thermodynamically more stable than their
related helical peptides that are not assembled onto a template. Variations in the design of the
protein structure
90 will also contribute to the differences in the reported stabilities given in Table
1.1.
1.4.1  Cyclic peptides
Templates based on cyclic peptides typically consist of ten amino acids. Four residues (usually
lysine or cysteine) are then positioned in such a way that their side chains are orientated to
provide a well-defined spatial arrangement to accommodate a four-helix bundle.
53,69,71,73 As
illustrated in Figure 1.7a, the use of linkers directs the α-helices away from the template.
Therefore, the template only facilitates and directs the assembly and folding of the peptide
chains without interfering with the stabilising interactions that drive the assembly. Peptide loops
are also commonly encountered as a scaffold for TASPs.
53,78,79,91 Although most of the presented
work is related to four-helix bundles on one side of the template, some additional work has also
led to the construction of TASPs with two bundles; one on either side of the template.
53,91
The peptides can be grafted onto the template via their N- or C-terminus using standard
peptide coupling reactions as in the case of lysines for attachment sites. Cysteine is also
frequently used, which enables peptides to be coupled via the halide displacement of a halo-
acylated N-terminus, or by disulphide formation (Scheme 1.3). Nowadays, with the availability
of a wide range of (un)natural amino acids and a choice of numerous orthogonal protecting
groups, these peptidic templates are suited for structural variations and are readily available via
SPPS. The strength of utilising templates that contain selectively removable protecting groups is
that up to four different peptide sequences can be grafted selectively and modularly onto the
template, both in a parallel or anti-parallel orientation.
Due to the ease of a selective modular assembly of peptides onto a peptide template, these
templates have been widely used to study the relationships between the protein structure and its
stability, and the protein structure and its function.
53d,e As an example, Rau and Haehnel have
designed a modular anti-parallel protein (MOP) that is based on a cyclopeptide as a template
(Figure 1.7b).
62 This structure was further stabilised by the incorporation of two haem groups
sandwiched between two parallel helices, as observed in cytochrome b. These haem groups are
axially ligated by histidines in the peptide sequences.
Cyclic peptides have also been applied to TASPs that are
immobilised onto a solid phase to facilitate their synthesis and
purification.
92 Recently, Haehnel and co-workers assembled a
combinatorial library of amphiphilic peptides in an anti-
parallel orientation onto a cellulose-bound template (right).
93
This demonstration of the TASP concept resulted in the
construction of the first copper binding four-helix bundle by
incorporating cysteines and histidines into the peptide
sequences.
93b Similarly, a library of cytochrome b mimics was
created by incorporating haem-binding sites into the design.
93a13
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1.4.2  Porphyrins
Construction of novel proteins with functional properties can be achieved, for instance, when a
flavin moiety
94–96 or a metal binding site is incorporated.
7c,97 Commonly, haem (iron
protoporphyrin IX) or porphyrins are used in the de novo design to provide an electron transfer
or redox function to the artificial haemoprotein.
97b Metalloporphyrins in nature are commonly
found in haemoglobins, cytochromes, and peroxidases.
98 The different types of porphyrin
structures are bound either via co-ordination to histidines residues or by covalent binding to the
protein scaffold. Natural haemoproteins can perform dioxygen transport and storage, in
addition to oxygen and hydrogen peroxide activation during catalytic oxidation reactions.
However, examples of synthetic haemoproteins mimicking these functions are less abundant in
the literature.
99–101
Co-ordination of a haem or a porphyrin unit to a de novo designed haemoprotein can be
obtained by incorporating binding sites into the sequences (Figure 1.7b).
62,75,97b,102,103 The four-
helix bundle motif is flexible and can diverge to accommodate a prosthetic haem group as
observed in the natural cytochromes c’ and b562.
23 In general, the co-ordination of a haem or a
porphyrin structure results in an increased stability of the bundle.
38b,75,102 To obtain a tightly
packed hydrophobic core, a pocket can be introduced into the design to accommodate the
haem more effectively.
95,104 The stabilising effect of porphyrin structures on helical bundles does
not solely stem from the axial ligation of co-ordinating histidines. It has been shown that
hydrophobic interactions between the (hydrophobic) surfaces of the porphyrin and the
hydrophobic face of the helices also stabilise haemoproteins.
105 In contrast to the
aforementioned TASPs based on peptidic templates, the metal centre of these metalloproteins
can be located anywhere within the protein bundle depending on the position of the chelating
residues. The peptides that encapsulate the metal centre can in principle influence the
accessibility of a substrate to the embedded active site, and thus might be used to induce
substrate specificity.
Choma et al. were the first to prepare a four-helix bundle in which a single haem (iron
protoporphyrin IX) was sandwiched between α-helices by bis-axial ligation of the imidazole
groups of histidine residues (Figure 1.8).
104 The four-helix bundle was constructed by linking two
redesigned α2 units via a disulphide bridge. The introduction of additional histidines into the
peptide sequences can result in multi-haem proteins,
62,97,102,106,107 a s  d e m o n s t r a t e d  b y  t h e
designed maquettes of Dutton and co-workers (see Section 1.5).
32,87,108
Figure 1.8. A haem-stabilised four-helix bundle; side view (left) and top view (right).
10414
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Porphyrins bearing four functional groups can be used as templates for the covalent
attachment of peptides at the periphery of the macrocycle (Figure 1.7c,d).
63,64,76,81,96,97b,106,109
These functionalities are commonly located in the ortho-positions of tetraphenylporphyrin (TPP)
derivatives to facilitate the close proximity of the peptide chains. Only the α,α,α,α-atropisomer
of TPP derivatives will uniformly align the attached peptides to establish the formation of the
four-helix bundle. When a flexible linker is used, the energy barrier for atropisomerisation can
be sufficiently reduced to enable free rotation.
109 The hydrophobic effect will subsequently drive
the amphiphilic peptides to assemble into a four-helix bundle. Due to this design strategy, the
porphyrin template will be positioned on one side of the bundle. The appending porphyrin ring
in Helichrome thereby provides a hydrophobic pocket, which is also active in the catalytic cycle
(Figure 1.7d).
64 Similarly, Åkerfeldt et al. successfully constructed a membrane ion channel
mimic, called Tetraphilin, by coupling unprotected peptides to a TPP scaffold (Figure 1.7c).
63
1.4.3  Metal ion-assisted self-assembly
Metal-binding sites in proteins can be classified on the basis of either structural or functional
roles. In protein design, co-ordination of metal binding sites (ligands) in peptides to a transition
metal ion is a means of controlling the assembly process during the formation of helical bundles.
Complexation of the α-helices can occur via the covalently bound chelating groups (like
pyridine or bipyridine) at the peptide terminus,
65,66,110 or via metal-binding sites inside the
hydrophobic core.
47,111 The hydrophobic interactions are the driving force for the formation of
the helix bundle, whereas complexation of the ligands to the metal ion controls the number of
participating peptide chains. Lieberman and Sasaki have described the use of a 15-residue
amphiphilic α-helix with a N-terminal bipyridine tether for complexation to an iron(II) ion.
110
Similarly, Ghadiri and co-workers have obtained the resulting parallel three-helix bundle by
co-ordination of bipyridine-modified 15-residue peptides around a ruthenium(II) ion (Figure
1.7e).
65 This synthetic metalloprotein was used to measure electron-transfer rates, thus providing
a function for the de novo designed structure. The assembly resulted in the formation of a three-
helix bundle, due to the co-ordination of these bipyridyl moieties to the transition metals. A
stable parallel four-helix bundle was assembled by Ghadiri et al. by co-ordinating four pyridine-
modified 15-residue α-helices around a ruthenium(II) ion with two additional chloride anions as
axial ligands (Figure 1.7f).
66
1.4.4  Carbohydrates
The cyclic structure of carbohydrates has also been applied as a rigid template in the
construction of TASPs. Jensen and Barany have outlined a solid-phase preparation of a
derivatised D-galactopyranose that enabled the attachment of four identical 16-residue peptides.
These peptides are linked to the four available hydroxyl functionalities of the monosaccharide
via a short spacer to yield a stable four-helix bundle (Figure 1.7g).
67 The structure, however,
lacks function and has only been employed for the design study of a native-like protein.
The rigid cyclic structure of α-, β-, and γ-cyclodextrins makes it possible to assemble six,
seven, and eight peptide chains, respectively. Åkerfeldt and DeGrado have been able to prepare
a heptameric assembly by coupling 7-residue peptides to a β-cyclodextrin scaffold.
112 Although15
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the cyclodextrin template can potentially function as a receptor,
113 practical applications for
cyclodextrins in the design of artificial enzymes have as yet not been reported by the authors.
1.4.5  Macrocycles
A number of approaches utilising macrocyclic scaffolds have been described in recent years.
These more or less rigid organic molecules contain hydrophobic cavities that offer a potential
binding site for substrate recognition, although so far no such function has been presented in the
literature. Cavitands have been applied as a template for four-helix bundles by Sherman and
co-workers (Figure 1.7f).
57,68 These authors proposed the name caviteins for the de novo
designed proteins, originating from the words cavitand and proteins. By varying the length of
the spacer between the peptide and the template, they were able to study the influence of the
flexibility and rigidity of the scaffold on the overall stability of the structure. Causton and
Sherman have also designed and synthesised a three-helix bundle by attaching the peptide
chains to a rigid cyclotribenzylene (CTB) macrocycle (Figure 1.9).
76 The three thiol groups on
the periphery of CTB were used to covalently link unprotected peptides with N-terminal
cysteines via disulphide bonds. Similarly, van Wageningen and Liskamp have used a
cyclotriveratrylene-based scaffold (CTV) that enabled the covalent attachment of three amino
acid sequences via amide bonds.
72 The calix[4]arene has been used by Hamilton and
co-workers as a scaffold for the attachment of four peptide loops to mimic an antibody
recognition site.
114
Figure 1.9. Schematic representation of CTB as a template for three-helix bundles.
18,76
1.5  Artificial proteins: Function by design
Until recently, the major focus of protein design has been the understanding of the protein
folding processes and the construction of small tertiary polypeptide structures with a pre-defined
conformation. Without such an understanding of folding principles and structure-stability
relationships, the introduction of useful function into the design of artificial proteins will be
unsuccessful. It has already been mentioned that many designed protein structures behave as
molten globules. The fluctuating conformations will therefore have a negative effect on the
spatial organisation of the artificial protein, and hence its active site.
MeO SH
MeO SH
HS OMe
OMe HS
OMe HS
SH MeO
or
where
= X–CEKLLKELKELLEKG–NH2
(X = Ac–, Ac–EGG–, or H–EGG–)
=16
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With regard to the designed functional proteins in this section, the focus will be directed
towards helical bundles. The active centre of the functionalised structures is usually located
inside the hydrophobic core of the four-helix bundle. Their relatively small size and ease of
modification has made four-helix bundles the most commonly studied motif for the design of
synthetic proteins. Furthermore, they have high solubilities in water and are in general relatively
stable over a wide pH-range.
Natural haemoproteins are capable of catalysing redox reactions, binding small molecules
(e.g. CO, NO, CN), and performing electron transfer reactions. These enzyme functions have all
been established by de novo designed haemoproteins.
101
1.5.1  Artificial enzymes
Artificial enzymes are, almost by definition, inspired by natural enzymes.
8,115 The residues used
to form the active site often resemble the substrate binding pockets of the native protein. The
substrate specificity of enzymes is determined by the arrangement of amino acid residues in the
active site that bind to the functional groups of the substrate molecules, and in the case of
metalloproteins also by the positioning of the metal ion. Therefore, in order for a designed
peptide to act truly as an enzyme mimic, these characteristics will need to be incorporated and
expressed by the artificial protein. The use of templates in the de novo design of functional four-
helix bundles not only offers the opportunity to construct more native-like proteins; the size and
shape of the template can in principle allow for selectivity during the reaction, based on the size
and nature of the substrate.
The main disadvantage of porphyrin-based (per)oxidases is their sensitivity towards
oxidative degradation, either by the oxidant or by the reactive metal-oxo intermediate.
However, it has been found that the stability of a peroxidase can be increased by the nature of
the peptide surrounding.
116 The peptides are thought to act as radical scavengers or as an
alternative source for hydrogen abstraction, which would otherwise take place on the porphyrin
ring.
Substrate recognition
30,117,118 and rate enhancements of more than three orders of
magnitude over background reactions
117a,118,119 have been reported for reactions catalysed by
designed helical bundles (vide infra). So far, artificial proteins capable of stereospecific reduction
and oxidation have yet to be constructed, but taking into consideration the progress made over
the last few decades, even this function might become reality in the near future.
Mihara  et al. have constructed an artificial flavin protein that is capable of oxidising
dihydronicotinamides.
95,96 Their design consisted of a 53-residue single chain four-helix
bundle,
95 or four appending α-helices on a Mn–TPP moiety
96 in which all helices were identical
except for one helix with a flavin-modified cysteine in the centre of the hydrophobic core. The
oxidation of 1-benzyl-1,4-dihydronicotinamide, with a rate constant of 290 M
–1s
–1, was 1.35
times faster than the reaction catalysed by the unbound 7-acetylflavin moiety.
95 This rate was
more than doubled (k 660 M
–1s
–1) when a second flavin group was introduced into the helix
bundle. By electron transfer via the flavin unit the liberated electrons in this oxidation process
were also capable of reducing the manganese(III) in the porphyrin ring to Mn
II–TPP.
9617
An introduction to artificial proteins
By employing a combinatorial approach to the design of single chain four-helix bundles,
Hecht and colleagues have been able to obtain some haem-binding peptides that displayed
peroxidase activity.
103 Although a haem-binding site had not been incorporated into the design
itself, one protein in particular, protein 86, was capable of oxidising ABTS with a maximum
turnover frequency of 17,000 min
–1. Even though this is over forty times faster than any other
artificial porphyrin-based peroxidase, it is still much slower than the native horseradish
peroxidase (HRP) (∼60,000 min
–1).
103b Peroxidase activity has also been achieved with a
disulphide linked three-helix bundle to which a haem is covalently attached,
76 and a disulphide
linked dimeric four-helix bundle that contained a co-ordinated haem group.
75b The potential
oxidation of the disulphide bonds by the terminal oxidant hydrogen peroxide was not addressed
by the authors.
Mono-oxygenation of styrene and its derivatives to their epoxides has been achieved by a
peptide-modified manganese(III)TPP, using iodosylbenzene as the oxidant.
80 Substrate
discrimination could be established depending on the solvent. The authors did not mention any
oxidation of the thioether linkage that had been used to span the peptide across the porphyrin.
Benson et al. have designed novel proteins that displayed superoxide dismutase (SOD)
activity of about 1% of the wild-type SOD.
120
A de novo designed peptide ligase, consisting of a dimeric 33-residue amphiphilic helical
sequence, catalysed the ligation of hydrophobic peptides (Scheme 1.4) with rate enhancements
of up to five orders of magnitude over that of the uncatalysed reaction.
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Scheme 1.4. The peptide ligation reaction.
Broo and co-workers have constructed a symmetric 42-residue helix-loop-helix homo-dimer
(KO–42) with a reactive site consisting of twelve histidine residues.
30,117 This artificial enzyme is
capable of substrate specific transesterification reactions, as well as nucleophilic and general acid
hydrolysis of p-nitrophenyl esters. The pH-dependent reaction rate is up to three orders of
magnitude faster than compared to the 4-methylimidazole catalysed reaction.
Hahn et al. have reduced the sequence of the protease chymotrysin, a single chain peptide
with 245 residues, to a 73-residue protein, called Chymohelizyme.
50 Although the substrate
specificity was of a similar nature and the catalyst achieved over a hundred catalytic turnovers,
the rate of hydrolysis was about one hundred times less effective than that of the natural
enzyme.
In an effort to construct a synthetic decarboxylase, Benner and co-workers have designed a
de novo enzyme, called oxaldie, that self-assembles in solution to form helical structures.
119 The
rate of decarboxylation of oxaloacetate is about five orders slower than that of the natural
enzyme. However, this is still about nine hundred times faster than the uncatalysed
decarboxylation and three to four orders of magnitude faster than the reaction catalysed by
simple amines. Remarkably, oxaldie does not require any metal ions, as opposed to the natural18
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oxaloacetate decarboxylases, which require magnesium or manganese ions as a cofactor. Even
less effective is the dimeric four-helix bundle NP–42, designed by Baltzer and co-workers, that
decarboxylates oxaloacetate only ten times faster than butylamine.
121
The coproporphyrin-based four-helix bundle Helichrome, which was designed by Sasaki
and Kaiser to function as an aniline hydroxylase, produces p-aminophenol in the presence of
NADH and oxygen with a rate comparable to that of the natural haemoprotein haemoglobin.
64
The examples presented here of functional four-helix bundles are capable of catalysing a
variety of enzymatic reactions, although most of them are often inferior to their natural
equivalents. Even though the reports in the literature only describe the successful attempts, the
fact that protein designers are now capable of designing and constructing functional synthetic
proteins, it is still seen as a quite remarkable achievement. With an increased understanding of
the processes involved, the implementation of the required adjustments into the design will no
doubt facilitate the construction of more native-like performances by artificial enzymes.
1.5.2  Redox activity
Many approaches to redox active four-helix bundles have been followed in recent years.
4,7e For
the design of redox proteins the co-ordination environment for the metal can be provided by
correctly positioning two to four amino acids with chelating side chains, commonly histidine or
cysteine. These residues can be co-ordinated to a transition metal or a prosthetic group (haem
or porphyrin) with a vacant or loosely bound site for its function, such as carbon monoxide
binding.
101 Metallo- and haemoproteins can display a pH-dependence for the binding of metal
ions or haem groups, as protonation of histidine will result in the dissociation of the cofactor.
With precise design, site-selective binding of different metals,
122 or iron(III) and zinc(II)
protoporphyrin IX can be accomplished.
108e
The work carried out by Dutton and co-workers serves as an
illustrative example of the de novo design of novel redox
proteins based on the four-helix bundle topology.
32,87,108 The
initially designed assembly consisted of a parallel dimer of two
identical, disulphide-linked α-helices, each containing thirty-one
residues.
32 The authors refer to these (α–SS–α)2 motifs as
‘maquettes’; simplified synthetic protein scaffolds that still retain
some of the functions of the native enzyme. Structural variations
enabled them to incorporate up to four iron haem units inside
the hydrophobic core (right)
108a without significantly affecting the
helical content of the four-helix bundle.
87b The nature of the
prosthetic groups was found to be able to control the parallel or
anti-parallel orientation of the protein bundle through steric
interactions.
108g By connecting two helix-loop-helix (α–l–α)
units via a disulphide bridge a single chain four-helix bundle (α–
l–α–SS–α–l–α) was obtained that was somewhat more
resistant to denaturation than the dimer (Table 1.1).
87b19
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The use of de novo designed maquettes allowed Dutton and colleagues to selectively
introduce different haem groups,
108g and construct a protein with an affinity for halothane,
123 a
volatile anaesthetic guest molecule.
108c In addition, they succeeded in constructing proteins with
a pH-controlled redox potential.
108d Conversely, major pKa shifts were observed for the acidic
and basic groups upon reduction or oxidation of the haem group, as oxidation of the cofactor
increased its positive charge and, thereby, reduced its proton affinity. The multi-haem
maquettes display a co-operative redox behaviour, which is thought to arise from the electronic
interactions between the individual haems. As a result, they were able to acquire significant
diversity in the haem reduction midpoint potential (–350 to +175 mV at neutral pH compared
to –400 to +400 mV for natural haem proteins).
108h,i A photosynthetic reaction centre was
introduced by integrating two appending coproporphyrin I moieties. However, this approach
resulted in a disappointing quantum yield of <0.01.
108a
In view of the number of possible structural variations in the amino acid sequence, de novo
design of artificial (metallo)proteins lends itself to combinatorial design strategies. As an example
of a library approach, McLendon and co-workers have mutated cytochrome b562, a haem-
binding four-helix bundle peptide, at two positions in the sequence near the site for haem
binding while maintaining the original structural motif.
124 The resulting structures displayed
redox potential variations of over 1000 mV.
A great deal of research has been devoted to the study of (light-induced)
62b electron transfer
for de novo designed redox proteins.
65,108a,124 Willner et al. have presented an elegant example
by incorporating two iron(III) protoporphyrin IX (Fe–PP) units into a four-helix bundle that was
assembled as a monolayer onto a gold electrode.
106 Electron transfer was made possible by a
difference in the redox potential of the Fe–PPs due to a difference in the distance to the gold
surface. The helix bundle has also been connected covalently to a cytochrome b1-dependent
nitrate reductase, establishing a bioelectrocatalysed reduction of NO3
– in 80% yield (Figure
1.10).
107 Alternatively, cross-linking the helix bundle to Co–PP–reconstituted myoglobin
enabled the electrocatalysed hydrogenation of acetylene dicarboxylic acid to maleic acid
possible in 85% yield.
107b
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Figure 1.10. Electrochemical reduction of cytochrome c.
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1.5.3  Membrane proteins and ion channels
Helical bundles have also been designed to function as ion channels that can distinguish
between small ions, like H
+, Li
+, K
+, Na
+, and Cs
+. In order to act as a pore, these bundles
need to span the cell membrane. Incorporation into the lipophilic membrane requires a
hydrophobic exterior, which is contrary to the helical bundles that have been discussed so far. A
representative example by DeGrado and colleagues utilises amphiphilic helices consisting of
only leucines and serines that self-assembled into a four-helix bundle.
125 The exact sequence
composition affected the packing of the protein core, which as a result directed the cation-
selectivity of the ion channel. The membrane protein in turn could be ‘coated’ by amphiphilic
helices to change the hydrophobic nature of its exterior, making the protein soluble in water.
126
As observed for other TASPs, covalent attachment of the sequences to a (cyclic) peptide
69,79b,127
or TPP
63 template (Figure 1.7c) enhanced the stability of the synthetic pore.
1.5.4  Antibody recognition
Template-assembled synthetic proteins have also been described as functional mimics in
antibody recognition.
60,114 The template is often a cyclic peptide, but also self-assembled
tetrameric and dimeric four-helix bundles have been described as an antigenic determinant.
44a
By duplicating only the functional part of a protein (Figure 1.11), the properties of the large
natural enzyme can be effectively replicated. Normally, small antigen mimics are rapidly
degraded in vivo, unless the sequences are assembled as loops onto a scaffold or protein.
128
Antibody TASP
Figure 1.11. Receptor mimetics using regioselectively addressable templates.
53f
These small designed, synthetic peptides are capable of liberating antibodies that can for
instance recognise the natural HLA–A2 antigen.
128 It is also worthwhile mentioning that self-
assembled monolayers of TASP molecules on a gold surface have been examined as potential
biosensors.
53e
1.6  Research objectives and outline of this thesis
The presented examples of functional enzyme mimics based on the four-helix bundle motif
clearly demonstrate that these small peptide bundles can be provided with a function that
resembles that of a larger protein structure. Although a great deal of progress has been made in
the last decade towards the design of small peptide structures, designing architectures that have
function as well as a defined construction still remains an extremely difficult task to master and
should not be underestimated.
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Despite all the examples of functional four-helix bundles presented in the literature, so far
no examples have been published for the design of a synthetic peroxidase or oxygenase-based
on a non-haem catalytic centre. The small oxidising catalyst N4PyFe that was developed in our
group opens up an opportunity to create such a functional enzyme mimic. The design strategy is
to embed the catalyst inside a four-helix bundle by attaching four helical peptides via a cysteine
residue to a tetrafunctionalised N4Py ligand. Suffice it to say that the position of the cysteine in
the peptide sequence will enable a site-specific introduction of the catalyst into the core of the
bundle. In Scheme 1.5 a schematic representation of this concept is depicted where the four-
helix bundle is tethered to the catalyst via a terminal cysteine residue. Alternatively, if the
cysteine residues are positioned centrally in the peptide sequence, the N4PyFe catalyst will be
situated in the middle of the bundle (Figure 1.2). The relative orientation of the individual
helices is then an issue, which could be controlled by directed interactions that will favour the
designed helix bundle. First, we need to evaluate the feasibility of this ambitious project.
Scheme 1.5. Schematic representation of tethering a four-helix bundle to the N4PyFe
catalyst.
The aim of the research presented in this thesis is to develop modified N4Py ligands that will
enable the covalent attachment of four peptide chains. Once that has been accomplished
successfully, peptide sequences can be selected, which have been designed to fold into a four-
helix bundle. However, before the catalyst is incorporated into a bundle protein, it needs to be
ascertained whether or not the attached peptides can withstand the oxidising conditions, as well
as the highly reactive iron-oxo intermediate, and thereby do not diminish the catalyst activity.
We first tested this concept by attaching two peptide chains to a disubstituted N4Py ligand
(Chapter 2).
15 The iron(II) complex retained its catalytic oxidation activity with hydrogen
peroxide in water. Subsequently, the N4Py ligand was successfully modified into a template by
the introduction of functional groups. This enabled the application of the TASP methodology to
the N4Py ligand and established the incorporation of the N4PyFe catalyst in a peptide
environment by the covalent attachment of four peptides (Chapter 3).
The presented synthetic route follows a convergent strategy for the construction of
tetrafunctionalised N4Py ligands. An alternative, a divergent synthesis has also been developed
that facilitated the construction of the N4Py skeleton prior to its functionalisation (Chapter 4).
The potential strength of this latter method is that it will also enable structural variations using
for instance cross coupling reactions to prepare a small library of functionalised N4Py ligands.
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And finally, the application of several tetrasubstituted N4PyFe catalysts in oxidation reactions
will be discussed in Chapter 5, as well as the peroxidase activity of an assembled N4PyFe-
peptide complex. As is commonly found for oxidising haemoproteins, the N4PyFe catalyst and
the peptide-bound equivalents are also susceptible to oxidative degradation. Optimisation of the
peptide surrounding could eventually result in a prolonged lifetime of the future non-haem
peroxidase.
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2  Models for non-haem iron-containing oxygenases
2.1  Introduction
Several micro-organisms facilitate the metabolism of various hydrocarbons and aromatic
compounds via the activation of molecular oxygen by metalloproteins to provide a vital source
of energy for the organism.
1 Many of these enzymes contain a transition-metal ion at the
reactive site of the protein. The rate of aerobic degradation of these substrates is in general
relatively slow. Metalloenzymes, one class of nature’s catalysts, provide a low energy pathway
for oxidation by either enhancing the susceptibility of the substrate towards molecular oxygen,
or by increasing the reactivity of dioxygen. A great deal of research has been dedicated to the
development of small synthetic catalysts that are also capable of activating molecular oxygen or
oxidising hydrocarbons.
2,3
Oxidases form a category of enzymes that employ dioxygen as an electron acceptor.
1,4 The
reduction products are either water or hydrogen peroxide, depending on the number of
electrons involved. The oxygenases are a distinct class of enzymes that are able to incorporate
dioxygen into (in)organic substrates.
1,3,4 This conversion is crucial to their aerobic degradation,
which is accompanied by, for example, the oxygenation or cleavage of the aromatic ring. These
oxidising enzymes can be divided into mono-oxygenases or dioxygenases, depending on the
R-H + O2 R-OH H2O
R(OH)2
mono-oxygenase
+
dioxygenase
O2 + R-H
+
peroxidase
2 H2O R H2O2 + R-H
Figure 2.1. Classification of oxidising enzymes (R–H=substrate).32
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number of oxygen atoms that are introduced into the substrate. For mono-oxygenases the
remaining oxygen atom is reduced to water. Another class of oxidising enzymes are the
peroxidases, like horseradish peroxidase.
5 These natural antioxidants are able to facilitate the
oxidation of a variety of (in)organic compounds with the concomitant reduction of hydrogen
peroxide or alkyl peroxides to water or alcohols, respectively.
6
In a number of metalloproteins the transition metal can be positioned in a prosthetic haem
group where it is able to activate dioxygen.
4,7 In other enzymes a mononuclear or dinuclear
metal centre is present that functions as a cofactor in a non-haem environment.
1,8 This leads to a
distinction between haem and non-haem enzymes, although this subdivision is not restricted
exclusively to oxidising enzymes.
1,5,9
Metalloporphyrins and haem systems in nature can be found in haemoglobin, cytochromes,
oxidases and peroxidases.
4,5,9 A well-studied family of haem-containing mono-oxygenases
includes the cytochromes P-450, which can catalyse the epoxidation of olefins, and the
hydroxylation of aromatic or saturated hydrocarbons by molecular oxygen in the presence of
the reducing agent NADH or NADPH.
4,5,10 These haemoproteins are also capable of oxidising
inactive hydrocarbons to functionalised compounds by using oxidants like hydrogen peroxide,
iodosylbenzene, and peracids.
11 Therefore, a number of approaches to haem mimics have been
presented in recent years.
12
Rieske oxygenases are able to cis-dihydroxylate inactivated benzene rings. These non-haem
mononuclear iron(II) dioxygenases require NADH as a source of electrons to perform the
oxidation reaction.
1,3a The diol products are then converted into catechols, which are
subsequently degradated by catechol dioxygenases. These non-haem mononuclear iron(II)
enzymes accept the required electrons from the substrate molecules after binding dioxygen.
3a
2.2  Bleomycin
Although bleomycin (BLM) is not formally considered to be a protein, this natural glycopeptide
is often referred to as a non-haem oxidising enzyme.
13 It has been administered as an
antitumour antibiotic for the treatment of different types of cancers,
14,15 and is most active as the
corresponding mononuclear iron(II) complex, Fe–BLM. Its structure, depicted in Figure 2.2,
H
H
O
Fe
N HN
N N
N
NH2
N
CH3 H2N
O
O
H2N
O H2N
O NH
S
N
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N
N
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CH3
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CH3
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HO CH3
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H
O
OH
O HO
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O
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H H
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H
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H
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Figure 2.2. Structure of iron bleomycin (Fe–BLM).
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was deduced from the spectroscopic and NMR investigations of several metallo-BLMs.
16
Recently, X-ray structures of Cu-BLM complexed with a bleomycin-binding protein have also
been reported.
17
An activated species is formed by reacting Fe–BLM with molecular oxygen,
8,15,18 and this
“activated BLM” is the last detectable intermediate in the catalytic cycle of BLM that leads to an
oxidative cleavage of DNA.
15,19 This reactive intermediate of Fe–BLM is a low-spin iron(III)
hydroperoxo (Fe
IIIOOH, 1) species.
The reaction of Fe–BLM towards DNA proceeds through one of three possible pathways
(Scheme 2.1): (a) a heterolytic cleavage of the O–O bond in (BLM)Fe
IIIOOH furnishing the
high-valent Fe
V=O species 2; (b) an O–O bond dissociation to produce the Fe
IV=O species 3
and a hydroxyl radical; or (c) (BLM)Fe
IIIOOH reacts directly with DNA (R–H) to generate the
Fe
IV=O moiety 3, a DNA radical, and water without invoking a high-valent intermediate or free
hydroxyl radicals. Qualitative investigations on metallo-BLMs tend to favour option (c) as the
undiscriminating behaviour of free hydroxyl radicals is inconsistent with the highly specific DNA
degradation by Fe–BLM.
16 However, results with non-haem iron oxidation catalysts have been
interpreted to indicate that the end-on hydroperoxo ligand in the Fe
IIIOOH intermediate 1
functions as a precursor for the highly oxidative hydroxyl radical and the Fe
IV=O species via a
homolytic cleavage of the O–O bond.
20,21
(c) 
(b) 
(a) 
R
R + H2O +
OH
R-H
[(BLM)FeIV=O]2+
R-H
[(BLM)FeIIIOO H ] 2+
1
H+
H2O +
2
[(BLM)FeV=O]3+
3
[(BLM)FeIV=O]2+ +
3
Scheme 2.1. Possible pathways for DNA (R–H) degradation mediated by
(BLM)Fe
IIIOOH (1) after heterolytic (a) or homolytic (b) O–O bond cleavage, or
directly by 1 (c).
The chemistry of (BLM)Fe
IIIOOH is also utilised in reactions other than those involving DNA.
Organic substrates can also be oxidised, examples include the epoxidation of styrene,
22 the
oxidation of stilbene to the corresponding epoxide with the additional formation of
benzaldehyde,
23 and the hydroxylation of aromatic compounds like naphthalene and anisole.
24
In recent years several BLM analogues have been synthesised in order to gain a better
understanding of the mechanism, and to study the effect of structural changes on the activity
and selectivity of metallo-BLMs.
15,22,25
2.3  N4Py synthesis and chemistry
Many research groups have invested a great deal of effort into unravelling the intricate
mechanisms of various natural enzymes.
8a Due to their complex composition and immense size,
these enzymes and their active species are often studied by investigating the mechanisms of
smaller catalytic structures that resemble their behaviour. The data gathered from these34
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functional mimics can then be compared to that obtained with the native enzyme.
26 For
instance, a mononuclear non-haem iron(II) complex has been developed as a functional model
for Rieske oxygenases.
27 Non-haem diiron oxygenase mimics have also been designed,
28 as well
as metalloporphyrins as versatile oxidation catalysts.
29
A model has been developed in our group to study the oxidation mechanism of Fe–BLM,
as well as to provide an approach to new iron-based oxidation catalysts. The model for the apo-
enzyme BLM is a pentadentate ligand, called N4Py.
30 This neutral ligand consists of four
pyridine rings that are anchored to a central nitrogen atom (Scheme 2.2).
13 N4Py (6a) and its
disubstituted derivatives 6b–d are obtained by dialkylating bis(2-pyridinyl)methylamine (2) with
the picolyl chlorides 5a–d, respectively, in the presence of a base. The amine 4 can be obtained
from the commercially available 2,2’-dipyridyl ketone by conversion to the corresponding
ketoxime, and subsequent reduction to afford 4. The synthesis of the picolyl chlorides 5b–d has
previously been described.
20,31
5a-d 6a-d
NN
N
NN
R R
NN
NH2
4
MeCN
∆
N
Cl
R
+ base
a: R = H
b: R = Br
c: R = CO2Me
d: R = OMe
Scheme 2.2. Synthesis of N4Py (6a) and disubstituted derivatives (6b–d).
The monosubstituted N4Py derivatives 9 have previously been prepared in a similar fashion.
20
Prior to the alkylation step using a functionalised picolyl chloride, the amine 4 is converted to
the secondary amine N3Py (8) via a reductive amination using 2-pyridinecarboxaldehyde (7)
(Scheme 2.3).
MeCN
∆
base 2) NaBH4
MeOH
1)  4
7 89
NN
N
NN
R
NN
NH
N
N
O
N
R
Cl
Scheme 2.3. Synthesis of monosubstituted N4Py ligands.
To encapsulate an iron metal ion, five co-ordination sites are occupied by the ligand 6a,
resulting in the iron(II) complex [(N4Py)Fe(MeCN)](ClO4)2 (10) (Scheme 2.4). Consequently,
the metal ion is positioned in the centre of the generated cavity at 0.2071(5) Å above the mean
plane that is formed by the four iron-bound pyridine nitrogen atoms.
30c The sixth co-ordination
site is therefore accessible to axial ligands like the solvent-derived acetonitrile molecule in 10.35
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Although N4Py was developed as a model for bleomycin, the co-ordination environment around
the iron metal centre is quite different from that of Fe–BLM (Figure 2.2). The
[(N4Py)Fe(MeCN)](ClO4)2 complex 10 has been characterised by 
1H NMR and EPR as a low-
spin iron(II) complex with a high redox potential (E½=1010 mV vs. SCE) for the Fe
III/Fe
II
couple.
30c The effect of ligand modification on the electron density of the iron metal was
determined by measuring the Fe
III/Fe
II couples of the low-spin iron(II) complexes of disubstituted
N4Py derivatives 6b–d. It was established that substituents at the 5-position of the pyridine ring
only have a minor effect on the redox potential of these iron complexes (E½=996–1100 mV
vs. SCE).
20 The UV-Vis spectrum of 10 displays an absorption band at 458 nm in acetone
(ε 4000 M
–1cm
–1). EPR and NMR studies revealed that the spin state of the iron atom is
dependent on the temperature and the charge of the axial ligand.
30c Thus, the replacement of
the neutral acetonitrile molecule by a chloride anion leads to a high-spin iron(II) complex.
Similarly, a methoxy anion as an axial ligand gives rise to a high-spin iron(III) at room
temperature.
H2O2 base
acid
10
N N
Fe
N
N
N
N
II
11 12
N N
Fe
N
N
O
N
O
H
III N N Fe
N
NN
OO
III
Scheme 2.4. Proposed reaction intermediates 11 and 12 that originate from N4PyFe
(10) and hydrogen peroxide.
When N4PyFe (10) is allowed to react with one equivalent of hydrogen peroxide, 10 is
converted to an iron(III) complex. A large excess of hydrogen peroxide is required to produce
the iron(III) hydroperoxide intermediate 11. This purple species has been characterised by UV-
Vis spectroscopy, EPR, ESI-MS, and resonance Raman spectroscopy
32 as a low-spin iron(III)
hydroperoxide in which the hydroperoxo ligand is co-ordinated to the iron centre in an end-on
η
1-binding mode (Scheme 2.4).
30 Only in acetone and methanol is the formation of this
transient Fe
IIIOOH species quantitative.
33 The slow and incomplete formation of 11 in
acetonitrile is substantiated by the unfavourable equilibrium for the displacement of the axial
ligand in 10. The purple intermediate 11 has a characteristic absorption band at 530 nm in
acetone (ε 1100 M
–1cm
–1) and 548 nm in methanol (ε 1100 M
–1cm
–1). The observed EPR
signals at g=2.17, 2.12, 1.98 resemble those of the low-spin iron(III) species of activated
BLM.
18 This Fe
IIIOOH intermediate is capable of catalytically reducing hydrogen peroxide in the
concomitant oxidation of a wide variety of organic compounds.
20,34 Similar reactivity has been
observed with non-haem dinuclear
35 and mononuclear
20,36 iron complexes of N3Py derivatives,
the iron complex of the pentadentate ligand 5Py,
37 as well as many other non-haem iron
catalysts.
2,38
Furthermore, N4PyFe is able to cleave DNA in the absence of hydrogen peroxide.
20 The
efficiency of this oxidation reaction was substantially enhanced by attaching a DNA-intercalating36
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acridine moiety to the N4Py ligand. The resulting iron complex was found to cleave DNA using
molecular oxygen without requiring any additional reducing agents.
39 These findings established
that this modified N4PyFe catalyst functioned as an effective mimic for Fe–BLM.
These mechanistic studies have led to a proposed catalytic cycle in which
[(N4Py)Fe(MeCN)](ClO4)2 ( 10) is initially converted into the mononuclear species
[(N4Py)Fe
IIIOH]
2+ 14 and the dinuclear species [{(N4Py)Fe
III}2(µ–O)]
4+ 15 (Scheme 2.5).
20,30c
In methanol as the solvent, these aforementioned intermediates are also in equilibrium with the
Fe
IIIOMe species 16.
30c However, upon addition of excess hydrogen peroxide these species are
converted into the transient intermediate 11.
Mechanistic studies have provided evidence that the Fe
IIIOOH intermediate 11 is in fact not
the active species, but merely serves as a precursor in the catalysed oxidation of alkanes.
Although an oxoferryl (Fe
IV=O) species with a porphyrin π-radical cation is often observed
during the reduction of molecular oxygen by haem peroxidases
4,29 and other mononuclear iron
centres,
8 a heterolytic cleavage of the O–O bond in 11 to a high-valent, formally iron(V)-oxo
intermediate is considered energetically too unfavourable to occur (Scheme 2.1).
16,34
MeOH
H2O
OH +
O2 or 13
ROH  +  R(O)
R
RH
homolysis
H2O2
H2O2
base
acid
[(N4Py)FeII(MeCN)]2+
10
[(N4Py)FeIIIOMe]2+  
16
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Scheme 2.5. Proposed catalytic cycle for the oxidation of alkanes by N4PyFe (10) and
hydrogen peroxide.
A homolytic scission of the O–O bond in 11 would produce two one-electron oxidants,
[(N4Py)Fe
IVO]
2+ (13) and a hydroxyl radical (•OH). The involvement of hydroxyl radicals in the37
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catalytic cycle of [(N4Py)Fe(MeCN)](ClO4)2 (10) was established by employing radical traps
such as acetone,
40 benzene,
41 and dibromomethane
11c during the oxidation reaction. The
rationale for these observations is that the neutral pentadentate ligand N4Py is not capable of
stabilising the high valent iron in the formally iron(V) oxidation state, and therefore leads to a
homolytic rather than a heterolytic scission of the O–O bond.
34 In addition, resonance Raman
spectroscopy demonstrated that the O–O bond in the Fe
IIIOOH intermediate 11 is unusually
weak.
In the oxidation of alkanes catalysed by N4PyFe the hydroxyl radical produced reacts with
a substrate molecule to give rise to a substrate radical after hydrogen abstraction (Scheme 2.5).
This intermediate subsequently reacts with dioxygen or 13 to propagate a radical chain auto-
oxidation pathway to furnish the oxidation products and the intermediates 14 and 15.
42 The
proposed catalytic cycle has been elucidated by employing radical scavengers and mechanistic
probes to determine the kinetic isotope effects, the ratio of oxidation at the tertiary over
secondary carbon centres in adamantane, and the stereoselectivity in the hydroxylation of trans-
1,2-dimethylcyclohexane.
20,34 However, these mechanistic studies have indicated that another,
more selective oxidising intermediate is also involved in the hydrogen abstraction of alkanes
catalysed by 10, which is most probably the [(N4Py)Fe
IVO]
2+ species 13.
20,34
When the reactivities of the iron(II) complexes of 6b–d towards the oxidation of alkanes
were investigated, the results were comparable to those of N4PyFe.
20 This suggests that a similar
mechanism must be involved, irrespective of the electronic properties of the ligand. This is not
surprising when taking into account the good correlation between the analytical data of these
iron(II) complexes and the corresponding Fe
IIIOOH species. However, the number of free
co-ordination sites at the iron centre in the complex has been found to determine the type of
chemistry observed during the catalysed oxidation reactions. This is clearly demonstrated by the
difference in oxidation behaviour and the proposed mechanism for N3Py derivatives with
respect to N4Py ligands (Scheme 2.6).
20,36 The effect of the co-ordination mode of non-haem
ligands, as well as their electronic and steric factors on the oxidation chemistry of the Fe
IIIOOH
intermediate has recently been described by Que and co-workers.
43
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Scheme 2.6. The effect of the co-ordination mode of the hydroperoxo ligand on the type
of oxidation chemistry in reactions catalysed by the iron complexes of N4Py (left) and
N3Py (right).38
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The fact that acetone effectively traps hydroxyl radicals can result in different catalytic activities
(or turnover number, TON) for the catalyst upon changing the solvent from acetonitrile to
acetone. As a result, the selectivity in the oxidation of cyclohexane has been found to be
noticeably solvent-dependent. For instance, the ratio of cyclohexanol over cyclohexanone (A/K)
changed from 1.4 to 2.6 in acetonitrile and acetone, respectively. When only free radical
intermediates are involved in the catalytic cycle, oxidation generally results in A/K∼1.
42a By the
slow addition of hydrogen peroxide to the reaction mixture the A/K ratio could be increased
even further to 5.2, which indicates that oxidation by the non-selective hydroxyl radicals is
suppressed in favour of a more selective oxidising species, presumably 13.
34
When the axial ligand of the [(N4Py)Fe(MeCN)](ClO4)2 complex is a chloride anion, the
purple intermediate 11 cannot be formed. This is presumably due to the strong binding of the
anion to the metal, which prevents the displacement of the ligand.
30c The catalyst is deactivated
to a certain extent during the catalytic cycle, which is probably due to the oxidative degradation
of the ligand by the hydroxyl radicals that are formed.
The purple Fe
IIIOOH intermediate 11 can be converted reversibly into its conjugate base 12
upon the addition of aqueous ammonia in methanol at –45°C. The resulting blue species has
been characterised by UV-Vis (λmax 685 nm, ε 520 M
–1cm
–1), ESI-MS, and resonance Raman
spectroscopy as a high-spin [Fe
IIIO2]
+ species.
44 In the proposed structure the peroxo ligand is
co-ordinated to the iron metal via a side-on binding mode,
33b,c,45 whereby the weakly bound
tertiary nitrogen is detached from the metal centre (Scheme 2.4).
44
Related [Fe
III–η
2–O2]
+ intermediates have also been proposed as the source of nucleophilic
peroxides in the oxidation mechanism of haem enzymes (Figure 2.3).
46 This [Fe
IIIO2]
+ species is
completely unreactive towards the oxidation of alkanes until the Fe
IIIOOH intermediate 11 is
regenerated by the addition of acid.
44 This observation seems to support the hypothesis that
protonation of the peroxo species is a prerequisite for catalytic activity.
47
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Figure 2.3. Possible transition states for oxygen transfer of peroxo ferric haem
complexes: closed (left) and open (right) peroxo complexes (X=substrate).
46b
2.4  An initial step towards artificial peroxidases
The mechanistic studies of [(N4Py)Fe(MeCN)](ClO4)2 (10) and its oxidation chemistry correlate
very well with the reactivity and spectroscopic data of Fe–BLM, suggesting that a comparable
mechanistic pathway is plausible for both catalysts. Therefore, the iron complex 10 poses as  a
good functional mimic for Fe–BLM. It will be interesting to ascertain whether or not the
incorporation of this model catalyst in a peptide environment will facilitate the construction of a
synthetic peroxidase. The outline of this project has already been discussed briefly in Chapter 1.39
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The four-helix bundle motif has been selected as a potential scaffold to embed the N4PyFe
catalyst, where it will hopefully function as a synthetic co-factor. It was illustrated in Chapter 1
that the four-helix bundle appears to be able to accommodate the N4PyFe catalyst. The peptide
chains will be attached to a modified N4Py ligand via a cysteine residue in the peptide
sequence. Halide displacement on the ligand by the cysteine thiolate is the key to a site-specific
attachment of the peptides. This concept has been tested in a preliminary study whereby two
unprotected peptides were coupled to the difunctionalised N4Py ligand 18.
48
It had already been shown that substituents at the 5-position of the pyridine rings have no
major effect on the electron density of the iron centre (vide supra).
20 Therefore, it is unlikely that
substituents at this position will interfere with the redox potential of the catalyst. Furthermore,
these attachment sites will direct the peptides away from the iron centre (Scheme 2.7), which
allows the formation of the Fe
IIIOOH intermediate without affecting its oxidation chemistry.
Steric properties in the ligand too close to the iron centre could result in a change in oxidation
behaviour, as was described by Que and co-workers for 5- and 6-methyl-substituted tris(2-
pyridinylmethyl)amine (TPA) iron catalysts.
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Scheme 2.7. Synthesis of the N4PyFe-dipeptide complex 19.
49
The dichloride N4Py derivative 18 was prepared from 6c by initially reducing the ester groups
and subsequently converting the alcohol functionalities to the chlorides.
48 The reported low yield
of only 8% was due to the decomposition of 18 during purification by column chromatography.
This can probably be attributed to the benzylic nature of the two chlorides.
The methodology of coupling peptides via a cysteine thioether linkage has several
advantages. Firstly, the position of the cysteine residue in the peptide sequence can facilitate a
site-specific attachment of the ligand and thereby control the location of the catalyst in the
prospective four-helix bundle structure. Secondly, the cysteine thiolate is an efficient nucleophile
that can enable the successful coupling of unprotected peptides.
50 The presence of other
nucleophilic side chains in the sequence (from histidine, lysine, and glutamic acid for instance)
can interfere with the chloride displacement in 18. The selected peptide sequence for this
experiment consisted of a representative number of residues with nucleophilic side chains
(Scheme 2.7). However, the use of caesium carbonate as a base and an excess of peptide
afforded a selective and clean conversion to the dipeptide complex 19 after chelation to iron.
48
The use of excess peptide was required, as oxidation to the corresponding disulphide occurs
readily. UV-Vis, electrospray ionisation mass spectrometry, and protolytic digestion by a40
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protease verified the incorporation of iron in 19 and the presence of covalently linked peptide
chains.
48
The retained catalytic activity of 19 was successfully demonstrated by its ability to oxidise
the peroxidase activity probes ABTS
51 and 1,2,4,5-tetramethoxybenzene (20)
52 in water with a
performance that was comparable to N4PyFe under identical conditions. In addition, the
oxidation of 20 by catalyst 10 gave rise to a benzene radical cation that was also detected by
EPR when horseradish peroxidase (HRP) was employed as the catalyst (Scheme 2.8).
48
products 
20 21
HRP or 10
H2O2
OMe
OMe
MeO
MeO
OMe
OMe
MeO
MeO
Scheme 2.8. Formation of the radical cation 21 in the oxidation of methoxybenzene
20 catalysed by horseradish peroxidase (HRP).
The pH-dependence of the catalytic system was optimal at pH 4 or lower. At higher pH ranges
the activity of the catalyst rapidly diminished. Examination of the reactions over time revealed
that after five minutes the oxidation had essentially terminated for both
[(N4Py)Fe(MeCN)](ClO4)2 ( 10) and 19, presumably due to an oxidative degradation. The
similar oxidation behaviour of 10 and 19 clearly demonstrated that the attachment of two
peptide chains to the catalyst had no significant effect on its performance.
2.5  Conclusions
Earlier work by Gerard Roelfes lead to the formulation of a mechanism for the oxidation catalyst
[(N4Py)Fe(MeCN)](ClO4)2 (10). The good correlation between the oxidation chemistry and the
spectroscopic data of the reactive intermediates proved that 10 functions as an effective mimic
for Fe–BLM.
The oxidation behaviour and performance of the N4PyFe catalyst remains unaffected by
the attachment of two peptide chains in close proximity to the iron complex. These findings
suggest that the catalyst can be embedded into a peptide environment without substantial loss
of activity. This paves the way for the design of water-soluble peroxidase mimetics. At the same
time this sets the stage for the challenging task to modify the N4Py ligand in order to host four
peptide chains. This will hopefully facilitate the incorporation of the catalyst into a four-helix
bundle. The synthesis of such a tetrafunctionalised N4Py derivative will be presented in Chapter 3.
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Tetrasubstituted N4Py ligands
as templates for peptide attachment
3  Tetrasubstituted N4Py ligands as templates for
peptide attachment
3.1  Introduction
Over the past few years a number of different approaches to modified enzymes and artificial
functional proteins have been developed. However, despite the synthetic or modified oxidases
and peroxidases reported so far, artificial proteins based upon a non-haem reaction centre in a
four-helix bundle have not yet been described (See Chapter 1). In an attempt to initiate the
construction of such a functional artificial enzyme an ambitious strategy was formulated in
which the N4PyFe catalytic unit is embedded inside a four-helix bundle.
1 This concept was
initially tested by the construction of the dipeptide system described in Chapter 2.
2 The positive
results of the oxidation reactions implied that the oxidising capability of the N4PyFe catalyst was
not affected by the peptide surrounding. More importantly, these results indicated that the
concept of embedding the N4PyFe catalyst into a more organised peptide environment might in
fact be feasible. The work described in this chapter outlines the exploratory preparation of a
tetrafunctionalised N4Py derivative with four appending peptide chains as a basis for the design
and synthesis of an artificial peroxidase in the future.
The methodology that had been applied successfully to make the dipeptide N4PyFe
complex involved the use of chloromethylene (–CH2Cl) groups as sites for peptide attachment.
2
These peptides were coupled to the ligand by a nucleophilic substitution reaction of cysteine
thiolates with the halide leaving groups of the ligand. The key feature of this procedure infers
that the position of the cysteine in the peptide sequence will facilitate the site-specific attachment
of the ligand to the peptide chains. In a four-helix bundle this methodology will in turn
determine the position of the catalyst inside the hydrophobic core of the bundle. The same
approach will now be employed to prepare the corresponding tetrasubstituted N4Py ligand in
order to tether four peptides to the N4PyFe catalyst. Ultimately, by selecting a peptide sequence
that will fold into an α-helix, the catalyst can be incorporated inside a four-helix bundle.
In the following sections compounds and ligands with a one carbon linker (–CH2–) at the
periphery will be referred to as comprising of a C1-spaced functionality. From modelling studies46
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it was deduced that these groups should be positioned at the 5-position of the pyridine ring, so
that the 2-positions can be used to construct the N4Py ligand core. For reasons that will become
more apparent later in this chapter, N4Py derivatives with four propyl linkers
(–CH2CH2CH2–) have also been prepared, which will be referred to as C3-spaced moieties.
Disubstituted N4Py ligands are readily available from the dialkylation of
di(2-pyridinyl)methylamine with an appropriate picolyl chloride derivative as described in
chapter 2.
3 Construction of a tetrafunctionalised N4Py ligand therefore requires the introduction
of functionalities in the bis(2-pyridinyl)methylamine moiety for which a new synthetic route had
to be developed. As a result, the desired functionalities in the final N4Py derivative need to be
carefully selected, as these must be introduced in the initial steps of the synthetic pathway. The
choice of these functionalities, however, might be limited due to its incompatibility towards the
required synthetic procedures.
The retrosynthesis of the target tetrasubstituted
N4Py derivatives 1 and 2 involves two main
disconnection paths (Scheme 3.1). Following path A,
bis(2-pyridinyl)methylamines  3 and 4 are dialkylated
with picolyl chlorides 5 and 6, respectively. All of these
2,5-disubstituted pyridine compounds can be obtained
from the corresponding bromopyridines 7 and 8, making
these important, and versatile building blocks for the
synthesis of tetrasubstituted N4Py ligands 1 and 2.
Finally, bromopyridines 7 and 8 can be prepared from
the commercially available 2,5-dibromopyridine (9).
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Scheme 3.1. Retrosynthesis of tetrasubstituted N4Py ligands 1 and 2.
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Alternatively, 1 and 2 can be obtained from the alkylation of the secondary amines 12 and 13
with the bis(2-pyridinyl)methylene chlorides 10 and 11, respectively (Scheme 3.1, path B). These
in turn can be prepared from the corresponding aforementioned bromopyridines 7 and 8.
From hands-on experience with N4Py chemistry within our research group, a decision was
taken to follow path A for the synthesis of tetrasubstituted N4Py derivatives 1 and 2. The
synthesis of the required building blocks will be elaborated upon in subsequent chapters. After
completing the synthesis of 1 and 2 the protecting groups, like silyl ether groups, can be
removed. The corresponding hydroxyl moieties can then be converted into leaving groups to
enable these ligands to act as templates for the covalent attachment of peptides via a cysteine
residue in the sequence.
3.2  2,5-Disubstituted pyridines as synthons
As briefly mentioned above, the resulting functionality at the periphery of the ligand has to be
introduced at the start of the synthetic route. The developed synthetic route, therefore, needed
to be carefully selected to minimise the conflict that might arise between the functionalities and
the applied reaction conditions throughout the synthetic pathway. Fortunately, a number of
procedures are available for acquiring various 2,5-disubstituted pyridines that can be used as
synthons for the construction of tetrafunctionalised N4Py ligands. Outlined in Scheme 3.2 are
some typical synthetic approaches to picolyl chloride derivatives that have previously been used
to synthesise N4Py derivatives.
3
N
R
N
R
OH
N
R
Cl
mCPBA
CH2Cl2
1) Ac2O
2) K2CO3
MeOH
N
R
O
14a-c 15a-c 16a-c
17a-c
SOCl2
CH2Cl2
TsCl
1,4-dioxane a: R = CO2Me
b: R = Br
c: R = OMe
Scheme 3.2. Synthesis of 5-substituted 2-picolyl chlorides 17a–c.
Although 14a is commercially available, it is more expensive than 14b
4 and 14c,
3 which can be
obtained from cheaper starting materials. These pyridine derivatives are readily oxidised to the
corresponding N-oxides, and after acylation by acetic anhydride the intermediate acetates can
be hydrolysed to produce the alcohols 16a–c.
5 It is also possible to obtain picolyl alcohol 16a
from the reduction of dimethyl 2,5-pyridinedicarboxylate with sodium borohydride in the
presence of calcium chloride (Scheme 3.3).
6 However, due to the poorly described experimental
conditions, it was not possible to reproduce the high yield reported by the authors. The48
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subsequent reaction of picolyl alcohols 16a–c with thionyl chloride furnished the corresponding
picolyl chlorides 17a–c. A synthetic shortcut to 17a was established by the reaction of N-oxide
15a with p-toluenesulphonyl chloride (TsCl), which is probably also applicable to 17b–c.
3
Using the developed synthetic route to tetrasubstituted N4Py ligands as depicted in Scheme
3.1, the starting materials 14a–c do not permit the synthesis of the required corresponding
bis(2-pyridinyl)methylamines. The preparation of the latter compounds utilises the lithiation of
2-bromopyridine derivatives to couple two pyridine moieties together. This will be dealt with in
more detail in Section 3.3.3. Although a small number of 5-substituted 2-bromopyridines are
commercially available, their functionalities limit the structure variations possible for
tetrasubstituted N4Py ligands onto which peptides can be assembled. Examples of synthetic
pathways to the required 5-substituted 2-bromopyridines for the C1-spaced N4Py ligand are
depicted in Scheme 3.3.
Dimethyl 2,5-pyridinedicarboxylate (18) was converted to the monoester N-oxide 19 by a
reaction with hydrogen peroxide in boiling acetic acid.
7 The diacid from which 18 was obtained,
could not be converted directly into the N-oxide due to its zwitterionic nature,
7 although some
success has been reported utilising tungsten catalysts.
8 After alkaline hydrolysis of 19 and
subsequent acidification the diacid was obtained. Unfortunately, the described experimental
conditions proved to be difficult to reproduce. Using a patented procedure the diacid was
converted conveniently to 6-bromo-nicotinic acid (20).
9 Alternatively, 20 could also be obtained
from 2,5-dibromopyridine (9) by lithiation with n-butyllithium (n-BuLi), followed by quenching the
2-bromo-5-lithiopyridine with carbon dioxide. The latter procedure is more efficient, and provides
20 in a single step in 82% yield from the commercially available 2,5-dibromopyridine (9).
Ac2O,
1) OH-
∆
AcOH
H2O2
TEA
2) CO2
1) n-BuLi
3) NaBH4
2) DMF
1) n-BuLi
LiAlH4
N Br
OH
N Br
Br
CaCl2
NaBH4
9 21 16a
20 18
2) CH2Br2 N Br
CO2H
19
N HO2C
CO2Me
O
N
CO2Me
OH
N MeO2C
CO2Me
Scheme 3.3. Examples of synthetic pathways to 2,5-disubstituted pyridines.
The method in which two pyridine units will be coupled together for the preparation of
bis(2-pyridinyl)methylamines 3 and 4 involves a lithiation reaction (vide infra), and thereby
limits the use of an ester or acid functionality. Despite this problem, it is of interest to note that
procedures have recently been described utilising halogen-magnesium exchange reactions that
tolerate ester and nitrile functionalities.
10 However, by reducing carboxylic acid 20 to alcohol 21,
and subsequent protection of the hydroxyl group, the compound can be subjected to a lithiation49
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reaction. Alternatively, 21 can also be obtained directly from dibromopyridine 9 by reducing the
intermediate aldehyde in situ using sodium borohydride.
For practical reasons a decision was taken to construct tetrasubstituted N4Py ligands 1 and
2 starting from 9. This facilitates the versatile and controlled introduction of the desired
functionalities at the correct position on the pyridine ring. In principle, by employing various
electrophiles to quench the lithiated species derived from 9, a wide range of tetrafunctionalised
N4Py derivatives should be accessible.
3.3  Synthesis of tetrasubstituted N4Py ligands
As indicated in the retrosynthesis outlined in Scheme 3.1, bromopyridine 7 is a particularly
important building block for the synthesis of the C1-spaced N4Py derivative 1. All other pyridine
units that are required to obtain the ligand structure can be prepared from 7. Similarly, the
building block 8 has been used to construct the corresponding C3-spaced N4Py ligand 2. The
developed synthetic route makes it imperative that the essential functionalities for the targeted
ligand are incorporated into these building blocks before the core of the ligand is constructed.
This approach of building the functionalised N4Py framework entails the convergent synthesis of
the ligand.
11
3.3.1  Preparation of the building blocks
The C1-spacer in building block 7 has been introduced by preparing 2-bromo-5-
pyridinecarboxaldehyde (22). This aldehyde is commonly obtained from the oxidation of
2-bromo-5-methylpyridine to the acid, followed by reduction to the aldehyde.
12 However, as the
starting material is expensive and the reaction proceeds in a low yield, a preferred method
involves the use of the commercially available 2,5-dibromopyridine (9). Subsequent lithiation
with  n-BuLi at –80°C afforded 2-bromo-5-lithiopyridine,
13 which was quenched with
N,N-dimethyl-formamide (DMF) to furnish the aldehyde 22 in 96% yield (Scheme 3.4).
When tetrahydrofuran (THF) was selected as the solvent, the monolithiation of 9 was found
to be less selective than the results described in the literature.
14 The intermediate lithiated species
is commonly quenched with electrophiles such as aldehydes,
14b nitriles,
14a and secondary
amides
14a to provide the corresponding alcohols and ketones, respectively. When DMF was used
to quench 2-bromo-5-lithiopyridine in diethyl ether as the solvent, aldehyde 22 was obtained in
a near quantitative yield and in high purity.
15 Similar results were obtained via a bromine-
magnesium exchange of 9 using isopropylmagnesium chloride in THF at room temperature.
16
For the synthesis of the C1-spaced N4Py ligand 1 the aldehyde 22 was reduced with NaBH4 in
methanol to furnish the alcohol 21. When 21 was subsequently allowed to react with tert-
butyldimethylsilyl chloride (TBDMSCl)
17 in DMF in the presence of triethylamine (TEA) the
C1-spaced building block 7 was obtained in 85% yield after purification.
18
In order to obtain the building block 8 for the construction of the C3-spaced N4Py ligand 2,
aldehyde 22 was converted to the α,β-unsaturated ester 24 by a Horner-Emmens reaction using
triethyl phosphonoacetate (23). Only the E-isomer of 24 was observed by 
1H NMR. Subsequent
reduction by LiAlH4 to the saturated alcohol 25 was followed by a silylation to afford the silyl
ether 8 in 81% yield after purification. Normally, LiAlH4 is not known to reduce the carbon–50
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Scheme 3.4. Synthesis of building blocks 7 and 8.
carbon double bond of α,β-unsaturated esters, unless it is conjugated with a phenyl group, like
for example in cinnamic esters.
19 Under the applied conditions full reduction of 24 was
observed, although the saturated alcohol 25 could only be isolated in a moderate yield of 61%.
Therefore as an alternative, hydrogenation using palladium on carbon was attempted to
reduce the double bond, followed by the reduction of the remaining ester functionality in 26
(Figure 3.1) using LiAlH4. However, under these hydrogenation conditions reductive
debromination occurred to furnish 27.
20 Using Adam’s catalyst (platinum oxide) under similar
conditions also resulted mainly in reductive debromination. In both cases the saturated ester 26
was only observed in small quantities.
21 Furthermore, the complete reduction of the pyridine
ring to yield the corresponding piperidine derivative 28 was observed under these conditions.
22
26
N Br
OEt
O
N
OEt
O
27 28
N
OEt
O
H
Figure 3.1. Observed products from the metal-catalysed hydrogenation.
In conclusion, building blocks 7 and 8 have been prepared in good to excellent yields. It is of
interest to note that, due to the high purity of the isolated intermediates, the crude end products
of each step can be used without any deleterious effects in subsequent reactions.51
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3.3.2  Preparation of 5-substituted 2-picolyl chlorides
Depending on the desired spacer length in the final ligand, the required 2-picolyl chlorides 5
and 6 can be obtained from building blocks 7 and 8, respectively (Scheme 3.5). These building
blocks were lithiated with n-butyllithium in THF at –80°C and subsequently quenched with
DMF to provide the aldehydes 29 and 30. In contrast to the lithiation of 2,5-dibromopyridine,
employing THF instead of diethyl ether as a solvent led to superior results. An aqueous workup
was sufficient enough to hydrolyse the intermediate DMF adduct to the aldehyde, as an acidic
workup would have led to the hydrolysis of the silyl ethers. These aldehydes can in principle be
reduced in situ to the picolyl alcohols 31 and 32. However, since both aldehydes are also
required for the synthesis of di(2-pyridinyl)methylamine 3 and 4 (Scheme 3.6), the reduction
was carried out separately. Finally, the reaction of alcohols 31 and 32 with thionyl chloride in
the presence of triethylamine cleanly and quantitatively afforded the 2-picolyl chlorides 5 and 6.
Flash column chromatography proved to be crucial to minimise decomposition during the
purification of the product on the column. The synthesised 2-picolyl chlorides 5 and 6 were fully
characterised by 
1H and 
13C NMR, and mass analysis.
MeOH
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N
OTBDMS
Cl
n
TEA, CH2Cl2 N
OTBDMS
HO
n
(n=3)
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NaBH4
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N
OTBDMS
O
H
n
N Br
OTBDMS n
(n=3)
(n=1) 7 (72-80%)
THF, -80°C
1) n-BuLi, 
2) DMF, -80°C
8
Scheme 3.5. Synthesis of picolyl chloride derivatives 5 and 6.
Again as before, all of the reaction steps proceeded smoothly, thereby eliminating the need to
purify the intermediate products, with one exception: when the aldehydes 29 and 30 were
employed for the synthesis of bis(2-pyridinyl)methylamines 3 and 4, respectively (Scheme 3.6).
3.3.3  Preparation of disubstituted dipyridinyl methylamines
The key step in the synthesis of tetrasubstituted N4Py ligands is the coupling of two
functionalised pyridine rings via a methylene bridge, preceding the formation of the required
bis(2-pyridinyl)methylamines 3 and 4. This coupling reaction was carried out by reacting the
lithiated 7 or 8 with the 2-formylpyridine derivatives 29 or 30, respectively, under the same
conditions that were applied to prepare these aldehydes (Scheme 3.6). The intermediate
bis(2-pyridinyl)methanols were subsequently oxidised by manganese dioxide to produce
bis(2-pyridinyl) ketones 33 and 34 in good overall yields. In contrast to the commercially52
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Scheme 3.6. Synthesis of bis(2-pyridinyl)methylamine derivatives 3 and 4.
available 2,2’-dipyridinyl ketone that is used for the synthesis of N4Py itself, five or six reaction
steps had to be performed to obtain the related ketones for the C1- and C3-spaced N4Py
ligands, respectively.
Subsequently, 33 and 34 were converted to the bis(2-pyridinyl) ketoximes 35 and 36 by
reacting with hydroxylammonium chloride in the presence of a base. The purification of the
preceding intermediates was deemed unnecessary due to the ease with which these ketoximes
were crystallised from ethanol and water. Finally, the bis(2-pyridinyl) ketoximes 35 and 36 were
converted to bis(2-pyridinyl)methylamines 3 and 4 by a mild and quantitative reduction using
zinc powder under basic conditions.
23 Hydrogenation of 35 and 36 utilising palladium on
carbon as an alternative reduction procedure failed: even after prolonged reaction times and
elevated temperatures, only the starting material could be isolated. It is assumed that the amine
products poisoned the catalyst, thus preventing further hydrogenation.
The prepared bis(2-pyridinyl)methylamines 5 and 6 were characterised by 
1H and 
13C
NMR, and mass analysis. The doubly benzylic hydrogen atoms of these amines give rise to a
distinctive signal in the 
1H NMR with a chemical shift at δ 5.3 ppm. Furthermore, a dramatic
shift of the 
1H NMR signals in the aromatic region was observed due to the reduction of the
oxime double bond.
3.3.4  Construction of the N4Py scaffold
Analogous to other N4Py derivatives that have been made in the past,
3 tetrasubstituted N4Py
ligands can be prepared by the dialkylation of bis(2-pyridinyl)methylamines 3 and 4 with 2-picolyl
chloride derivatives 5 and 6 in the presence of base. The first alkylation step to the secondary
amines 37 and 38 (Figure 3.2) proceeded quickly. In contrast, the reaction of these so-called
N3Py derivatives with a second equivalent of 2-picolyl chloride proved to be more difficult.
Nevertheless, the tertiary amines 1 and 2 were eventually isolated in moderate yields after
purification.53
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Scheme 3.7. Synthesis of tetrasubstituted N4Py derivatives 1 and 2.
A variety of bases and solvents have been tested to find the optimal conditions to obtain 1 and
2. Decomposition of the starting materials was observed when N,N-diisopropylethylamine
(DIEA) was employed as a base in boiling chloroform. Potassium carbonate in refluxing
acetonitrile is commonly applied to the synthesis of various N4Py ligands.
3 However, when
these conditions were used to prepare 1 and 2, decomposition of the starting materials was also
observed. Attempts to improve the reaction by adding catalytic amounts of 18-crown-6 or
sodium iodide proved to be unfruitful. A clean but slow conversion was observed when a two-
phase system of dichloromethane and aqueous sodium hydroxide was used at room
temperature or under reflux conditions. The addition of tetrabutylammonium iodide to the
reaction mixture as a phase-transfer catalyst did not enhance the reaction rate. Other methods
that were attempted with little success involved the use of sodium hydride, potassium carbonate,
or DIEA in DMF as the solvent. Fortunately, successful conversion to 1 and 2 was accomplished
by utilising DIEA or caesium carbonate as a base in refluxing acetonitrile. The advantage of
using caesium carbonate over DIEA is that it resulted in a cleaner conversion to the desired
product.
42
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(n=3) 
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(n=3) 
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n
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n
2
n
N
TBDMSO
CH2
Figure 3.2. Observed side-products in the preparation of tetrasubstituted N4Py ligands 1
and 2.
The moderate yields of 1 and 2 are partly attributed to the formation of side-products 39–42,
24
a problem that became more pronounced as the reaction time was extended. Furthermore,
the conversion of N3Py derivatives 37 and 38 to the products 1 and 2 did not proceed to54
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completion, despite the presence of excess picolyl chloride derivatives. Additional loss of
product occurred during purification by flash column chromatography, which was further
hampered by the poor separation of the N3Py compounds from the N4Py products. It is crucial
that the obtained tetrasubstituted N4Py derivatives are free of N3Py structures, as subsequent
reactions with peptide sequences will also be susceptible to the N3Py analogues. As a result,
separation of these peptide-coupled N4Py ligands will then be hampered by their structural
similarities.
Once the construction of tetrasubstituted N4Py ligands had been accomplished, all that
remained was removal of the silyl protecting groups, followed by the conversion of the hydroxyl
functionalities into suitable leaving groups for the covalent attachment of peptides.
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Scheme 3.8. Deprotection of the silyl ethers 1 and 2.
A variety of standard conditions were employed to remove the silyl protecting groups. The first
method involved tetrabutylammonium fluoride, which resulted in a fast and complete
conversion. Unfortunately, removal of the resulting silyl products proved to be troublesome due
to the high polarity and water solubility of 43. The use of Zn(BF4)2 as an alternative method was
successful, although this did not afford the desired free ligand 43 but its zinc complex instead.
The best results obtained so far involved using dilute hydrochloric acid in methanol or ethanol.
However, the removal of residual solvent was complicated by hydrogen bond formation to the
four hydroxyl groups of the N4Py derivatives 43 and 44. After prolonged high-vacuum
conditions the pure product was obtained, as verified by 
1H and 
13C NMR, and mass analysis.
3.4  Chlorination attempts
Many attempts have been undertaken to convert 43 to the tetrachloride N4Py derivative 45,
either to be isolated as such or converted in situ to a sulphide. As indicated in Scheme 3.9, all
attempts so far have proven to be unsuccessful. It appears that replacing the four hydroxyl
groups for (chloride) leaving groups leads to the formation of an intrinsically unstable structure.
The exact origin of this intrinsic instability can only be speculated upon, although the probable
source is attributed to the doubly benzylic, tertiary hydrogen in 45 (Scheme 3.9).
In the dichloride N4Py ligand that was discussed in Chapter 2, the benzylic chlorides were
positioned within the upper half of the ligand structure. This structural feature did not prevent its
formation. In the tetrachloride N4Py derivative 45, however, the doubly benzylic proton is now
flanked by two pyridine groups that each contain a benzylic chloride moiety. Such benzylic55
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positions are often reactive sites, especially in pyridine compounds as they can be susceptible to
N-alkylation. This significant difference can be sufficient enough to lead to the observed
decomposition of 45, presumably initiated by an elimination of the doubly benzylic proton.
43
N
HO
N
OH
N
N
HO
N
OH
H
45
N
Cl
N
Cl
N
N
Cl
N
Cl
H
Scheme 3.9. The unsuccessful attempt to prepare 45 from 43
The anticipated instability and disappointing initial results suggested that mild reaction
conditions needed to be employed to convert 43 to 45. These experiments involved the use of
methanesulphonyl chloride, collidine, and lithium chloride in DMF at 0°C to room
temperature.
25 Other attempts involved the use of thionyl chloride in the presence of TEA or
pyridine in dichloromethane and/or DMF, or triphenylphosphine and tetrachloromethane
26 in
acetonitrile and/or pyridine. Solvent mixtures were often required due to the poor solubility of
43 in common solvents like chloroform, dichloromethane, and acetonitrile due to its four
hydroxyl groups. Nevertheless, 45 (or any other related N4Py structure) could not be isolated,
even at low temperatures.
Tetrachloride  45 could only be detected by electrospray mass analysis (ESI-MS) as its
hydrochloride salt from the reaction using thionyl chloride in DMF.
27 Unfortunately, as soon as
water or base was added, the product decomposed immediately upon contact. After further
attempts, it quickly became apparent that 45 could not be isolated nor prepared due to its
instability. It was also impossible to convert 45⋅ ⋅⋅⋅HCl  in situ into a N4Py ligand with four
appending sulphide groups via the addition of a thiol like benzyl mercaptan or
p-methylthiophenol. The required basic conditions resulted in the decomposition of the
intermediate at a rate that was apparently faster than its conversion to the sulphide. Although
the advanced intermediate 43 had been synthesised successfully, the sensitivity to
decomposition of the tetrachloride 45 precluded its application as a template for peptide
attachment.
In order to establish that the doubly benzylic proton in 45 is the origin of its intrinsic
instability, attempts have been made to replace the proton by a methyl group. This had already
been accomplished successfully for N4Py (46) by Gerard Roelfes during his postgraduate
research.
3 However, lithiation of 1 in the presence of N ,N,N’,N’-tetramethylethylenediamine
(TMEDA), followed by quenching with methyl iodide resulted repeatedly only in the recovery of
starting material, and not to the desired product 48. The unsuccessful methylation might be due
to the steric hindrance of the four bulky TBDMS groups at the periphery of the ligand. Another
explanation implies that the lithiated species is stabilised by the co-ordination of the silyl ether
groups, thereby preventing alkylation.56
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Scheme 3.10. Methylation of the doubly benzylic position in N4Py structures.
Another speculated approach to introduce the N4PyFe catalyst inside a four-helix bundle
involved connecting two helix-loop-helix units via two chloromethylene linkers on the ligand
(See Section 1.2). To obtain an anti-parallel orientation of the helix macrodipoles in the four-
helix bundle, these linkers will have to be positioned on opposite sides of the ligand. To meet
this prerequisite the synthesis of the dissymmetric ligand 51 was initiated, but due to the
unsuccessful attempts to prepare tetrachloride 45 this synthetic route has not been examined
any further (Scheme 3.11).
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1) n-BuLi, 
2) 2-pyridine- N Br
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Scheme 3.11. Discontinued synthesis of the N4Py derivative 51.
3.5  Model reactions
A number of reactions have been performed to understand the origin of the decomposition of
tetrachloride 45 when prepared from the tetrahydroxyalkyl N4Py derivative 43. The attempt to
replace the doubly benzylic proton by a methyl group was unfortunately unsuccessful (vide
supra). Some of the model reactions on 3-(hydroxymethyl)pyridine (52) discussed here could
also provide alternative means of functionalising the N4Py structure 43.57
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Scheme 3.12. Thioether functionalisation of 52 via an electrophilic leaving group.
The hydroxyl group of 52 was converted into a leaving group using thionyl chloride to yield
53a, which was only stable when isolated as its hydrochloride salt (Scheme 3.12). A rapid
decomposition was observed when attempts were made to isolate the free pyridines 53a–b
(n=0). Despite this fact, these unprotonated pyridines could be converted in situ to the
sulphides 54a–b in excellent yields. In contrast to these successful conversions of the benzylic
hydroxyl group in 52, the experimental conditions applied to the tetrahydroxy N4Py derivative
43 as mentioned earlier were fruitless. Similarly, the Mitsunobu reaction
28 of 52, utilising
triphenylphosphine and diethyl azodicarboxylate, and the subsequent reaction with ethanol,
ethyl glycolate, or methyl N-acetylcysteine (57) also proved to be unsuccessful. The presence of
triphenylphosphine oxide was established by 
31P NMR, but mass analysis and 
1H NMR clearly
indicated that the desired (thio)ether products had not been formed. One reason for the
unsuccessful outcome might lie with the intermediate of this reaction, which again converts the
benzylic hydroxyl function in 52 into a leaving group.
These findings appear to support the assumption that the benzylic chloride segments in 45
might be the source of its instability. Replacement of the chlorides by different leaving groups,
therefore, does not offer any further hope. This instability of 45 presented a problem for the
proposed methodology in which peptides can be attached to 45 via a nucleophilic substitution
using a cysteine thiolate.
A thioether linkage can also be achieved by converting the hydroxyl groups of 43 into
thiols, which can then react with a N-chloroacetylated peptide chain. To test this concept, 52
was initially converted into the thiourea adduct 55, followed by hydrolysis to furnish the free
thiol,
29 and then alkylated by reacting with ethyl bromoacetate to produce 56 in an excellent
yield of 93% (Scheme 3.12). In spite of this successful model reaction, employing this
methodology with the tetrahydroxy N4Py 43 would mean that peptide sequences could only be
linked via an amide bond. This in turn would obstruct the coupling of unprotected peptides to
the N4PyFe catalyst, as the side chains of certain residues will interfere with the reaction of
interest. The use of protected peptides would make it possible to bypass these unwanted side
reactions, but then the peptide chains can be only be tethered to the ligand through their
N-terminus, unless selectively removable protecting groups are employed.58
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Circumventing the instability problem associated with 45 could involve converting the
benzylic hydroxyl groups in 43 into nucleophiles rather than electrophilic groups. By simply
deprotonating the hydroxyl group and quenching the oxy anion with an alkyl halide, a variety
of ether products can be envisaged. Model reactions that made use of 52 have proven to be
successful in the formation of the ethers 58a–b by utilising ethyl bromoacetate and
p-methoxybenzyl bromide, respectively (Scheme 3.13). However, attempts to alkylate 52 with
p-nitrobenzyl chloride failed.
In sugar chemistry ether bonds are commonly formed by converting the targeted hydroxyl
group into a trichloroacetimidate, followed by a (Lewis) acid-catalysed reaction with a second
alcohol.
30 Accordingly, trichloroacetimidate 59 was prepared from alcohol 52 by a base
catalysed reaction with trichloroacetonitrile. Unfortunately, the subsequent conversion into an
ether was unsuccessful, despite the addition of more than one equivalent of a (Lewis) acid (LA).
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Scheme 3.13. Other examples of converting the benzylic hydroxyl group in 52.
If the instability of the N4Py structure 45 is attributed to the benzylic chlorides, this complication
can be resolved by modifying the spacer by re-positioning the leaving group into a non-benzylic
site. To test this approach, 52 was acylated by chloroacetyl chloride to furnish 60, followed by
the reaction with benzyl mercaptan or methyl N-acetylcysteine (57) in the presence of caesium
carbonate as a base to yield 61a and 61b, respectively (Scheme 3.13). However, if this
methodology was to be used for the preparation of a peptide-bound N4PyFe catalyst, the
introduced ester linkage might be prone to hydrolysis. A more stable linker, therefore, can be
acquired via an ether bond (Scheme 3.14). For this reason, the sodium salt of 52 was allowed
to react with 1-bromo-2-chloroethane (62a) to yield 63a. Unfortunately, the reaction failed as59
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only the starting material was recovered. Similar results were obtained using ethoxy ethyl (EE)
protected 2-iodoethanol (62b). The use of N-protected bromoalkylamines 62c–e
31 would not
only increase the length, but also modify the nature of the linker. When applied to the N4Py
derivative  43 and after deprotection of the amine functionality, protected peptides can in
principle be coupled through their C-termini. Many procedures are known in peptide chemistry
for such an amide bond formation. The observed reaction in the preparation of 63c–e,
however, led to the elimination of hydrogen bromide to yield alkenes 64c–d.
32 In the case of
62e decomposition of the starting materials was observed, rather than the formation of 63e or
64e. Changing the order of addition of the sodium salt of 52 and the reagents 62c–e had no
effect on the outcome of the reaction.
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Scheme 3.14. Unsuccessful alkylations to increase both the length and the nature of
the spacer.
1
Another strategy to attach peptides to the N4Py ligand 43 is through their N-termini via a
carbamate linkage (Scheme 3.15). This approach was tested by the preparation of carbamate
66 via a two step procedure starting with 52 and p-nitrophenyl chloroformate (65). The
intermediate carbonate was allowed to react with methyl L-valine hydrochloride in boiling
chloroform and in the presence of TEA to furnish 66 in 54% isolated yield in two steps. This
successful coupling of an amino acid to a pyridinyl methanol group illustrates the potential
application of this methodology to couple peptides to 43.
52
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Scheme 3.15. Carbamate group as a potential linker for peptide attachment.
In relation to any of these functionalisation reactions of 52 it is imperative that the conversion is
accompanied by a high yield, as an incomplete conversion of the four hydroxyl groups in 43
will result in product mixtures, and thereby reduce the yield of the targeted ligand structure. In
Scheme 3.13 a method is presented to enable the attachment of cysteines to 43 via an ester
linker. In this reaction in particular it is even more important that the reactions proceed to
completion as two consecutive transformations are required. When applied to 43, indeed only
the tetracysteine derivatised ligand 72 was observed (Scheme 3.16). Mass analysis of the
reaction mixture established that both the esterification and the alkylation step were successful,
as side-products resulting from incomplete reactions were not observed. It is therefore apparent60
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that this methodology can be used successfully to attach four peptide chains to the N4Py ligand
43. However, as mentioned earlier, the ester linkage might present a complication with regard
to the stability when the structure forms part of an iron complex that is applied to catalytic
oxidation reactions in an aqueous medium.
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Scheme 3.16. Alkylation of tetrahydroxy derivatised N4Py ligands 43 and 44 and
attachment of cysteine residues to 43 via ester linkages.
The hydroxyl groups of 43 and 44 were successfully alkylated with methyl iodide or benzyl
bromide after deprotonation by sodium hydride (Scheme 3.16). Although the resulting N4Py
derivatives 67–69
33 do not present an alternative means of attaching peptides to the ligand,
these tetrafunctionalised N4Py ligands might provide interesting iron(II) complexes for the
catalytic oxidation of organic substrates (See Chapter 5). Although p-methoxybenzyl bromide
has been used successfully for the alkylation of 52, similar conditions did not yield satisfactory
results when applied to 43.
When ethyl bromoacetate is used for the alkylation of 43, the introduced ester groups can
in principle create the possibility to couple peptides via an amide bond through their N-termini.
Unfortunately, under the experimental conditions that were employed full substitution of 43 to
furnish 70 was not observed. Instead, a mixture of di-, tri-, and tetra-alkylated products was
identified by mass analysis.
34 In an attempt to introduce four amino acids into 43, the tetra-
alcohol was deprotonated and subjected to N-bromoacetyl  L-phenylalanine ethyl ester to
prepare 71. Using this methodology, N-bromoacetylated peptides can in principle be coupled to61
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the ligand. Unfortunately, no conversion of deprotonated 43 to 71 was observed under these
conditions either. As the reaction conditions have not yet been optimised for compounds 69–
72, no yields are shown in Scheme 3.16.
3.6  Increasing the spacer length
The decomposition of the tetrachloride 45 is probably inherent to its structure and might be
triggered by hydrogen chloride elimination. The mechanism is, unfortunately, still insufficiently
understood. As suggested above, one option to circumvent the instability induced by benzylic
chlorides is to extend the linkers between the pyridine moieties and the leaving groups. These
linkers should be short, stable, and readily introduced. Although the model studies presented in
Section 3.5 provide some alternatives for a successful functionalisation of the C1-spacer in 43,
the application and the effect on the stabilisation are not by any means straightforward. For
example, the unsuccessful formation of the ether 63a (Scheme 3.14) illustrated that
modification of 43 in a similar fashion is unlikely to be fruitful. A chloroacetyl linker can be
readily introduced (see 72 in Scheme 3.13), although the resulting ester linkage is not very
stable. This instability was exposed when the iron(II) complex of 72 was found to decompose
during crystallisation.
An all-carbon linker at the periphery of the ligand presents another alternative to place the
leaving groups further away from the benzylic position. However, using the currently developed
methodology this approach implies that these linkers will have to be introduced at the start of
the synthetic pathway. A C2-spacer can be created by quenching 2-bromo-5-lithio-pyridine with
ethylene oxide, analogous to the synthesis of the aldehyde 22 (Scheme 3.4). The resulting
C2-spaced hydroxyl group can also be obtained via the Wittig reaction of 22 with
methoxymethylenephosphorane, followed by the reduction of the extended aldehyde
functionality. The synthetic pathway would lead to the corresponding N4Py derivative with
C2-spaced hydroxyl functionalities that will have to be converted into chloride groups.
However, if hydrogen chloride elimination triggered the decomposition of 45, then this might
also be applicable to the C2-spaced analogue. The elimination of hydrogen chloride can be
anticipated due to the energetically favourable conjugation between the ethylene groups with
the pyridine rings of the ligand.
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Scheme 3.17. Synthesis of the tetrabromide N4Py ligand 73.
The decision was taken to prepare the C3-spaced N4Py derivative 2, as the preparation of the
C2-spaced ligand would involve an extensive synthesis of a structure that could potentially62
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decompose. The synthesis of 2 is outlined in Scheme 3.4 to Scheme 3.7 for n=3. In order to
enhance the leaving group ability of the non-benzylic leaving group, a bromide was introduced
by converting the silyl ether groups directly into bromides by reacting with triphenylphosphine
dibromide (Scheme 3.17).
30,35
Intra- or intermolecular alkylation of the pyridine or tertiary amine nitrogens in 73 is a
potential problem, but from our past experience it is known that this does not occur even for
hexyl chains (n=6).
36 The long synthetic route to prepare 73 was rewarded by the observed
enhanced stability of the ligand, enough to bear more reactive
bromides as terminal leaving groups. Electrospray mass
analysis of 73 ([M+H]
+ at m/z 848.0) corresponded to the
calculated isotope distribution pattern (top and bottom right,
respectively).
It is of interest to note, that 3’-(3-bromopropyl)-pyridine
37
as a model compound for 73 decomposed rapidly upon
isolation, whereas 71 w a s  f o u n d  t o  b e  s t a b l e  a t  r o o m
temperature for at least a day. Therefore, it is quite surprising,
and satisfying, that the introduction of the labile terminal
bromide functionalities did not lead to the formation of a
more unstable compound.
3.7  Cysteine substitution and peptide coupling
In order to tether four peptides to N4Py (46) the ligand had to be modified. For this purpose the
synthesis of the tetrachloride 45 was attempted as it would enable the attachment of peptides
via a cysteine residue in the sequence. Although this C1-spaced template was found to be too
unstable, the C3-spaced tetrabromide 73 was obtained successfully. The peptide coupling to this
ligand can formally be considered an alkylation reaction of cysteine. With regard to the ligand, it
is imperative that the nucleophilic substitution reaction goes to completion, as an incomplete
reaction with the peptides would result in a mixture of mono-, di-, tri-, and tetrasubstituted
template-assembled peptide complexes. To force the substitution reaction to go to completion,
an excess of peptide must be used.
Another hurdle to overcome relates to the peptides that will be used in the absence of side
chain protecting groups. Various reactive functionalities in the amino acid side chains in, for
instance, histidine and lysine might interfere in the alkylation reaction.
38 It is therefore important
to elucidate the optimal conditions for the alkylation of the cysteine thiolate substitution
reaction. Some of the methods that have been described in the literature for cysteine alkylation
involve (a) ammonia in methanol,
39 (b) DIEA or TEA in polar non-protic solvents, like DMSO,
DMF, or acetonitrile,
40 (c) sodium ethoxide in refluxing ethanol,
41 or (d) caesium carbonate in
aqueous DMF at pH 9.
2,42 Previously in the preparation of the N4PyFe-dipeptide complex
(Chapter 2),
2 caesium carbonate was applied with great success. Deprotonation of the cysteine
under these conditions converts the thiol group into an excellent nucleophile (‘caesium effect’),
which is well suited for SN2 substitution of primary and secondary halides.
43 Under these
conditions the peptides are coupled to the ligand solely via the cysteine residue, even in the
presence of other nucleophilic side chains.
2 To test the potential use of 73 as a template for the
840 850 860
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attachment of peptides, the nucleophilic substitution reaction was first tested by a cysteine
thiolate displacement of the bromides (Scheme 3.18). Compound 74 was obtained in a 12%
isolated yield after purification by preparative reversed-phase high-performance liquid
chromatography (RP-HPLC). Its structure was verified by 
1H NMR and mass analysis.
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Scheme 3.18. Cysteine and peptide coupling to tetrabromide 73.
38
After establishing the successful coupling of four protected cysteines to 73 to furnish 74, the
peptide coupled products 75 and 76 were obtained after using the corresponding unprotected
peptides in excess (vide infra). These peptides have been selected only on the basis of their
representative amino acid content and length that might lead to complications during the
coupling reactions. Furthermore, it is imperative to note that these peptide sequences have not
been designed to fold into a four-helix bundle.
Upon complexation of the ligands 74–76 with iron(II) perchlorate, the corresponding
iron(II) complexes were obtained with four appending cysteines or peptides, respectively
(Scheme 3.19). The iron(II) complexes 78–79 were prepared in situ after coupling the peptides
to the ligand. The tetracysteine adduct 74 was purified by preparative RP-HPLC prior to
complexation with iron(II) perchlorate (Figure 3.3).
L
MeCN
77: L = 74
78: L = 75
79: L = 76
Fe(ClO4)2 6H 2O .
(L) Fe (MeCN)  (ClO4)2
Scheme 3.19. Complexation of ligands 74–76 with iron(II) perchlorate.
The ESI-MS spectrum of purified 74  exhibited two peaks at m/z 1236.7 and 619.1,
corresponding to [M+H]
+ and [M+2H]
2+, respectively. Its iron(II) complex 77 displayed an
UV-VIS spectrum that is characteristic for iron(II) complexes of N4Py ligands (Figure 3.4, left).
3
Electrospray mass analysis of 77 revealed the masses of [M–(ClO4)
––(MeCN)]
+ (m/z 1390.4),
and the doubly-charged particle of [M–2(ClO4)
––(MeCN)]
2+ (m/z 646.0) (Figure 3.4, right). The
singly-charged peak observed at m/z 1326.5 was assigned as [(74)Fe(MeCN)](Cl), because64
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Figure 3.3. HPLC profile of the crude (A) and purified (B) 74 with ESI-MS analysis of
the purified sample (C).
the observed and calculated isotope patterns were identical. Its formation could stem from the
reaction of 77 with traces of chloride salts present during the sample preparation. The peak at
m/z 707.5 was attributed to an unknown contaminant.
The uniformity of the peptide coupling was confirmed by MALDI mass analysis of the crude
template-assembled peptide complexes 78 and 79. It is important to note that side-products
from incomplete substitution reactions were not detected. The peptide complexes 78 and 79
were purified by preparative RP-HPLC. The absorption band around 450 nm, which is
characteristic for N4PyFe complexes (see Figure 3.4, left), makes it possible to distinguish
readily between the single peptide chains and the N4PyFe-peptide complexes. This point is
illustrated in Figure 3.5, which shows the same HPLC run that was used for the purification of
79, monitored at all wavelengths (TIC) and at 450 nm.
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Figure 3.4. UV-Vis spectrum of 77 in acetone (A) and its ESI-MS spectrum (B).
The chemical integrity and the inclusion of iron in the peptide complexes was verified by MALDI
mass analysis of the collected homogeneous fractions. The calculated mass for 78 corresponded
to the detected mass (Figure 3.6A) (calcd for [78– 2(ClO4)
– – (MeCN)]
2+  m/z 4620.38 amu
(monoisotopic), 4623.43 amu (average isotope composition), found 4619.2 amu). This is
equally valid for 79 (Figure 3.6B) (calcd for [79– 2(ClO4)
– – (MeCN)]
2+  m/z 6121.3 amu
(monoisotopic), 6125.1 amu (average isotope composition), found 6124.0 amu). Remarkably,
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Figure 3.5. RP-HPLC plot of crude 79 monitored at all wavelengths (TIC, left) and
450 nm (right).
these doubly-charged species for 78 and 79 are not observed at m/2z, but at m/z. For both
peptide complexes higher charged species have also been detected. The m/2z species (2309.6
for 78, 3063.5 for 79) were always observed as a set of four signals. In the lower regions, two
masses were detected that were assigned to the m/4z species, which did not match exactly the
calculated values (calcd for 78 m/4z 1154.8, found 1158.0; calcd for 79 m/4z 1531.2, found
1536.0). The patterns observed for multiply-charged species were similar for both 78 and 79,
although an appropriate explanation for these observations is not available at the present time.
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Figure 3.6. MALDI mass analyses of the purified 78 (A) and 79 (B).
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The examination of the catalytic oxidative activity of the peptide complexes 77–79 will be
elaborated upon in Chapter 5, where the results for other tetrasubstituted N4Py derivatives will
also be described with regard to their ability to act as oxidation catalysts.
3.8  Discussion and conclusions
Chapter 2 described the work previously carried out on the modification of the non-
functionalised N4PyFe catalyst to enable the covalent attachment of two peptide chains.
2 For
this purpose, two chloromethylene groups had been introduced at the periphery of the N4Py
ligand. The intention to use the same methodology for the introduction of four equivalent
attachment sites for the coupling of four peptides, was clearly over-estimated. So far, all
attempts to synthesise and convert tetrachloride 45 have been unproductive. The intrinsic
instability of this compound makes it unlikely that this ligand can be used to incorporate the
N4PyFe complex inside a four-helix bundle. Alternative coupling strategies will have to be
employed to tether peptides to the C1-spaced N4Py template, some of which have been
presented by the model reactions in Section 3.5. However, a satisfactory solution for coupling
peptide chains to the C1-spaced ligand 43 has yet to be found.
To overcome the instability of the tetrachloride 45, structural changes had to be incorporated
into the N4Py ligand. Although extended spacers enabled the synthesis of the tetrabromide 73,
this approach at the same time illustrated the flaw in the developed synthetic route. Even though
in principle various spacers can be tethered to the N4Py framework, these modifications entail the
reconstruction of the ligand from scratch. It would therefore be more practical to synthesise a
N4Py ligand that can be modified after it has been constructed, which also allows a variety of
spacers to be introduced (a divergent synthesis). At the same time, such a ligand will also enable a
range of structural variations to be created at the periphery of the N4Py ligand. These ligands in
turn can be screened for their catalytic activity towards the oxidation of organic substrates. The
synthesis of such a ligand will be discussed further in Chapter 4.
In spite of the encountered synthetic problems, the developed convergent synthesis has led
to the preparation of a tetrasubstituted N4Py ligand to which four peptides can be attached.
This was demonstrated by MALDI mass analysis of the peptide complexes 78 and 79. The
pentadentate nature of the N4Py ligand makes it possible to use tetrabromide 73 as a functional
template for the covalent attachment of peptide chains. The oxidation behaviour of the iron(II)
peptide complexes 78 and 79, and their resistance towards oxidative degradation will be
presented in Chapter 5.
3.9  Experimentals
Instrumentation
The NMR spectra were recorded on a Varian Gemini-200 (
1H NMR at 200 MHz, 
13C NMR at
50.3 MHz), a Varian VXR-300 (
1H NMR at 300 MHz, 
13C NMR at 75.5 MHz), or on a Varian
Unity Plus (
1H NMR at 500 MHz). Chemical shifts (δ ) are denoted in ppm and referenced to the
residual proton resonance in CDCl3 (
1H: δ 7.25 ppm, 
13C: δ 77.0 ppm), CD3OD (
1H: δ 3.30
ppm, 
13C: δ 49.0 ppm), DMSO–d6 (
1H: δ 2.49 ppm, 
13C: δ 39.5 ppm), or CD3CN (
1H: δ 1.93
ppm). The splitting patterns are designated as follows: s (singlet), d (doublet), dd (double67
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doublet), t (triplet), q (quartet), m (multiplet), br (broad), and for 
13C NMR determined with the
ATP pulse sequence. The mass spectra were recorded by Albert Kiewiet on a JEOL JMS-600H
for electron impact (MS EI), chemical ionisation (MS CI), and exact mass determination
(HRMS). Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI)
analyses were carried out on a Micromass TofSpec E, equipped with a N2 UV-laser (λ=337 nm,
4 ns pulse, Epulse=180 mJ). Samples were prepared in an α-cyano matrix (1:1, dissolved in
MeCN and 0.1% TFA (7:3), 20 mg/mL). Electrospray ionisation mass spectrometry (ESI-MS)
was performed by Margot Jeronimus-Stratingh on a Nermag mass spectrometer. Elemental
analysis was carried out in the microanalytical department of the University of Groningen by
Harm Draaier, Jan Ebels, and Jannus Hommes on an EuroVector CHNS-O Elemental Analyzer
Euro EA 3000. Melting points were determined on a Mettler FP-2 melting point apparatus,
equipped with a Mettler FP-21 microscope, and are uncorrected. UV-Vis spectra were recorded
on a Hewlett-Packard 8453 single-beam spectrophotometer. Data acquisition was performed
using the UV-Visible ChemStation software package by Agilent Technologies. Reversed-phase
high-performance liquid chromatography (RP-HPLC) was conducted on a Waters 2690
Separations Module equipped with a Waters 996 Photodiode Array Detector (set at TIC and
450 nm) and a Micromass ZMD Quadrupole mass spectrometer with the co-operation of Marc
van Gelder. The Alltech Econosil C18 analytical column (150x2.1 mm, 5µ) was run at a flow of
0.3 mL/min, and the semi-preparative column (250x4.5 mm, 5µ) at a flow of 1.5 mL/min. The
peptide complexes were purified using linear gradients of mixtures of solvent A (10%
acetonitrile in water with 0.1% TFA) and solvent B (95% acetonitrile in water with 0.1% TFA).
The crude products were dissolved in mixtures of solvents A and B. Ligand 74 was purified
using a linear gradient of MeCN in 0.05 M ammonium acetate. The homogeneous fractions
were collected, lyophilised, and analysed by ESI-MS or MALDI.
Methods and chemicals
Glassware used for the reactions performed under dry conditions were first flame-dried under
vacuum. For lithiation reactions THF and diethyl ether were freshly distilled from
sodium/benzophenone, and toluene from sodium under a nitrogen atmosphere. For other
purposes, dichloromethane, diethyl ether, and hexane were distilled from P2O5 and stored over
4Å molecular sieves. DMF and acetonitrile were distilled from calcium hydride, and TEA from
potassium hydride, and were stored over 4Å molecular sieves under nitrogen. Sodium hydride
(60% in mineral oil) was washed three times with dry hexane prior to use. Commercially
available reagents were purchased from Acros, Aldrich, Fluka, or Merck, and employed as
received. Butyllithium (n-BuLi) was used as a 1.6 M solution in hexane. Flash column
chromatography was performed on aluminium oxide 90 (neutral, act. III) from Merck or silica
gel 60 (230–400 mesh) from Aldrich. The peptide sequences have been synthesised using
conventional solid-phase Fmoc-chemistry.
44 The IUPAC names of novel compounds were
generated using the software package ACD/IUPAC Name Pro, version 3.50.
5-Bromonicotinic acid (20)
To a suspension of 9 (0.47 g, 2.0 mmol) in dry diethyl ether (50 mL) at –80°C was added
n-BuLi (1.4 mL, 2.2 mmol, 1.1 equiv) under a nitrogen atmosphere. After 60 min at –80°C the
reaction mixture was poured onto a solution of CO2 in diethyl ether, and allowed to warm to68
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room temperature. The organic layer was washed with water (3x10 mL). The aqueous layer was
acidified and extracted with diethyl ether (3x10 mL). After washing with brine (10 mL), drying
over Na2SO4, and evaporation of the solvent, a white solid was obtained (0.33 g, 82%).
mp 191.7–192.8°C (lit.
12 195°C). 
1H NMR (DMSO–d6, 300 MHz) δ 7.80 (d, J = 8.2 Hz, 1H),
8.16 (dd, J = 8.2, 2.2 Hz, 1H), 8.85 (d, J = 2.2 Hz, 1H), 13.65 (br.s, 1H). 
13C NMR (DMSO–
d6, 75.5 MHz) δ 126.2 (s), 128.1 (d), 139.7 (d), 145.4 (s), 150.9 (d), 165.3 (s). HRMS calcd for
C5H4BrNO2 200.942, found 200.944.
2-Bromo-5-pyridinecarbaldehyde (22)
45
n-BuLi (62 mL, 99 mmol, 1.05 equiv) was added to a suspension of 9 (22.7 g, 94.1 mmol) in dry
diethyl ether (1 L) at –80°C under a nitrogen atmosphere. Dry DMF (8.0 mL, 103 mmol, 1.1
equiv) was added after stirring the suspension at –80°C for 1 h. After an additional hour at –80°C
the reaction mixture was allowed to warm to room temperature. Dilute HCl (1 M, 200 mL) was
added and the mixture was stirred for 15 min. After separation the aqueous layer was extracted
with diethyl ether (3x100 mL). The organic layer was washed with water (2x100 mL), brine
(100 mL), and dried over Na2SO4. Concentration by rotary evaporation yielded 22 as a light
brown solid (16.8 g, 96%). Rf = 0.49 (SiO2, hexane/ethyl acetate=3:1).
mp 100.7–102.2°C (lit.
12 100°C). 
1H NMR (CDCl3, 300 MHz) δ 7.67 (d, J = 8.4 Hz, 1H), 8.01
(dd, J = 8.4, 2.2 Hz, 1H), 8.82 (d, J = 2.2 Hz, 1H), 10.08 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz)
δ 129.0 (d), 130.5 (s), 137.5 (d), 148.2 (s), 152.4 (d), 189.4 (d). HRMS calcd for C6H4NOBr
184.948, found 184.949.
(6-Bromo-3-pyridinyl)methanol (21)
NaBH4 (2.28 g, 60.3 mmol, 0.5 equiv) was added to a solution of 22 (22.4 g, 120 mmol) in
methanol (400 mL) at 0°C. After 15 min concentrated HCl was added until pH 2 was reached.
Then saturated aqueous Na2CO3 solution was added until pH 10 was observed. The solution
was concentrated and extracted with ethyl acetate (4x100 mL). The organic layer was washed
with brine (75 mL) and dried over Na2SO4. When the solvent was evaporated, the product was
obtained as a yellow/brown oil that solidified upon standing (21.8 g, 96%). Rf = 0.12 (SiO2,
hexane/ethyl acetate=3:1).
mp 42.5–45.0°C (lit.
18 49–51°C). 
1H NMR (CDCl3, 300 MHz) δ 2.82 (br.s, 1H), 4.68 (s, 2H),
7.45 (d, J = 8.1 Hz, 1H), 7.57 (dd, J = 8.1, 2.2 Hz, 1H), 8.29 (s, 1H). 
13C NMR (CDCl3, 75.5
MHz)  δ 61.6 (t), 128.0 (d), 135.8 (s), 137.5 (d), 140.8 (s), 148.5 (d). HRMS calcd for
C6H6BrNO 186.963, found 186.964.
2-Bromo-5-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine (7)
18
To a stirred solution of 21 (21.8 g, 116 mmol) and TEA (25.0 mL, 179 mmol, 1.5 equiv) in dry
DMF (50 mL) was added tert-butyldimethylsilyl chloride (18.8 g, 125 mmol, 1.05 equiv). After
stirring for 15 min, protected from moisture, the mixture was diluted with diethyl ether (200 mL)
and washed with water (4x150 mL) and brine (150 mL). The organic phase was dried over
Na2SO4 and concentrated by rotary evaporation to yield a yellow/brown oil (35.0 g, quant.).
Purification by flash column chromatography over silica using a gradient of hexane/diethyl ether
(19:1 to 9:1) yielded 7 as colourless oil (29.8 g, 85%). Rf=0.43 (SiO2, hexane/diethyl
ether=9:1).69
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1H NMR (CDCl3, 300 MHz) δ 0.09 (s, 6H), 0.92 (s, 9H), 4.69 (s, 2H), 7.43 (d, J = 8.1 Hz, 1H),
7.52 (dd, J = 8.1, 2.2 Hz, 1H), 8.30 (d, J = 2.2 Hz, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.4
(q), 18.2 (s), 25.7 (q), 61.9 (t), 127.5 (d), 136.0 (s), 136.5 (d), 140.4 (s), 148.0 (d). HRMS calcd
for C12H20BrNOSi 303.048, found 303.048.
Ethyl (E)-3-(6-bromo-3-pyridinyl)-2-propenoate (24)
A solution of triethyl phosphonatoacetate (12.0 g, 53.6 mmol) in dry diethyl ether (50 mL) was
added over 10 min to a suspension of NaH (2.35 g, 58.8 mmol) in dry diethyl ether (130 mL) at
5°C. The icebath was removed and after 10 min a solution of 22 (9.97 g, 53.6 mmol) in dry
THF/diethyl ether (250 mL, 1:1) was added over 10 min. After 15 min water (150 mL) was
added and the phases were separated. The aqueous layer was extracted with diethyl ether (50
mL). The combined organic layer was washed with brine (100 mL) and dried over Na2SO4.
Evaporation of the solvent produced 24 as a brown solid. Recrystallisation from hexane yielded
analytically pure product as white needles (9.96 g pure E-isomer, 75%). From the concentrated
filtrate a further 1.24 g of 24 (85% combined yield) was obtained after flash column
chromatography over silica using hexane/diethyl ether (9:1) as the eluent. Rf = 0.53 (SiO2,
hexane/ethyl acetate=3:1).
mp 83.6–84.1°C. 
1H NMR (CDCl3, 300 MHz) δ 1.33 (t, J = 7.3 Hz, 3H), 4.26 (q, J = 7.3 Hz,
2H), 6.48 (d, J = 16.1 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 16.1 Hz, 1H), 7.67 (dd,
J = 8.4, 2.2 Hz, 1H), 8.47 (d, J = 2.2 Hz, 1H). 
13C NMR (CDCl3, 50.3 MHz) δ 14.2 (q), 60.9
(t), 121.2 (d), 128.3 (d), 129.5 (s), 136.2 (d), 139.3 (d), 143.4 (s), 149.8 (d), 166.0 (s). HRMS
calcd for C10H10NO2Br 254.989, found 254.990. Anal. calcd for C10H10BrNO2: C 46.90; H 3.90;
N 5.50; Br 31.20. Found: C 46.96; H 3.97; N 5.43; Br 31.18.
3-(6-Bromo-3-pyridinyl)-1-propanol (25)
To a stirred suspension of LiAlH4 (1.90 g, 50.1 mmol) in dry diethyl ether (75 mL) at 0°C was
added a solution of 24 (6.40 g, 25.0 mmol) in dry diethyl ether (75 mL) over 20 min. After 10
min at 0°C the reaction mixture was allowed to warm to room temperature and stirred for 45
min. The reaction was quenched by carefully adding Na2SO4⋅10H2O and stirring the mixture for
1 h. The solids were removed by filtration and washed with diethyl ether. Evaporation of the
solvent yielded 25 as a light brown oil (3.27 g, 61%), which was used without any further
purification. Rf = 0.29 (SiO2, hexane/ethyl acetate=1:1).
1H NMR (CDCl3, 300 MHz) δ 1.84 (m, 2H), 2.68 (t, J = 7.9 Hz, 2H), 3.66 (t, J = 6.0 Hz, 2H),
7.38 (s, 1H), 7.39 (s, 1H), 8.19 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ 28.2 (t), 33.3 (t), 60.9
(t), 127.6 (d), 136.7 (s), 138.8 (d), 139.0 (s), 149.8 (d). HRMS calcd for C8H10NOBr 214.995,
found 214.996.
2-Bromo-5-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)pyridine (8)
The same procedure was used as described for 7. Starting from 25 (12.7 g, 58.7 mmol) the
product was obtained as a brown oil (18.6 g, 96%). Purification by flash column
chromatography over silica using a gradient of hexane/diethyl ether (19:1 to 9:1) yielded 8 as a
light brown oil (15.7 g, 81%). Rf = 0.43 (Al2O3, hexane/diethyl ether=19:1).
1H NMR (CDCl3, 300 MHz) δ 0.03 (s, 6H), 0.89 (s, 9H), 1.79 (m, 2H), 2.64 (t, J = 7.9 Hz, 2H),70
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3.60 (t, J = 6.0 Hz, 2H), 7.36 (s, 1H), 7.37 (s, 1H), 8.20 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ
–5.4 (q), 18.2 (s), 25.8 (q), 28.3 (t), 33.6 (t), 61.4 (t), 127.5 (d), 136.7 (s), 138.6 (d), 139.2 (s),
150.2 (d). MS CI [M+H]
+ calcd for C14H25BrNOSi m/z 330.1, found 330.2.
46
5-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-2-pyridinecarbaldehyde (29)
45
Method A: To a solution of 7 (10.4 g, 34.3 mmol) in dry THF (450 mL) at –80°C under a
nitrogen atmosphere was slowly added n-BuLi (24.0 mL, 38.4 mmol, 1.1 equiv). After 40 min
at –80°C dry DMF (3.0 mL, 39 mmol, 1.1 equiv) was added to the red solution. The reaction
mixture was allowed to warm to room temperature after 1 h at –80°C. Brine (100mL) and
diethyl ether (50 mL) were added and the layers were separated. The aqueous layer was
extracted with diethyl ether (50 mL). The combined organic layers were washed with brine (50
mL) and dried over Na2SO4. Concentration by rotary evaporation afforded a light brown oil
(8.98 g).
47 Purification by flash column chromatography over silica using hexane/ethyl acetate
(9:1) as the eluent yielded 6.88 g (80%) of 29 as a light brown oil. Rf = 0.54 (SiO2, hexane/ethyl
acetate=3:1).
Method B: To a solution of isopropylmagnesium bromide (11 mL, 22 mmol, 2 M in THF) in dry
THF (10 mL) was added 7 (6.02 g, 19.9 mmol). Heat was evolved during the reaction and after
1 h dry DMF (1.7 mL, 22 mmol) was added. The reaction was quenched after an additional
hour by the addition of a saturated aqueous NH4Cl solution (20 mL). Diethyl ether was added
and the layers separated. The aqueous layer was extracted with diethyl ether (2x5 mL). The
combined organic layers were washed with water (3x5 mL), brine (5mL), and dried over
Na2SO4. Evaporation of the solvent furnished an orange/brown oil (5.12 g).
48
1H NMR (CDCl3, 300 MHz) δ 0.12 (s, 6H), 0.94 (s, 9H), 4.84 (s, 2H), 7.82 (d, J = 8.1 Hz, 1H),
7.94 (d, J = 8.1 Hz, 1H), 8.72 (s, 1H), 10.06 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.4 (q),
18.2 (s), 25.8 (q), 62.4 (t), 121,9 (d), 134.4 (d), 141.7 (s), 148.0 (d), 151.8 (s), 193.1 (d).
HRMS calcd for C13H21NO2Si 251.134, found 251.133.
5-(3-{[tert-Butyl(dimethyl)silyl]oxy}propyl)-2-pyridinecarbaldehyde (30)
Starting from 8 (9.90 g, 30.0 mmol) and following Method A as described for 29, the product
was obtained as a light brown oil (6.03 g, 72%) after purification by flash column
chromatography over silica using a gradient of hexane/diethyl ether (9:1 to 3:1).
49 Rf = 0.25
(SiO2, hexane/diethyl ether=9:1).
1H NMR (CDCl3, 300 MHz) δ 0.04 (s, 6H), 0.89 (s, 9H), 1.85 (m, 2H), 2.79 (t, J = 7.9 Hz, 2H),
3.62 (t, J = 6.0 Hz, 2H), 7.68 (dd, J = 7.7, 1.5 Hz, 1H), 7.88 (d, J = 7.7 Hz, 1H), 8.61 (d, J =
1.5 Hz, 1H), 10.04 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.5 (q), 18.2 (s), 25.8 (q), 29.4 (t),
33.5 (t), 61.5 (t), 121.4 (d), 136.7 (d), 142.8 (s), 150.5 (d), 150.9 (s), 193.0 (d). MS CI [M+H]
+
calcd for C15H26NO2Si m/z 280.2, found 280.3.
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[5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-pyridinyl]methanol (31)
To a solution of 29 (5.87 g, 23.3 mmol) in methanol (90 mL) at 0°C was slowly added NaBH4
(0.44 g, 12 mmol, 0.5 equiv). The reaction mixture was allowed to warm to room temperature
and after 30 min dilute HCl (2 M) was added until pH 7, followed by a saturated aqueous
Na2CO3 solution (20 mL). The solvent was evaporated and the residue was extracted with71
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diethyl ether (3x30 mL). The organic layer was washed with brine (40 mL), dried over Na2SO4,
and concentrated by rotary evaporation to yield 31 as a light yellow oil (5.73 g, 97%). The
crude product was used without any further purification.
1H NMR (CDCl3, 300 MHz) δ 0.09 (s, 6H), 0.92 (s, 9H), 3.93 (br.s, 1H), 4.74 (s, 4H), 7.21 (d, J
= 8.1 Hz, 1H), 7.64 (d, J = 8.1 Hz, 1Hz), 8.48 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.3 (q),
18.3 (s), 25.8 (q), 62.5 (t), 64.1 (t), 120.2 (d), 134.9 (s), 135.3 (d), 146.5 (d), 158.1 (s). HRMS
calcd for C13H23NO2Si 253.150, found 253.149.
[5-(3-{[tert-Butyl(dimethyl)silyl]oxy}propyl)-2-pyridinyl]methanol (32)
The same procedure was used as described for 31. Starting from 30 (3.91 g, 14.0 mmol) the
product was obtained as a light brown oil (3.91 g, 99%). Rf  = 0.20 (SiO2, hexane/ethyl
acetate=3:1).
1H NMR (CDCl3, 300 MHz) δ 0.04 (s, 6H), 0.89 (s, 9H), 1.80 (m, 2H), 2.68 (t, J = 7.9 Hz, 2H),
3.47 (br.s, 1H), 3.61 (t, J = 6.0 Hz, 2H), 4.71 (s, 2H), 7.15 (d, J = 8.1 Hz, 1H), 7.50 (dd, J =
8.1, 1.8 Hz, 1H), 8.37 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.4 (q), 18.2 (s), 25.9 (q), 28.8
(t), 34.0 (t), 61.8 (t), 64.1 (t), 120.3 (d), 136.1 (s), 136.8 (d), 148.5 (d), 156.8 (s). MS CI
[M+H]
+ calcd for C15H28NO2Si m/z 282.2, found 282.3.
46
5-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-2-(chloromethyl)pyridine (5)
To a solution of 31 (5.98 g, 23.6 mmol) and TEA (6.6 mL, 47 mmol, 2 equiv) in dry CH2Cl2
(100 mL) at 0°C under a nitrogen atmosphere was slowly added SOCl2 (2.6 mL, 35 mmol, 1.5
equiv). The reaction mixture was allowed to warm to room temperature and stirred overnight.
Saturated aqueous NaHCO3 solution (100 mL) was added. After separation the aqueous layer
was extracted with CH2Cl2 (3x40 mL). The combined organic layers were washed with brine (40
mL), dried over Na2SO4, and the solvent was evaporated by rotary evaporation. The product
was obtained as a dark red/brown oil (6.08 g, 95%). The crude product was purified over
alumina using hexane/ethyl acetate/TEA (200:9:1) as the eluent to provide pure 5 (4.24 g,
66%). Rf = 0.32 (Al2O3, hexane/diethyl ether=9:1).
1H NMR (CDCl3, 300 MHz) δ 0.10 (s, 6H), 0.93 (s, 9H), 4.66 (s, 2H), 4.75 (s, 2H), 7.43 (d, J =
8.1 Hz, 1H), 7.69 (dd, J = 8.1, 2.2 Hz, 1H), 8.51 (d, J = 2.2 Hz, 1H). 
13C NMR (CDCl3, 75.5
MHz) δ –5.4 (q), 18.2 (s), 25.8 (q), 47.5 (t), 62.5 (t), 120.7 (d), 134.5 (s), 134.6 (d), 147.3 (d),
160.5 (s). HRMS calcd for C13H22ClNOSi 271.116, found 271.118.
5-(3-{[tert-Butyl(dimethyl)silyl]oxy}propyl)-2-(chloromethyl)pyridine (6)
The same procedure was used as described for 5. Starting from 32 (3.91 g, 14.0 mmol) flash
column chromatography over alumina using a gradient of hexane/diethyl ether (9:1 to 5:1)
afforded 6 as a light brown oil (3.14 g, 75%). Rf = 0.31 (SiO2, hexane/diethyl ether=9:1).
1H NMR (CDCl3, 300 MHz) δ 0.04 (s, 6H), 0.89 (s, 9H), 1.81 (m, 2H), 2.69 (t, J = 7.9 Hz, 2H),
3.62 (t, J = 6.0 Hz, 2H), 4.64 (s, 2H), 7.36 (d, J = 7.9 Hz, 1H), 7.53 (dd, J = 7.9, 2.0 Hz, 1H),
8.41 (d, J = 2.0 Hz, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.4 (q), 18.2 (s), 25.8 (q), 28.8 (t),
33.8 (t), 46.6 (t), 61.7 (t), 122.3 (d), 136.9 (d), 136.9 (s), 149.6 (d), 153.9 (s). MS CI [M+H]
+
calcd for C15H27ClNOSi m/z 300.2, found 300.5.72
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Bis[5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-pyridinyl]methanone (33)
45
To a solution of 7 (6.36 g, 21.0 mmol) in dry THF (250 mL) at –80°C was added n-BuLi (36.0
mL, 22.5 mmol, 1.07 equiv) under a nitrogen atmosphere. After 40 min at –80°C a solution of
29 (5.29 g, 21.0 mmol) in dry THF (50 mL) was added to the red reaction mixture. The
blue/purple reaction mixture was stirred at –70°C for 1 h, and then allowed to warm to room
temperature. Brine (100mL) and diethyl ether (50 mL) were added and the layers were
separated. The aqueous layer was extracted with diethyl ether (2x50 mL). The combined
organic layers were washed with brine (50 mL), dried over Na2SO4, and concentrated by rotary
evaporation to yield an orange/brown oil. This residue was then dissolved in chloroform (130
mL). Activated MnO2 (4.4 g, 43 mmol) was added and the suspension was heated under reflux.
At 1 h intervals 13.2 g MnO2 was added in portions of 4.4 g. The reaction mixture was refluxed
overnight. After evaporation of the solvent the residue was filtered through Celite and washed
with diethyl ether. The filtrate was dried over Na2SO4 and concentrated by rotary evaporation to
yield a brown solid (8.97 g, 90%).
47 The crude product was purified over silica using
hexane/ethyl acetate (5:1) as the eluent (7.76 g, 78%). Rf  = 0.40 (SiO2, hexane/ethyl
acetate=3:1).
1H NMR (CDCl3, 300 MHz) δ 0.12 (s, 12H), 0.94 (s, 18H), 4.84 (s, 4H), 7.84 (d, J = 8.1 Hz,
2H), 8.08 (d, J = 8.1 Hz, 2H), 8.69 (s, 2H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.4 (q), 18.2 (s),
25.8 (q), 62.4 (t), 124.9 (d), 134.0 (d), 139.8 (s), 147.0 (d), 153.2 (s), 192.5 (s). HRMS calcd
for C25H40N2O3Si2 472.258, found 472.258.
Bis[5-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)-2-pyridinyl]methanone (34)
The same procedure was used as described for 33. Starting from 8 (5.11 g, 15.4 mmol) and 30
(4.47 g, 16.0 mmol) ketone 34 was obtained as a light brown solid (6.49 g, 80%) after flash
column chromatography over silica using hexane/ethyl acetate (6:1) as the eluent. Rf = 0.42
(SiO2, hexane/ethyl acetate=3:1).
1H NMR (CDCl3, 300 MHz) δ 0.05 (s, 12H), 0.90 (s, 18H), 1.85 (m, 4H), 2.78 (t, J = 7.9 Hz,
4H), 3.65 (t, J = 6.0 Hz, 4H), 7.68 (dd, J = 8.1, 1.5 Hz, 2H), 8.02 (d, J = 8.1 Hz, 2H), 8.58
(d, J = 1.5 Hz, 2H). 
13C NMR (CDCl3, 50.3 MHz) δ –5.4 (q), 18.2 (s), 25.8 (q), 29.2 (t), 33.6
(t), 61.7 (t), 125.1 (d), 136.4 (d), 140.9 (s), 149.4 (d), 152.2 (s), 192.5 (s). HRMS calcd for
C29H48N2O3Si2 528.320, found 528.321.
Bis[5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-pyridinyl]methanone oxime (35)
A mixture of hydroxylammonium chloride (2.60 g, 37.4 mmol, 2 equiv) and TEA (7.8 mL, 56
mmol, 3 equiv) in ethanol (50 mL) was stirred at room temperature for 0.5 h. The salts were
removed by filtration and the filtrate was added to 33 (8.84 g, 18.7 mmol). After heating under
reflux for 1 h the solvent was removed by rotary evaporation, and the residue was extracted
with ethyl acetate (2x50 mL). The organic layer was washed with brine (25 mL), dried over
Na2SO4, and concentrated to give a brown oil that solidified on standing (7.51 g, 83%). The
crude product was recrystallised from ethanol/water to yield analytically pure 35 as white plates.
mp 106.3–107.4°C. 
1H NMR (CDCl3, 300 MHz) δ 0.11 (s, 6H), 0.12 (s, 6H), 0.93 (s, 9H), 0.94
(s, 9H), 4.81 (s, 4H), 7.64 (d, J = 8.4 Hz, 1H), 7.75 (dd, J = 8.1, 2.0 Hz, 1H), 7.80 (dd, J =
8.4, 2.0 Hz, 2H), 8.55 (s, 1H), 8.59 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.4 (q), 5.3 (q),73
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18.3 (s), 25.8 (q), 25.9 (q), 62.3 (t), 62.6 (t), 123.8 (d), 124.7 (d), 134.9 (d), 135.2 (d), 136.6
(s), 138.4 (s), 143.6 (d), 146.5 (d), 150.0 (s), 150.1 (s), 153.5 (s). HRMS calcd for
C25H41N3O3Si2 487.269, found 487.268. Anal. calcd for C25H41N3O3Si2: C 61.56; H 8.47; N
8.61. Found: C 61.48; H 8.58; N 8.50.
Bis[5-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)-2-pyridinyl]methanone oxime (36)
The same procedure was used as described for 35. Starting from 34 (1.12 g, 2.06 mmol) the
product was obtained as a brown oil that solidified on standing (1.06 g, 93%). The crude
product was recrystallised from ethanol/water to yield analytically pure 36 as white plates.
mp 110.1–110.4°C. 
1H NMR (CDCl3, 300 MHz) δ 0.05 (s, 12H), 0.90 (s, 18H), 1.85 (m, 4H),
2.76 (m, 4H), 3.64 (m, 4H), 7.57 (d, J = 8.1 Hz, 1H), 7.62 (dd, J = 8.1, 2.0 Hz, 1H), 7.67 (dd,
J = 8.1, 2.0 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 8.44 (d, J = 2.0 Hz, 1H), 8.47 (d, J = 2.0 Hz,
1H). 
13C NMR (CDCl3, 50.3 MHz) δ –5.3 (q), 18.2 (s), 25.9 (q), 29.0 (t), 29.2 (t), 33.7 (t), 33.9
(t), 61.5 (t), 61.8 (t), 123.9 (d), 124.8 (d), 137.1 (d), 137.5 (s), 137.6 (d), 139.4 (s), 145.7 (d),
148.6 (d), 150.1 (s), 152.2 (s). HRMS calcd for C29H49N3O3Si2 543.331, found 543.333. Anal.
calcd for C29H49N3O3Si2: C 64.04; H 9.08; N 7.73. Found: C 63.97; H 9.03; N 7.70.
Bis[5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-pyridinyl]methylamine (3)
A mixture of 35 (2.00 g, 4.10 mmol) and NH4OAc (0.42 g, 5.5 mmol, 1.3 equiv) in ethanol (25
mL) and NH4OH (15 mL, 25% v/v) was heated under reflux. Zinc powder (1.34 g, 20.5 mmol,
5 equiv) was added in portions through the condenser at 15 min intervals over 2 h. After
refluxing for an additional hour the reaction mixture was cooled to room temperature and
concentrated NaOH was added until pH∼12 was reached. After filtration through Celite and
washing with diethyl ether the layers were separated. The aqueous layer was extracted with
diethyl ether (2x15 mL). The organic phase was washed with brine (15 mL), dried over Na2SO4,
and concentrated in vacuo to yield a green/brown viscous oil (1.91 g, 99%).
1H NMR (CDCl3, 300 MHz) δ 0.06 (s, 12H), 0.90 (s, 18H), 2.34 (br.s, 2H), 4.70 (s, 4H), 5.31 (s,
1H), 7.33 (d, J = 8.1 Hz, 2H), 7.58 (dd, J = 8.1, 2.2 Hz, 2H), 8.48 (d, J = 2.2 Hz, 2H). 
13C
NMR (CDCl3, 75.5 MHz) δ –5.4 (q), 18.3 (s), 25.8 (q), 61.8 (d), 62.5 (t), 121.3 (d), 134.7 (d),
135.0 (s), 147.2 (d), 161.5 (s). MS CI [M+H]
+ calcd for C25H44N3O2Si2  m/z 474.3, found
474.0.
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Bis[5-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)-2-pyridinyl]methylamine (4)
Prepared following the procedure as described for 3, starting from 36 (1.42 g, 2.61 mmol)
amine 4 was obtained as a green/brown viscous oil (1.34 g, 97%).
1H NMR (CDCl3, 300 MHz) δ 0.02 (s, 12H), 0.87 (s, 18H), 1.77 (m, 4H), 2.73 (br.s, 2H), 2.63
(t, J = 7.7 Hz, 4H), 3.60 (t, J = 6.2 Hz, 4H), 5.26 (s, 1H), 7.26 (d, J = 7.9 Hz, 2H), 7.43 (dd, J
= 7.9, 2.0 Hz, 2H), 8.38 (d, J = 2.0 Hz, 2H). 
13C NMR (CDCl3, 50.3 MHz) δ –5.5 (q), 18.0 (s),
25.7 (q), 28.6 (t), 33.8 (t), 61.4 (d), 61.6 (t), 121.1 (d), 135.5 (s), 136.5 (d), 149.0 (d), 160.0
(s). HRMS calcd for C29H51N3O2Si2 529.352, found 529.350.74
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N-{Bis[5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-pyridinyl]methyl}-N,N-bis{[5-
({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-pyridinyl]methyl}amine (1)
A mixture of 3 (0.21 g, 0.44 mmol), 5 (0.36 g, 1.3 mmol, 3 equiv), and Cs2CO3 (0.44 g, 1.4
mmol, 3 equiv) in dry acetonitrile (30 mL) was heated under reflux under a nitrogen
atmosphere for 60 h. The reaction mixture was filtered through Celite, washed with diethyl
ether, and concentrated in vacuo. Purification by flash chromatography over alumina using a
gradient of hexane/ethyl acetate/TEA (20:9:1 to 0:9:1) afforded 1 as a brown viscous oil (0.23 g,
56%).
1H NMR (CDCl3, 300 MHz) δ 0.08 (s, 24H), 0.91 (s, 36H), 3.92 (s, 4H), 4.69 (s, 4H), 4.70 (s,
4H), 5.30 (2, 1H), 7.61 (m, 8H), 8.43 (s, 2H), 8.49 (s, 2H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.4
(q), –5.4 (q), 18.2 (s), 25.8 (q), 56.6 (t), 62.6 (t), 62.6 (t), 71.0 (d), 122.3 (d), 123.4 (d), 134.1
(d), 134.4 (d), 134.5 (s), 134.7 (s), 147.0 (d), 147.2 (d), 158.6 (s), 158.7 (s). ESI-MS [M+H]
+
calcd for C51H86N5O4Si4 m/z 944.8, found 944.6.
N-{Bis[5-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)-2-pyridinyl]methyl}-N,N-bis{[5-
(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)-2-pyridinyl]methyl}amine (2)
Following the procedure for 1, starting from 4 (0.58 g, 1.1 mmol) and 6 (0.98 g, 3.3 mmol, 3
equiv) the product was obtained as a brown viscous oil (0.55 g, 48%).
1H NMR (CDCl3, 300 MHz) δ 0.02 (s, 24H), 0.87 (s, 36H), 1.77 (m, 8H), 2.61 (m, 8H), 3.60
(m, 8H), 3.87 (s, 4H), 5.24 (s, 1H), 7.41 (dd, J = 7.9, 2.0 Hz, 2H), 7.46 (dd, J = 7.9, 2.0 Hz,
2H), 7.51 (d, J = 7.9 Hz, 2H), 7.59 (d, J = 7.9 Hz, 2H), 8.30 (d, J = 2.0 Hz, 2H), 8.37 (d, J =
2.0 Hz, 2H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.5 (q), 18.0 (s), 25.7 (q), 28.6 (t), 28.7 (t), 33.7
(t), 33.9 (t), 56.7 (t), 61.7 (t), 61.8 (t), 71.2 (d), 122.3 (d), 123.3 (d), 135.0 (s), 135.2 (s), 135.9
(d), 136.0 (d), 148.8 (d), 149.1 (d), 157.2 (s), 157.5 (s). ESI-MS [M+H]
+ calcd for
C59H102N5O4Si4 m/z 1056.7, found 1056.9.
{6-[({Bis[5-(hydroxymethyl)-2-pyridinyl]methyl}{[5-(hydroxymethyl)-2-
pyridinyl]methyl}amino)methyl]-3-pyridinyl}methanol (43)
Dilute HCl (2 mL, 1 M) was added to a solution of 1 (0.22 g, 0.23 mmol) in ethanol (10 mL).
After 0.5 h the reaction mixture was extracted with diethyl ether (3x5 mL). The aqueous layer
was neutralised with solid Na2CO3 and lyophilised or azeotropically removed with ethanol. The
residue was taken up in dry ethanol, and after filtration and evaporation of the solvent 43 was
obtained as a viscous brown, hygroscopic oil (0.12 g, 100%).
1H NMR (CD3OD, 300 MHz) δ 3.86 (s, 4H), 4.58 (s, 4H), 4.91 (s, 4H), 5.32 (s, 1H), 7.39 (d, J
= 8.1 Hz, 2H), 7.63 (d, J = 8.1 Hz, 4H), 7.73 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H),
8.38 (s, 2H), 8.49 (s, 2H). 
13C NMR (CD3OD, 75.5 MHz) δ 58.3 (t), 62.3 (t), 62.4 (t), 74.3 (d),
124.6 (d), 125.3 (d), 137.0 (d), 137.0 (d), 137.1 (s), 137.7 (s), 148.7 (d), 149.3 (d), 158.8 (s),
159.4 (s). ESI-MS [M+H]
+ calcd for C27H30N5O4 m/z 488.2, found 488.0.
3-(6-{(Bis{[5-(3-hydroxypropyl)-2-pyridinyl]methyl}amino)[5-(3-hydroxypropyl)-2-
pyridinyl]methyl}-3-pyridinyl)-1-propanol (44)
The same procedure was used as described for 43. Starting from 2 (0.30 g, 0.28 mmol) 44 was
obtained as a viscous brown, hygroscopic oil (0.16 g, 95%).75
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1H NMR (CD3OD, 300 MHz) δ 1.78 (m, 8H), 2.65 (m, 8H), 3.55 (m, 8H), 3.85 (s, 4H), 5.24 (s,
1H), 7.44 (d, J = 8.1 Hz, 2H), 7.54 (dd, J = 8.1, 1.8 Hz, 2H), 7.61 (s, 2H), 7.62 (s, 2H), 8.22
(d, J = 1.8 Hz, 2H), 8.33 (s, 2H). 
13C NMR (CD3OD, 50.3 MHz) δ 29.7 (t), 34.9 (t), 35.0 (t),
58.4 (t), 61.8 (t), 74.2 (d), 124.4 (d), 125.3 (d), 137.6 (s), 138.2 (s), 138.3 (d), 149.5 (d), 150.1
(d), 157.7 (s), 158.3 (s). MS CI [M+H]
+ calcd for C35H46N5O4 m/z 600.3, found 600.6.
Attempted methylation at the doubly benzylic position in 1 to furnish 48
To 1 (160 mg, 0.17 mmol) in dry THF (2 mL) at –80°C was added n-BuLi (120 µL, 0.19 mmol,
1.1 equiv). The solution changed from brown to red. After 15 min at –80°C TMEDA (30 µL,
0.20 mmol, 1.2 equiv) was added, followed by MeI (16 µL, 0.26 mmol, 1.5 equiv) after stirring
at this temperature for 15 min. After 1 h at  –80°C the reaction mixture was allowed to warm to
–40°C over 30 min. A sample was taken, quenched with MeOH/water and analysed by ESI-MS
to reveal only [M+H]
+, [M+Li]
+, and a trace of [M+Na]
+ of the starting material. No product
(48) was present. The reaction mixture was cooled again to –80°C, MeI (20 µL) was added, and
the mixture was allowed to warm to room temperature overnight. Again, 48 could not be
detected by mass analysis, not even after stirring at room temperature for another 24 h. After
workup pure starting material (160 mg) was recovered.
[5-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-2-pyridinyl](2-pyridinyl)methanone (49)
To isopropylmagnesium chloride (11 mL, 22 mmol, 2 M in THF) was added 7 (6.04 g, 20
mmol). When no more heat was evolved, THF (15 mL) was added and the solution stirred at
room temperature for 1 h. A solution of 2-cyanopyridine (2.10 g, 20 mmol) in THF (20mL) was
added and after 1 h the reaction mixture was poured into a saturated aqueous NH4Cl solution.
Diethyl ether was added and after phase separation the aqueous layer was extracted with
diethyl ether (3x10 mL). The organic layer was washed with brine (15 mL), dried over Na2SO4,
and concentrated in vacuo to yield a brown oil (6.83 g).
50 The crude product was purified by
flash chromatography over silica using a gradient of hexane/diethyl ether (1:1 to 1:4) to afford
49 as a yellow viscous oil (3.46 g, 63%).
1H NMR (CDCl3, 300 MHz) δ 0.11 (s, 6H), 0.93 (s, 9H), 4.84 (s, 2H), 7.46 (m, 1H), 7.87 (m,
2H), 8.08 (m, 2H), 8.69 (s, 1H), 8.74 (d, J = 4.8 Hz, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.5
(q), 18.1 (s), 25.7 (q), 62.4 (t), 124.9 (d), 125.1 (d), 126.2 (d), 134.0 (d), 136.6 (d), 139.9 (s),
147.0 (d), 149.0 (d), 152.8 (s), 154.4 (s) 192.7 (s). HRMS calcd for C18H24N2O2Si 328.161,
found 328.158.
[5-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-2-pyridinyl](2-pyridinyl)methanone
oxime (50)
The same procedure was used as described for 35. Starting from 49 (0.54 g, 1.6 mmol) the
product was obtained as a light brown oil (0.55 g, 100%). The crude product was purified by
flash chromatography over silica using diethyl ether as the eluent to yield 50 as a viscous
colourless oil (0.45 g, 82%).
1H NMR (CDCl3, 300 MHz) δ 0.12 (s, 6H), 0.94 (s, 9H), 4.76 (s, 2H), 7.30 (m, 1H), 7.56 (d, J
= 8.1 Hz, 1H), 7.75 (m, 3H), 8.55 (m, 2H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.5 (q), 18.2 (s),
25.7 (q), 62.3 (t), 123.8 (d), 124.7 (d), 126.2 (d), 134.9 (d), 136.6 (d), 139.5 (s), 147.0 (d),
149.0 (d), 150.1 (s), 151.4 (s) 153.9 (s). HRMS calcd for C18H25N3O2Si 343.172, found
343.172.76
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Benzyl 3-pyridinylmethyl sulphide (54a)
SOCl2 (0.16 mL, 2.2 mmol) was slowly added to 52 (0.22 g, 2.0 mmol) in dry CH2Cl2 (5 mL) at
0°C. To the formed 53a⋅HCl was added a solution of benzyl mercaptan (0.24 mL, 2.0 mmol) in
dilute NaOH (8 mL, 1M). The yellow reaction mixture was allowed to warm to room
temperature and stirred for 4 h. The phases were separated and the aqueous layer was
extracted with CH2Cl2 (2x5 mL). The organic layer was washed with brine (10 mL), dried over
Na2SO4, and concentrated in vacuo to yield a yellow liquid (0.42 g, 99%). R f = 0.50 (Al2O3,
hexane/ethyl acetate=3:1).
1H NMR (CDCl3, 300 MHz) δ 3.56 (s, 2H), 3.60 (s, 2H), 7.28 (m, 6H), 7.62 (dd, J = 5.9, 1.8
Hz, 1H), 8.48 (m, 2H). MS CI [M+H]
+
 calcd for C13H14NS m/z 216.1, found 216.2.
4-Methylphenyl 3-pyridinylmethyl sulphide (54b)
The same procedure was used as described for 54a, using p-thiocresol (0.25 g, 2.0 mmol) to
afford 54b as a light brown oil (0.38 g, 90%).
1H NMR (CDCl3, 200 MHz) δ 2.30 (s, 3H), 4.01 (s, 2H), 7.13 (m, 5H), 7.55 (m, 1H), 8.39 (d, J
= 1.9 Hz, 1H), 8.45 (m, 1H). MS CI [M+H]
+ calcd for C13H14NSO2 m/z 216.1, found 216.1.
Ethyl 2-[(3-pyridinylmethyl)sulphanyl]acetate (56)
51
3-(Chloromethyl)pyridine hydrochloride (53a) was prepared as described for 54a, and then
isolated by filtration. A warm solution of 53a (0.33 g, 2.0 mmol) in absolute ethanol (10 mL)
was added to a refluxing solution of thiourea (0.17 g, 2.2 mmol) in absolute ethanol (10 mL).
After heating for 2.5 h the reaction mixture was allowed to cool to room temperature. The
product was precipitated by the addition of dry diethyl ether to give 55 as white solid (0.41 g,
86%).
1H NMR (D2O, 300 MHz) δ 4.52 (s, 2H), 7.96 (m, 1H), 8.56 (d, J = 8.1 Hz, 1H), 8.65 (d, J =
5.9 Hz, 1H), 8.77 (s, 1H). 
13C NMR (D2O, 50.3 MHz) δ 29.9 (t), 126.0 (d), 134.4 (s), 139.3 (d),
139.5 (d), 145.6 (d). MS EI [M]
+. calcd for C7H9N3S m/z 167.1, found 167.2.
Under a nitrogen atmosphere concentrated NaOH (0.31 mL) was added dropwise to a solution
of 55 (0.23 g, 0.95 mmol) in water (1 mL). After heating at 50°C for 15 min ethyl bromoacetate
(0.11 mL, 0.95 mmol) in CH2Cl2 (3 mL) and a catalytic amount of tetrabutylammonium
bromide were added. After 18 h the phases were separated and the aqueous layer was
extracted with CH2Cl2 (3x3 mL). The organic layer was washed with brine and dried over
Na2SO4. Evaporation of the solvent afforded 56 as a brown oil (0.19 g, 95%).
1H NMR (CDCl3, 200 MHz) δ 1.28 (t, J = 7.2, 3H), 3.04 (s, 2H), 3.82 (s, 2H), 4.16 (q, J = 7.2
Hz, 2H), 7.25 (m, 1H), 7.69 (m, 1H), 8.52 (s, 1H), 8.56 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ
13.9 (q), 32.0 (t), 33.1 (t), 61.2 (t), 123.3 (d), 132.9 (s), 136.4 (d), 148.4 (d), 150.0 (d), 169.8
(s). MS CI [M+H]
+ calcd for C10H14NSO2 m/z 212.1, found 212.1.
Methyl N-acetylcysteine (57)
SOCl2 (1.0 mL, 14 mmol) was slowly added to absolute methanol (40 mL) at –20°C. After 15
min a solution of N-acetylcysteine (2.01 g, 12.3 mmol) in absolute methanol (10 mL) was
added dropwise. When the addition was complete, the reaction mixture was allowed to warm to
room temperature. After 2.5 h the solvent was evaporated and the residue triturated with ethyl
acetate. After removal of the solvent the product was obtained as a white solid (1.33 g, 61%).
1H NMR (CDCl3, 300 MHz) δ 1.33 (t, J = 9.0 Hz, 1H), 2.06 (s, 3H), 3.00 (m, 2H), 3.78 (s, 3H),77
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4.88 (m, 1H), 6.40 (br.s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ 23.1 (q), 26.8 (t), 52.8 (q), 53.5
(d), 169.9 (s), 170.6 (s). HRMS calcd for C6H11NO3S 177.046, found 177.045.
Ethyl 2-(3-pyridinylmethoxy)acetate (58a)
To a stirred suspension of NaH (2.25 g, 56 mmol) in dry DMF (35 mL) was slowly added 52
(5.46 g, 50 mmol). After stirring at room temperature for 40 min the reaction mixture was
cooled to 0°C. Ethyl bromoacetate (5.9 mL, 53 mmol) was added neat and the mixture was
stirred for 18 h at room temperature. Ethyl acetate was added and the solution was washed with
water (5x20 mL), brine (20 mL), and dried over Na2SO4. Evaporation of the solvent yielded the
product as a brown oil (7.45 g, 76%).
1H NMR (CDCl3, 300 MHz) δ 1.28 (t, J = 7.0 Hz, 3H), 4.11 (s, 2H), 4.23 (t, J = 7.0 Hz, 2H),
4.64 (s, 2H), 7.29 (m, 1H), 7.74 (d, J = 7.7 Hz, 1H), 8.55 (d, J = 1.5 Hz, 1H), 8.59 (s, 1H).
13C NMR (CDCl3, 50.3 MHz) δ 13.9 (q), 60.9 (t), 67.4 (t), 70.7 (t), 124.6 (d), 135.7 (d), 138.8
(s), 148.4 (d), 148.5 (d), 169.8 (s). MS CI [M+H]
+ calcd for C10H14NO3 m/z 196.1, found
196.2.
4-Methoxybenzyl 3-pyridinylmethyl ether (58b)
The same procedure was used as described for 58a, using p-methoxybenzyl bromide
52 to afford
58b as a light brown oil (77%).
1H NMR (CDCl3, 200 MHz) δ 3.81 (s, 3H), 4.51 (s, 2H), 4.53 (s, 2H), 6.89 (d, J = 8.4 Hz, 2H),
7.27 (m, 1H), 7.29 (d, J = 8.4 Hz, 2H), 7.69 (m, 1H), 8.54 (d, J = 1.3 Hz, 1H), 8.56 (s, 1H).
MS CI [M+H]
+ calcd for C14H16NO2 m/z 230.1, found 230.2.
3-Pyridinylmethyl 2,2,2-trichloroethanimidoate (59)
To a stirred mixture of 52 (1.11 g, 10 mmol) and a catalytic amount of NaH in dry diethyl ether
(25 mL) was slowly added trichloroacetonitrile (1.05 mL, 10 mmol). After 0.5 h a small amount
of MeOH was added, the mixture was filtered through Celite and concentrated to dryness to
provide 59 as a light brown liquid (2.35 g, 93%).
1H NMR (CDCl3, 300 MHz) δ 5.35 (s, 2H), 7.31 (dd, J = 7.7, 4.8 Hz, 1H), 7.76 (d, J = 7.7 Hz,
1H), 8.45 (s, 1H), 8.58 (dd, J = 4.8, 1.6 Hz, 1H), 8.68 (d, J = 1.6 Hz, 1H). MS CI [M+H]
+
calcd for C8H8Cl3N2O m/z 253.0, found 253.1.
3-Pyridinylmethyl 2-(benzylsulphanyl)acetate (61a)
To a solution of 52 (0.55 g, 5.0 mmol) and TEA (0.77 mL, 5.5 mmol) in dry CH2Cl2 (10 mL) at
0°C was added dropwise a solution of chloroacetyl chloride (0.50 mL, 6.3 mmol) in dry CH2Cl2
(10 mL). After 1.5 h at room temperature the reaction mixture was washed with water (3x5
mL), brine (5 mL), and dried over Na2SO4. Evaporation of the solvent furnished the
intermediate chloroacetic ester 60 as a brown oil.
1H NMR (CDCl3, 300 MHz) δ 4.09 (s, 2H), 5.22 (s, 2H), 7.31 (dd, J = 7.7, 4.8 Hz, 1H), 7.70
(d, J = 7.7 Hz, 1H), 8.61 (s, 1H), 8.63 (s, 1H).
To a solution of 60 in dry CH2Cl2 was added K2CO3 (0.75 g, 5.4 mmol) and benzyl mercaptan
(0.64 mL, 5.4 mmol). After stirring overnight at room temperature the reaction mixture was
washed with water (3x5 mL), brine (5 mL), and dried over Na2SO4. Evaporation of the solvent78
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yielded 61a as a brown oil
53 that was purified by flash column chromatography over alumina
using hexane/ethyl acetate (3:1) as the eluent (0.22 g, 16%).
1H NMR (CDCl3, 300 MHz) δ 3.09 (s, 2H), 3.77 (s, 2H), 5.14 (s, 2H), 7.27 (m, 7H), 7.69 (d, J
= 7.7 Hz, 1H), 8.58 (d, J = 1.5 Hz, 1H), 8.62 (s, 1H). MS CI [M+H]
+ calcd for C15H16NO2S
m/z 274.1, found 274.2.
Cysteine derivative 61b
Similar procedure as is described for 61a, using methyl N-acetylcysteine (57) to afford 61b as a
light brown oil.
1H NMR (CDCl3, 300 MHz) δ 2.03 (s, 3H), 3.04 (m, 2H), 3.72 (s, 3H), 4.10 (s, 2H), 4.81 (m,
1H), 5.18 (s, 2H), 6.64 (br.d, 1H), 7.31 (m, 1H), 7.69 (m, 1H), 8.61 (m, 2H). MS CI [M+H]
+
calcd for C14H19N2O5S m/z 327.1, found 327.3.
N-[(3-Pyridinemethoxy)carbonyl]valine methyl ester (66)
54
A solution of 52 (0.55 g, 5.0 mmol) and TEA (0.77 mL, 5.5 mmol) in dry CH2Cl2 (20 mL) was
cooled to 0°C, and treated with p-nitrophenyl chloroformate (1.05 g, 5.0 mmol). The reaction
mixture was stirred at 0°C for 1 h and then allowed to warm to room temperature for 2 h.
Washing with saturated aqueous NaHCO3 solution (2x20 mL) and brine (20 mL), drying over
Na2SO4 and evaporation of the solvent yielded the carbonate as a yellow solid (1.36 g, 99%).
1H NMR (CDCl3, 300 MHz) δ 5.31 (s, 2H), 7.33 (m, 3H), 7.79 (m, 1H), 8.27 (m, 2H), 8.65 (dd,
J = 4.8, 1.5 Hz, 1H), 8.71 (d, J = 1.5 Hz, 1H).
A mixture of the carbonate (1.08 g, 3.9 mmol), L-valine methyl ester (0.66 g, 3.9 mmol), and
TEA (1.1 mL, 7.8 mmol, 2 equiv) was heated under reflux in CHCl3 (25 mL) overnight. The
reaction mixture was washed with saturated aqueous NaHCO3 solution (3x10 mL), brine (10
mL), and dried over Na2SO4. Evaporation of the solvent yielded 66 as a yellow oil that solidified
on standing. Flash column chromatography over alumina using a gradient of hexane/ethyl
acetate (3:1 to 1:1) provided the product as a yellow solid (0.57 g, 54%).
1H NMR (CDCl3, 300 MHz) δ 0.86 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 7.0 Hz, 3H), 2.14 (m, 1H),
3.71 (s, 3H), 4.26 (m, 1H), 5.10 (s, 2H), 5.40 (d, J = 8.8 Hz, 1H), 7.28 (dd, J = 7.7, 4.8 Hz,
1H), 7.68 (d, J = 7.7 Hz, 1H), 8.54 (d, J = 4.8 Hz, 1H), 8.59 (s, 1H). 
13C NMR (CDCl3, 75.5
MHz) δ 17.3 (q), 18.7 (q), 30.9 (d), 51.8 (q), 59.0 (d), 64.0 (t), 123.2 (d), 131.9 (s), 135.7 (d),
149.0 (d), 155.8 (s), 172.3 (s). MS CI [M+H]
+ calcd for C13H19N2O4 m/z 267.1, found 267.4.
N-{Bis[5-(methoxymethyl)-2-pyridinyl]methyl}-N,N-bis{[5-(methoxymethyl)-2-
pyridinyl]methyl}amine (67)
To a stirred suspension of NaH (55 mg, 1.4 mmol, 8 equiv) in dry DMF (1 mL) at 0°C was
added a solution of 43 (83 mg, 0.17 mmol) in dry DMF (1 mL). After 30 min MeI (85 µL, 1.4
mmol, 8 equiv) was added at 0°C. The reaction mixture was allowed to warm to room
temperature and stirred for 2 h. Water was added and the mixture extracted with CH2Cl2 (5x3
mL). The organic layer was washed with water (2x2 mL) and brine (2 mL). After drying over
Na2SO4 and evaporation of the solvent, the product was obtained as a red/brown oil (83 mg,
89%). Purification by flash column chromatography over alumina using hexane/ethyl
acetate/TEA (10:18:2) yielded 67 as a light brown oil (37 mg, 40%).79
Tetrasubstituted N4Py ligands as templates for peptide attachment
1H NMR (CDCl3, 300 MHz) δ 3.33 (s, 12 H), 3.91 (s, 4H), 4.83 (s, 8H), 5.30 (s, 1H), 7.60 (s,
4H), 7.62 (s, 4H), 8.40 (s, 2H), 8.46 (s, 2H). 
13C NMR (CDCl3, 75.5 MHz) δ 56.8 (t), 58.1 (q),
58.2 (q), 71.4 (d), 71.9 (t), 122.5 (d), 123.5 (d), 131.4 (s), 131.7 (s), 135.7 (d), 135.8 (d),
148.4 (d), 148.6 (d), 159.3 (s), 159.4 (s). ESI-MS [M+H]
+ calcd for C31H38N5O4 m/z 544.3,
found 544.4.
N-{Bis[5-(3-methoxypropyl)-2-pyridinyl]methyl}-N,N-bis{[5-(3-methoxypropyl)-2-
pyridinyl]methyl}amine (68)
The same procedure was used as described for 67. Starting from 44 (0.30 g, 0.28 mmol) 68
was obtained as a brown oil (0.14 g, 85%). Purification by flash column chromatography over
alumina using hexane/ethyl acetate/TEA (10:18:2) yielded the product as a light brown oil (80
mg, 49%).
1H NMR (CDCl3, 300 MHz) δ 1.82 (m, 8H), 2.61 (t, J = 7.0 Hz, 8H), 3.30 (s, 12H), 3.35 (m,
8H), 3.87 (s, 4H), 5.24 (s, 1H), 7.40 (dd, J = 8.0, 1.8 Hz, 2H), 7.45 (dd, J = 8.0, 1.8 Hz, 2H),
7.51 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 8.29 (d, J = 1.1 Hz, 2H), 8.36 (d, J = 1.5
Hz, 2H). 
13C NMR (CDCl3, 75.5 MHz) δ 29.0 (t), 29.1 (t), 30.8 (t), 30.9 (t), 56.8 (t), 58.6 (q),
71.3 (d), 71.5 (t), 71.6 (t), 122.5 (d), 123.5 (d), 135.0 (s), 135.3 (s), 136.2 (d), 136.3 (d), 149.0
(d), 149.3 (d), 157.4 (s), 157.6 (s). ESI-MS [M+H]
+calcd for C39H54N5O4 m/z 656.4, found
656.3.
N-{Bis[5-(3-bromopropyl)-2-pyridinyl]methyl}-N,N-bis{[5-(3-bromopropyl)-2-
pyridinyl]methyl}amine (73)
PPh3Br2 was freshly prepared by the addition of Br2 (75 µL, 1.4 mmol, 4.7 equiv) to a stirred
solution of Ph3P (395 mg, 1.51 mmol, 5. equiv) in dry CH2Cl2 (1 mL) under a nitrogen
atmosphere. To the resulting yellow suspension was added a solution of 2 (321 mg, 0.304
mmol) in dry CH2Cl2 (1 mL). The reaction mixture was stirred at room temperature until all the
solids had disappeared (2 d), and extracted with 1 M HCl (5x2 mL). The aqueous layer was
neutralised with solid NaHCO3, and extracted with CH2Cl2 (6x2 mL). The organic layer was
washed with brine (2 mL) and dried over Na2SO4. Evaporation of the solvent afforded 73 as a
red oil (190 mg, 74%).
1H NMR (CDCl3, 300 MHz) δ 2.07 (t, J = 6.6 Hz, 8H), 2.67 (t, J = 6.6 Hz, 8H), 3.32 (m, 8H),
3.84 (s, 4H), 5.22 (s, 1H), 7.34–7.58 (m, 8H), 8.28 (s, 2H), 8.34 (s, 2H). 
13C NMR (CDCl3,
75.5 MHz) δ 30.5 (s), 30.6 (s), 32.5 (s), 32.6 (s), 33.3 (s), 33.4 (s), 56.6 (s), 71.1 (d), 122.3 (d),
123.4 (d), 133.6 (s), 133.8 (s), 136.1 (d), 136.2 (d), 148.8 (d), 149.1 (d), 157.5 (s), 157.7 (s).
ESI-MS [M+H]
+ calcd for C35H42N5Br4 m/z 848.0, found 848.0.
Tetracysteine N4Py derivative 74
Methyl N-acetylcysteine (114 mg, 0.64 mmol) was dissolved in nitrogen-purged DMF (1 mL)
and titrated with a Cs2CO3 solution (∼100 mg/mL) to pH 9 under a nitrogen atmosphere. A
solution of 73 (53 mg, 0.062 mmol) in DMF (1 mL) was added and the reaction mixture was
stirred at room temperature overnight. The solution was diluted with water (5 mL) and
lyophilised. The brown residue was purified by preparative RP-HPLC with a gradient of 0.05 M
ammonium acetate/MeCN (50:50) to 100% MeCN over 10 min. The product eluted at tR=7.280
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min, was collected and lyophilised to yield a brown oil (9.5 mg, 12%).
1H NMR (CDCl3, 500 MHz) δ 1.88 (m, 8H), 2.04 (s, 12H), 2.55 (m, 8H), 2.68 (m, 8H), 3.00
(m, 8H), 3.78 (m, 12H), 3.90 (s, 4H), 4.83 (m, 4H), 5.28 (s, 1H), 6.39 (br.d, 4H), 7.47 (m,
8H), 8.35 (s, 2H), 8.41 (s, 2H). ESI-MS [M+H]
+ calcd for C59H82N9O12S4 m/z 1236.5, found
1236.1.
Peptide complex 78
The procedure for 74 using the peptide sequence Ac–Cys–Gly–Leu–His–Glu–Leu–Leu–Lys–
Gly–NH2 was employed.
55 After stirring overnight the solution was diluted with 0.1% TFA in water
and Fe(ClO4)2 (1.1 equiv) was added as a solution in MeCN. The orange/red solution was
purified by semi-preparative RP-HPLC using a linear gradient of 20–40% solvent B over 10
min. The product eluted at tR=8.6 min, was collected, and lyophilised to yield a yellow/orange
solid (2.1 mg, 18%).
MALDI calcd for [78–2(ClO4)
– – (MeCN)]
2+  m/z 4620.38 (monoisotopic), 4623.43 (average
isotope composition), found 4619.2.
Peptide complex 79
The same procedure was used as described for 78, employing the peptide sequence Ac–Cys–Gly–
Gly–Gly–Gly–Asp–Tyr–Lys–Asp–Asp–Asp–Asp–Lys–NH2.
56 The orange/red solution was
purified by semi-preparative RP-HPLC using a linear gradient of 20–40% solvent B over 4 min,
followed by 40–100% in 1 min. The product eluted at tR=4.6 min, was collected, and
lyophilised to yield a yellow/orange solid.
57 For analytical RP-HPLC a linear gradient of 0–100%
solvent B in solvent A was applied over 30 min. The product eluted at tR=16.9 min.
MALDI calcd for [79–2(ClO4)
––(MeCN)]
2+  m/z 6121.3 (monoisotopic), 6125.1 (average
isotope composition), found 6124.0.
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according to 
1H NMR.
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4  Tetrabromo N4Py as a versatile building block for
new non-haem metal catalysts
4.1  Convergent versus divergent ligand synthesis
In the previous chapter the synthesis of a tetrasubstituted N4Py ligand was described to which
four peptide chains could be coupled via spacers at the periphery of the N4Py template.
1 The
synthetic pathway that was designed required these spacers to be introduced into the building
blocks at the very beginning. This stipulation will be a major drawback if at the end of the
synthesis the prepared structure does not meet the requirements that were envisaged at the
outset. The introduction of new alternative spacers can result in different problems that are
encountered during the construction of the new target ligand. Also, once the ligand has been
prepared to all intents and purposes, its function still needs to be established. This, however, is
applicable to any chosen synthetic pathway. Therefore, flexibility in the developed synthetic
route is a prerequisite for an efficient access to a range of derivatives.
The synthesis of the functional template for the construction of a peptide-tethered N4PyFe
catalyst was therefore initiated using the 2,5-disubstituted pyridine compound 1 (Chapter 3).
The spacer, which provided the functionality to which the peptides would be attached in the
final ligand system, was subsequently introduced at the 5-position of the pyridine ring to furnish
compounds of the general structure 2 (Scheme 4.1). Depending on the electrophile used for the
introduction of the spacer, a variety of linkers can thereby in principle be obtained. The bromide
at the 2-position was used as a reactive site to construct the core of N4Py ligand 4. Such a long
and convergent synthesis is not ideally suited for a convenient modification of the attached
linkers in 4.
From a practical point of view it would be more beneficial to initially construct the ligand
scaffold, and subsequently introduce the required functionalities. If these functionalities were
then found to be unsatisfactory, modifications can be made to the ligand without having to start
from the initial building blocks. Such a divergent synthetic pathway would thus facilitate the
versatile preparation of alternative ligand systems. This accessibility and flexibility to a new86
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Scheme 4.1. Convergent vs. divergent synthesis of tetrasubstituted N4Py ligands
starting from 1 (FG=functional group).
range of N4Py templates could prove to be essential if the ligand needed to be redesigned or
improved to enable the incorporation of the N4PyFe catalyst into a four-helix bundle (see
Chapter 1). In addition, the possibility of simultaneously introducing a range of functionalities
creates an opportunity to potentially tune the oxidation behaviour of the corresponding iron(II)
complexes.
A potential N4Py framework that could enable a variety of derivatives to be generated via a
divergent synthesis is presented in Scheme 4.1 and Scheme 4.2 as the tetrabromide N4Py
derivative  3. Again starting from 2,5-dibromopyridine (1), tetrabromo N4Py (3) can be
prepared by initially using the bromide at the 2-position of the pyridine ring to construct the
core of the N4Py scaffold. This in turn leaves the remaining bromide at the 5-position of 1 in 3
available for further functionalisation. However, in order to establish the construction of 3 a
regioselective lithiation at the 2-position of 1 is an absolute prerequisite (vide infra). The
bromide functionalities in 3 can, in principle, be employed as sites for metal-catalysed cross
coupling methodologies or bromide-metal exchange reactions. A variety of substituents can be
introduced into the N4Py scaffold depending on the reagents employed, which in addition
could provide interesting features for novel oxidising catalysts, either directly or through
subsequent functional group interconversions (Scheme 4.2).
4.2  Selective lithiation of dibromopyridines
Several procedures have been reported for a regioselective bromine-metal exchange reaction
with 2,5-dibromopyridine (1). Although the 2-position in 1 is more electron-deficient than the
5-position, the mono-metalation occurs preferentially at the 5-position upon lithiation with
n-butyllithium (n-BuLi) at –100°C in THF (Scheme 4.3).
2,3 A more selective bromine-lithium
exchange,
4,5 however, is obtained using diethyl ether as the solvent at –80°C.
6 The low87
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Scheme 4.2. A selection of potential N4Py ligands that can be envisaged from
tetrabromo N4Py (3) by, for instance, cross coupling (5a–d) or lithiation reactions
(5e–f).
temperature is not only required to achieve a high regioselectivity, but it also helps to prevent
alkylation of the lithiopyridine by the n-butyl bromide that is formed during the reaction.
2
This halogen-metal exchange, which is a rapid and complete process, is controlled by
thermodynamic rather than kinetic factors.
2 This has been demonstrated by the resistance of
3-lithiopyridine towards a lithium exchange with 2-bromopyridine.
2 In contrast, 2-lithiopyridine
undergoes a rapid exchange with 3-bromopyridine to produce 2-bromopyridine and
3-lithiopyridine.
The selective mono-lithiation has also been described for 2,6-dibromopyridine at –78°C in
THF
7 or in dichloromethane.
8 Although n-BuLi can react with dichloromethane, it is stable in
this solvent in the absence of ethereal solvents.
8 In addition, the potential dilithiation of
2,6-dibromopyridine is reduced substantially in dichloromethane compared to diethyl ether or
THF as a solvent under identical conditions.
8
Surprisingly, when dichloromethane is used as the solvent for the mono-lithiation of 1, the
regioselectivity is completely reversed (Scheme 4.3). Wang et al. found that in non-
co-ordinating solvents like toluene and dichloromethane at low concentrations, lithiation
occurred preferentially at the 2-position rather than the 5-position of 1 (approximately in an
85:15 ratio).
4 A small excess of n-BuLi (1.2 equiv) was required to accomplish a complete
mono-lithiation of 1. Via the preparation of a 2-pyridinyltellurium derivative of 1, Sakamoto
and co-workers were also able to lithiate selectively at the 2-position.
3 This procedure is inferior
to that of Wang et al., as a separate reaction step is involved that proceeds only in a moderate
yield of 55%.
A bromine-magnesium exchange on dibromopyridines can also be carried out
regioselectively. Although a direct oxidative addition of magnesium to a halopyridine is known
to be problematic,
9 a pyridine Grignard reagent can be obtained via a halogen-metal exchange
with an alkylmagnesium halide in THF.
10,11 In contrast to the cryogenic conditions for the88
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Scheme 4.3. Solvent-dependent regioselective lithiation of 1.
halogen-lithium exchange, this Grignard interconversion can often be performed at room
temperature. Queguiner and co-workers have exploited this procedure to prepare various
functionalised pyridines from mono- and dibromopyridines using isopropylmagnesium
chloride.
10 The regioselectivity and yields were found to be comparable to the related bromine-
lithium exchange reactions. Triethylamine (TEA) was sometimes added to the reaction mixture
prior to the addition of the electrophile in order to increase the reactivity of the Grignard
reagent, and thereby enhance the reaction. It was found that a slight excess of
isopropylmagnesium chloride is required to achieve a complete bromine-magnesium exchange
with bromopyridines,
12 an observation also reported by other researchers.
3
An interesting alternative is the lithium tributyl magnesate complex that mediates a highly
selective mono-metalation of aryl and heteroaryl dibromides, even in the presence of excess
metalation reagent.
13 This n-Bu3MgLi complex, which can be readily prepared from n-BuMgCl
and n-BuLi, enabled Iida et al. to perform the mono-formylation of 2,6-dibromopyridine on a
twenty-five kilogram scale at only –10ºC in toluene in an excellent yield of 91%. In a similar
way the authors could obtain aldehyde 6 in a toluene/THF (1:1) mixture in 71% yield from 1.
Under these conditions, however, a lower regioselectivity was observed for the mono-lithiation
of 1.
In conclusion, the regioselectivity of the bromo-metal exchange in 2,5-dibromopyridine (1)
can be directed by the choice of solvent. The reversed regioselectivity, reported by Wang et al.,
4
for the lithiation of 1 was a prerequisite to facilitate the synthesis of tetrabromo N4Py (3) and at
the same time creates the opportunity to prepare tetrasubstituted N4Py derivative by
functionalising the remaining bromides in 3.
4.3  Synthesis of tetrabromo N4Py
The synthesis of tetrasubstituted N4Py derivatives is channelled through the preparation of the
desired disubstituted bispyridinyl ketones. The corresponding bispyridinyl ketoximes and
bispyridinyl amines are readily accessible and the required functionalised picolyl chlorides can
be prepared from a wide range of starting materials.
14 The difficulty with the synthetic pathway
outlined in the previous chapter is that two functionalised pyridines are linked via a carbon
bridge that is put in place by a lithiation reaction. Under these conditions some functionalities of
interest might not be stable, which would require the development of new synthetic procedures
to accomplish this pyridine linkage. This might limit the general application of the established
methodology.
With the realisation of a selective lithiation at the 2-position of 2,5-dibromopyridine (1) by
Wang  et al.,
4 a key transformation was accomplished that would enable the synthesis of
bispyridinyl ketone 8 (Scheme 4.4). The remaining two bromine atoms in 8 will thus provide
diethyl ether
or THF
toluene
or CH2Cl289
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sites for further functionalisation in the final N4Py derivative 3. As depicted in Scheme 4.4, 1
was lithiated at the 2-position by n-BuLi in toluene at –80°C and quenched with
N,N-dimethylformamide (DMF) to furnish 5-bromo-2-pyridinecarboxaldehyde (7) in 73% yield.
The aldehyde 7 was found to be contaminated with its regio-isomer 6 (approximately 18% from
1, 91% combined yield) due to an incomplete regioselectivity under these conditions.
Unfortunately, aldehyde 7 could not be purified due to its instability.
15
(26%) (73%) 1
1) n-BuLi,
toluene
2)  7
8
toluene
1) n-BuLi,
2) DMF
7
N
Br
O
H
3) MnO2
N Br
Br
N
Br
N
Br
O
Scheme 4.4. Synthesis of aldehyde 7 from 1, and its subsequent application in the
preparation of ketone 8.
In a subsequent step 2,5-dibromopyridine (1) was lithiated once more at the 2-position, as in
the preparation of 7, and now quenched with aldehyde 7 instead of DMF. The small amount of
aldehyde  6 present in crude 7 and the incomplete regioselectivity of the lithiation reaction
resulted in a mixture of products. However, after the oxidation of the bispyridinyl alcohol
product by manganese dioxide, precipitation of the crude product from diethyl ether furnished
pure bispyridinyl ketone 8. An excess of n-BuLi was used to ensure a complete bromide-lithium
exchange of 1,
4 the unreacted lithiating reagent, therefore, must also have reacted with the
aldehyde added, leading to a further reduction in the yield for the reaction. Therefore, the low
yield of 26% cannot solely be attributed to the ‘contaminated’ aldehyde 7.
The formation of ketone 8 was most effectively achieved by quenching in situ the prepared
5-bromo-2-lithiopyridine in toluene at –80°C with 0.5 equivalents of diethyl carbonate (Scheme
4.5).
16 Although the reaction conditions have not yet been optimised, bispyridinyl ketone 8 was
isolated in a higher yield of 37%. Reducing the number of reaction steps was not only practical,
(37%)
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Scheme 4.5. Synthesis of bis(5-bromo-2-pyridinyl)methylamine (10).90
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but it also resulted in an increase in the yield of 8. In order to optimise this reaction, the
regioselectivity of the bromide-lithium exchange will have to be enhanced. As the efficiency of a
halogen-lithium exchange is higher for an iodide than for a bromide, superior results can be
expected by initially converting 1 into 5-bromo-2-iodopyridine.
17,18 Recent work from Sauvage
and co-workers has indeed demonstrated that this preceding interconversion is accompanied by
a complete regioselectivity in the lithiation step.
19
Subsequent conversion of the ketone 8 into the bispyridinyl ketoxime proceeded smoothly
in 81% yield in a reaction using hydroxylamine as its hydrochloride salt. The synthesis of
bispyridinyl methylamine 10 was achieved by the highly efficient reduction of the ketoxime 9
using zinc in acetic acid at room temperature.
With the amine 10 in hand, the preparation of tetrabromo N4Py (3) was now within reach,
as the synthesis of the required corresponding picolyl chloride 13 had already previously been
achieved (Scheme 4.6).
20 Starting from 5-bromo-2-picoline
21 (11) the N-oxide 12 was obtained
in 98% yield after oxidation by meta-chloroperoxybenzoic acid (mCPBA). Subsequent reaction
of the N-oxide 12 with trifluoroacetic acid anhydride (TFAA), followed by the hydrolysis of the
resulting acetate furnished 5-bromo-2-(hydroxymethyl)pyridine in 81% yield.
21b Next, this
picolyl alcohol was allowed to react with thionyl chloride to furnish 13 in 97% yield (overall
yield of these two steps was 79%). The picolyl chloride 13 with its electron-withdrawing
bromide was unexpectedly found to be remarkably stable,
22 as 2-picolyl chlorides are generally
prone to self N-alkylation.
N
Br
11
N
Br
Cl
mCPBA
CH2Cl2
rt
(98%)
1) TFAA
2) NaHCO3
3) SOCl2
(79%)
N
Br
O
12 13
Scheme 4.6. Synthesis of 5-bromo-2-picolyl chloride (13).
In an alternative procedure, picolyl chloride 12 can also be obtained from aldehyde 7 via the
lithiation of 2,5-dibromopyridine (1) in toluene (Scheme 4.4), followed by a reduction of the
aldehyde to the picolyl alcohol, which can then be converted into 12. However, the incomplete
regioselectivity under these conditions in the lithiation of 1 results in a mixture of aldehydes 6
and 7 (vide supra). These could not be separated by column chromatography, and continuation
with this mixture would afford regio-isomers of picolyl chloride 12, and thus lead to
complications during the preparation of the N4Py ligand 3. Therefore, the procedure outlined in
Scheme 4.6 was undertaken, which allows full control over the position of the substituents.
Analogous to the previously described preparation of N4Py derivatives,
20,23 the dialkylation
of amine 10 with two equivalents of picolyl chloride 13 in the presence of a base enabled the
construction of tetrabromo N4Py (3) (Scheme 4.7). The first alkylation step proceeded rapidly in
the presence of N,N-diisopropylethylamine (DIEA) or caesium carbonate, as is observed in the
preparation of other N4Py derivatives as well. However, the rate of the second alkylation step
was retarded substantially by the electron-withdrawing nature of the bromides in the reactants.
This was generally observed for other picolyl chlorides with electron-withdrawing substituents.
2491
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Scheme 4.7. Synthesis of tetrabromo N4Py (3).
The best results were obtained by using a large excess of DIEA and a minimal amount of
acetonitrile to dissolve the reactants. Under these conditions the required reaction time was
reduced from a week to two days at reflux. Traces of mono-alkylated product could be removed
simply by precipitation of 3 in diethyl ether after the removal of other minor contaminants by
flash column chromatography. With a 58% yield in this final step the synthesis of tetrabromide
N4Py (3) was now finally completed as verified by 
1H NMR, 
13C NMR, mass analysis, and
elemental analysis.
4.4  Cross couplings reactions
It is not the purpose of this section to provide a complete overview of all available cross
coupling methodologies. Instead, the discussion will be focussed on cross coupling reactions on
halopyridine compounds, as the examined model reactions should serve as a possible means by
which the tetrabromo N4Py (3) can be functionalised. The selected test reactions will hopefully
provide a set of reaction conditions that will facilitate a flexible derivatisation of 3 by a number
of cross coupling methodologies.
In recent years the Suzuki
25 and the Stille
26 cross coupling reactions have developed into
commonly applied synthetic methodologies for the metal-catalysed C–C bond formation of
biaryl compounds as an alternative to the Ullmann reaction.
27 Since the initial reports
approximately two decades ago, many excellent examples of these cross coupling reactions
have been presented that can tolerate a wide variety of functional groups.
28–30 Recently, the use
of alkylboronic acids has been added to the long list of possible applications of the Suzuki
reaction,
31 as well as the reaction of alkylboranes
32 with alkyl bromides in the formation of an
alkyl-alkyl bond.
33 Other cross coupling methodologies have also been developed over the past
few decades. The Sonogashira
34 reaction involves the palladium-catalysed reaction of, for
instance, an aryl halide with a terminal acetylene in the formation of aryl acetylenes.
35 The Heck
reaction
36 is the palladium-catalysed arylation of olefins by aryl halides.
37 Within this still
developing field, the cross coupling methodology has established itself as one of the most
actively studied topics in synthetic organic chemistry.
38
The many variables in these cross coupling reactions need to be tuned in order to find an
effective catalytic system. The combinations that can be varied involve the choice of the catalyst
(or precursor), the catalyst loading, the solvent, and the addition of a supplementary base or
ligand. The multitude of structural variations that can be introduced is enormous, bolstered by a
continuously growing number of commercially available functionalised reagents. Also, many92
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newly developed synthetic procedures have been reported in the literature that, for instance,
enable the use of the less reactive aryl chlorides
39 or alkylboronic acids
31 in Suzuki reactions,
and a palladium-catalysed borylation of aryl halides and triflates.
40 Recently, the iridium-
catalysed activation of an aromatic C–H bond was described, which allows the direct
introduction of a boron moiety onto an arene, even in the presence of bromide or chloride
functionalities.
41
The metal-catalysed carbonylation,
18,42 allylation,
43 or arylation with arylzinc halides
43 of
2,5-dibromopyridine (1) occurs exclusively at the 2-position, indicating that this position in the
pyridine ring is more reactive in metal-mediated coupling reactions.
43–45 The bromine atom at
the 5-position, however, is quite capable of undergoing cross coupling reactions in the absence
of other functional groups that are susceptible to oxidative addition.
43,46–48 Minor changes in the
substrate and the palladium source can result in dramatic changes in the efficiency of the cross
coupling reaction,
42b,49 as exemplified by a more efficient palladium-catalysed arylation of
3-bromopyridine with respect to 2-bromopyridine.
46b,e
As already depicted in Scheme 4.2, the four bromides in the N4Py derivative 3 can in
principle be functionalised by a number of coupling reagents. However, because these bromides
are presented within a single molecule, a highly efficient coupling reaction at each site is a
prerequisite for acquiring the product in a high overall yield. If the four reactions on 3 each
proceed in a yield of 90%, the overall yield will only be 66%, and a yield of 80% per bromide
site will result in a final yield of only 41%! More importantly, complete substitution at all four
sites is imperative in order to reduce the amount of incompletely substituted N4Py structures.
Furthermore, as the side-products from these incomplete reactions will be structurally similar
compounds, these will be difficult to separate from the desired molecule.
4.4.1  The Suzuki reaction
The Suzuki, or Suzuki-Miyaura, reaction involves the palladium- or nickel-catalysed
50 cross
coupling of an aryl, alkenyl, or n-alkylboronic acid or ester and an aryl halide or triflate (Scheme
4.8).
25,28 The ever growing list of applicable and commercially available organoboronic reagents,
and its tolerance towards many functional groups, make the Suzuki reaction an effective and
flexible procedure for creating aryl-aryl C–C bonds. Recently, palladium-catalysed methods
have been reported by which pinacol arylboronates can be prepared from the corresponding
aryl chlorides,
51 or even by activation of an aromatic C–H bond,
41 thus broadening the range of
applicable substrates.
+
R
1
B(OR3)2
R
2
X
R
1
[Pd]
base
X = I, Br, Cl, OTf R3 = H, alkyl
R2
Scheme 4.8. The Suzuki reaction in the formation of biaryl compounds.
The most commonly employed palladium source is Pd(PPh3)4, a palladium(0) species that can
be used directly for the catalytic cycle (Scheme 4.9). Other palladium(II) catalysts like
PdCl2(PPh3)2 or Pd(OAc)2 are readily reduced to the active palladium(0) species by the addition93
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of base or phosphine ligands to form in situ the effective transient intermediate. Nowadays,
even palladium
52 or nickel
53 on carbon can affect the formation of biaryl compounds from aryl
chlorides.
According to the generally accepted mechanism of the Suzuki reaction,
28 the Pd
0 species is
inserted into the aryl C–X bond via an oxidative addition step to generate the Pd
II intermediate
I (Scheme 4.9). In this rate determining step the electronic effects of the aryl halide play an
important role, as the relative reactivity of the halide and triflate substrates decreases in the
order of I>OTf>Br>>Cl.
28 Furthermore, substrates bearing electron-withdrawing substituents
are more reactive towards the oxidative addition than those with electron-donating groups.
48 In
a subsequent ‘transmetalation’ step species I reacts with the organoboronic substrate to form the
trans–σ–Pd
II complex II. Generally, a base is added to the reaction mixture to activate the
boronic acid, presumably by creating an anionic boronic species. As the product of the cross
coupling reaction can only be released via the cis-complex, intermediate II has to undergo an
isomerisation step. The following reductive elimination of the cis-isomer III then affords the
product and simultaneously regenerates the Pd
0 catalyst.
Ar R
Pd X
L
L
Ar
Ar X
Pd0L2
RB ( O H ) 2
XB ( O H ) 2 B(OH)3 + HX
H2O
I
II
Pd R
L
L
Ar
II
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Pd R
L
Ar
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II
II
oxidative
addition
reductive
elimination
isomerisation
Scheme 4.9. The generally accepted mechanism for the Suzuki reaction.
28
The substrates 3-bromopyridine (14) and 5-bromo-2-picoline (11) were selected as test
reactions in order to find suitable conditions for the metal-catalysed cross coupling reactions on
tetrabromo N4Py (3). These bromopyridines were employed in the palladium-catalysed Suzuki
reaction with phenylboronic acid (15) and 3-amino-phenylboronic acid (16) in the presence of
base (Scheme 4.10).
46 The boronic acid 16 was chosen to provide an amine functionality in the
cross-coupled product that would allow the compound to be further derivatised by, for instance,
an amide bond formation. When applied to the tetrabromide N4Py ligand 3, this would provide
an alternative means of coupling peptides to the N4Py scaffold.
The reaction of 3-bromopyridine (14) with 15 was initially catalysed by 5 mol% Pd(PPh3)4
in a refluxing mixture of acetonitrile and aqueous sodium carbonate to furnish the cross-coupled
product 17, after eighteen hours and subsequent purification, in 83% yield.
46e Changing the
solvent to benzene or toluene, or reducing the catalyst loading to 3 mol%, had no significant94
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effect.
54 In THF as the solvent the yield of the reaction was marginally increased to 87% when
allowed to react overnight. Under identical conditions the corresponding Suzuki reaction of
3-bromopyridine (14) with 16 furnished the desired product 19 in 95% yield after purification.
Na2CO3 (aq)
B(OH)2
R2
N R
1
R2
17: R1 = H, R2 = H
18: R1 = Me, R2 = H
19: R1 = H, R2 = NH2
20: R1 = Me, R2 = NH2
11: R1 = Me
14: R1 = H
N
Br
R
1
+
Pd(PPh3)4
THF, ∆
15: R2 = H
16: R2 = NH2
(87-95%)
Scheme 4.10. The Suzuki reaction of bromopyridines 11 and 14.
The tetrabromide N4Py ligand 3, to which these cross couplings will ultimately be applied, is
structurally quite different from 3-bromopyridine (14). In order to account for the alkyl
substituents that constitute the core of ligand 3, the efficiency of the Suzuki reaction was also
examined using 5-bromo-2-picoline (11). Under conditions analogous to the preparation of 17,
the cross-coupled product 18 was isolated in an excellent yield of 95%. Similarly, the
disubstituted pyridine derivative 20 was obtained in a 90% isolated yield from the reaction of
11 with 16. Clearly, the substituents of the substrates employed have only a minor influence on
the outcome of this Suzuki reaction, which in turn appears to be promising for their application
to tetrabromo N4Py (3).
As an alternative procedure the boronic acid or ester moiety can in principle be introduced
into the ligand system of 3 and subsequently employed in cross coupling reactions with various
aryl halides or triflates. Procedures for an in situ palladium-catalysed halide displacement with a
boronate ester prior to the Suzuki reaction have previously been reported.
40 This approach was
tested on 2,5-dibromopyridine (1) and 3-bromopyridine (14) via their conversion into the
boronate esters 21–23 after lithiation of the bromopyridines, followed by quenching the lithiated
species with the corresponding boronate ester.
44,55–57 However, the subsequent Pd(OAc)2-
40e or
Pd(PPh3)4-mediated reactions employing iodoanilines 24–26 were fruitless despite numerous
attempts using refluxing mixtures of benzene and aqueous sodium carbonate or barium
hydroxide.
54 The unsuccessful formation of the desired products 27–29 (Scheme 4.11) is
presumably due to an ineffective formation of the intermediate boronates,
54 as related cross
coupling reactions utilising 21 have been reported recently.
57
The in situ hydroboration
45 of tetrahydropyranyl-protected allyl alcohol by 9-borabicyclo-
[3.3.1]nonane (9-BBN) and the subsequent cross coupling with 3-bromopyridine mediated by
PdCl2(PPh3)2 was also attempted, but this reaction was not successful.
54 Presumably, the
hydroboration of the alkene did not take place, which prevented the following Suzuki reaction.
However, it can safely be assumed that under different reaction conditions this functionalisation
of bromopyridines can be accomplished, as related procedures have been reported for the in
situ hydroboration of terminal alkenyl compounds by 9-BBN, followed by the Pd(PPh3)4-
catalysed Suzuki reaction of the resulting alkylborane with 3-bromopyridine.
58 Similarly, Reider95
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Scheme 4.11. Attempted synthesis of the 3-aryl pyridines 27–29 via the
pyridinylboronic esters 21–23.
and co-workers have successfully introduced two amine functionalities with a C3-spacer to
2,5-dibromopyridine by an efficient double Suzuki reaction via a 9-BBN-mediated
hydroboration of a phthalimide-protected allyl amine.
59
Other promising examples of successful Suzuki reactions have been described using
organoboronic acids
6,60 or potassium alkenyltrifluoroborates
61 on bromopyridines, which could
lead to other methods of preparing tetrasubstituted N4Py derivatives from tetrabromo N4Py (3).
4.4.2  The Stille reaction
The Stille reaction most often involves the palladium- or nickel-catalysed
62 cross coupling of an
aryl, alkynyl, or vinyl tin reagent with an electrophile, commonly an aryl halide, although alkyl
halides or triflates can also be employed.
26,29 This type of cross coupling reaction can be
performed under neutral conditions and can be used as an alternative to the Suzuki reaction for
the synthesis of biaryl compounds. Both cross coupling reactions are generally equally
efficient.
29 However, the troublesome removal of the residual tin salts from the reaction product
is the main disadvantage of the Stille reaction. Many authors have reported this complication
and, consequently, several purification methods have been developed to work around this
problem.
63
The catalytic cycle is considered to be comparable to that of the Suzuki reaction (Scheme
4.9). However, in the Stille cross coupling reaction the rate determining step is often the
transmetalation step instead of the oxidative addition, which is affected by the substituents of
the substrates in the reaction.
The number of commercially available organostannanes is still limited and the reagents,
therefore, generally need to be prepared prior to the Stille reaction. Their synthesis is usually
achieved via a separate reaction step by quenching an organolithio species with an alkyltin
chloride. Alternatively, these stannanes can sometimes be prepared separately by the palladium-
catalysed cross coupling of a hexa-alkylditin and an aryl halide,
64 or in situ for inter-
65 and
intramolecular reactions.
66 An intermolecular cross coupling of 2-bromopyridines
67 or
2-pyridinyl triflates
68 with functionalised aryl bromides has also been reported, in which a
selective formation of the organostannane was catalysed in situ by Pd(PPh3)4 to furnish
2-arylpyridines in moderate to good yields.96
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In order to evaluate the Stille reaction as a potential means to functionalise tetrabromo
N4Py (3), several test reactions were carried out on the 3-pyridinylstannanes 30 and 31
(Scheme 4.12). Bromopyridinylstannanes have often been utilised in the synthesis of
heteroarylene building blocks
44,69 for polyheterocyclic molecules.
17,19,70 The organostannanes 30
and 31 were obtained from 2,5-dibromopyridine (1) and 3-bromopyridine (14) in 99% and
93% isolated yields, respectively, via the lithiation of the bromopyridines and the subsequent
reaction with tributyltin chloride. Next, stannanes 30 and 31 were employed in a cross coupling
reaction with 4-iodo-aniline (24) and the phthalimide-protected 3-iodo-aniline
71 ( 26).
Unfortunately, 3-arylpyridine 27 could not be obtained from the reaction of stannane 30 with
aryl iodide 24 when catalysed by 2 mol% Pd(PPh3)4, even after refluxing in THF for three days.
In contrast, the use of the N-protected iodoaniline 26 under analogous conditions resulted in a
full and clean conversion to the cross-coupled product 32. Similarly, the 3-arylpyridine 29 was
selectively formed from stannane 31. Unfortunately, the tedious removal of the residual tin salts
resulted in poor isolated yields of the products that were still contaminated with traces of tin
residues.
54 Therefore, no yields are reported in Scheme 4.12. However, 
1H NMR indicated that
the cross-coupled products 29 and 32 were indeed obtained, as the characteristic aromatic
signals for 2,5-disubstituted pyridines were shifted compared to those of the starting material. In
addition, mass analysis of these products confirmed their structural composition.
N R
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∆
24: R2 = 4-NH2
26: R2 = 3-NPht
N
SnBu3
R
1
30: R1 = Br
31: R1 = H
THF
R2
I
R
2
+
Scheme 4.12. The Stille reaction applied in the formation of 3-arylpyridines 27, 29,
and 32 from the 3-pyridinylstannanes 30 and 31.
The use of toluene as a solvent or PdCl2(PPh3)2 as a catalyst in the presence of copper iodide
provided no significant improvements to the efficiency of the reaction. Copper iodide is
frequently used to activate the organostannane,
72 as well as other reagents in alternative cross
coupling reactions like the Heck and Sonogashira reaction (vide infra).
For the application of the Stille reaction to tetrabromo N4Py (3) it would be beneficial if the
cross-coupled products could be obtained directly from 3 via a metal-catalysed reaction with
organostannanes. This would eliminate the necessity to convert the bromides in 3 into
stannanes prior to the cross coupling reaction, either in situ or via a separate reaction step.
Therefore, the palladium-catalysed reaction of 3-bromopyridine (14) with tributyl(phenyl)tin
(33) was examined (Scheme 4.13). After three days in refluxing THF the product
3-phenylpyridine (17) was isolated, however the tin residues could not be removed completely
from the product by column chromatography. Due to the encountered problem with this route,
it was not explored any further.97
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Scheme 4.13. Formation of 3-phenylpyridine (17) via the Stille cross coupling
methodology.
4.4.3  The Sonogashira reaction
Metal-catalysed cross couplings of terminal acetylenes with aryl halides are referred to as
Sonogashira reactions.
34,35 Transition metals (commonly copper iodide
35 or silver iodide
73) as
co-catalysts assist the activation of the acetylene C–H bond, which enables these reactions to
proceed at room temperature and under mild conditions.
74 Nowadays, many variations of this
methodology are used as a convenient way of preparing a range of aryl acetylenes and
alkylenes, as well as allenyl acetylenes.
35
Again, the catalytic cycle is related to the mechanism of the Suzuki reaction (Scheme 4.9).
The main difference is the transmetalation step of the cycle, which now involves an in situ
formation of an alkynylcopper(I) species.
35 The reactive palladium species is a Pd
0 complex,
formed either from a palladium(0) catalyst like Pd(PPh3)4, or from a palladium(II) catalyst, which
is then reduced in situ by the alkynylcopper(I) species present. The reaction medium is most
often diethylamine or triethylamine, which serves both as a solvent and a base to trap the
hydrogen iodide formed during the reaction.
The Sonogashira reaction with bromopyridines
6,18,75,76 was examined on 14 as a test
substrate for the possible application of this cross coupling methodology to tetrabromo N4Py
(3). By employing 1 mol% PdCl2(PPh3)2 as the catalyst and 0.5 mol% copper iodide as a
co-catalyst, 14 was converted into the pyridine derivatives 36 and 37 by the reaction with
3-butyn-1-ol (34) or its acetyl-protected analogue 35, respectively.
N
Br
N
OR
14 34: R = H
35: R = Ac
36: R = H
37: R = Ac
OR
PdCl2(PPh3)2, CuI
(42-62%)
TEA, ∆
+
Scheme 4.14. The Sonogashira reaction of 3-bromopyridine (14) with the terminal
acetylenes 34 and 35.
Although diethylamine
77 as the solvent furnished the cross-coupled product 36, superior isolated
yields were obtained when triethylamine
78 (TEA) was used (62% vs. 42%). Despite a complete
and clean conversion of the starting materials according to NMR analysis, the product could
only be isolated in a moderate yield, presumably due to a loss of product during the purification98
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by column chromatography. The acylated propargylic alcohol 35 was employed under similar
conditions in the hope of improving the purification step, but unfortunately product 37 could
only be isolated in 48% yield. As an alternative procedure,
18 the cross coupling of 14 and 34
mediated by 5 mol% Pd(PPh3)4 was attempted in THF with 1.5 equivalent of TEA, but this
unfortunately resulted in an inferior reaction, as 36 was obtained only in 22% yield after column
chromatography.
4.4.4  Other metal-catalysed coupling reactions
The Heck reaction generally involves the palladium-catalysed arylation of olefins by aryl iodides
to furnish various substituted olefins, dienes or other unsaturated compounds.
36,37 Nowadays,
aryl chlorides
79 and aryl anhydrides
80 are also employed in this cross coupling reaction. The
Heck reaction has also been described for bromopyridines.
81 Generally, palladium(II) catalysts
like Pd(OAc)2 or PdCl2(PPh3)2 are used for this reaction, which are then reduced in situ to the
active palladium(0) species by the phosphine ligands or base present.
37 However, palladium(0)
complexes like Pd(PPh3)4 have also been employed successfully in the Heck reaction.
37
Again, 3-bromopyridine (14) was used as a model compound for the Heck reaction on
tetrabromo N4Py (3). In the cross coupling reaction with allyl alcohol (38) catalysed by
Pd(OAc)2, the aldehyde product 40 could not be obtained (Scheme 4.15). When
triphenylphosphine was used as an additive, sodium bicarbonate as a base, and
hexamethylphosphoramide (HMPA) as the solvent,
82 a complex product mixture was obtained
after seventeen hours under reflux conditions in which 40 could not be detected by NMR or
mass analysis. No conversion at all was observed when the solvent was changed to
N-methylpyrrolidinone (NMP) with sodium acetate as a base and tetrabutylammonium bromide
as the additive.
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Scheme 4.15. Unsuccessful Heck reaction of 3-bromopyridine (14).
Under different conditions the reaction might prove to be fruitful as bromopyridines have been
applied with some success in the Heck reaction.
81,83 The aldehyde 40 is the expected product of
this reaction, formed via tautomerisation of the initially formed cross-coupled product 39. The
terminal functionality could thus facilitate further derivatisation of the N4Py ligand once applied
to the tetrabromide N4Py derivative 3.
New cross coupling methodologies are continuously being reported, and these contributions
might in turn provide alternative means of functionalising tetrabromo N4Py (3). Other cross
coupling methods that have been described so far and that might be applied to halopyridines or
compounds obtained from these are, for instance, the Negishi
5 or the Kumada
84 cross coupling99
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reactions.
47 The Kumada coupling involves the palladium- or nickel-catalysed
85 cross coupling of
a Grignard reagent and an aryl or alkenyl halide or triflate.
86–88 The Negishi reaction
89 between
bromopyridines and a n-alkyl iodide is catalysed by PdCl2(PPh3)2.
90 A transformation of the
alkyl halide occurs in situ with a zinc-copper couple to produce the reactive alkylzinc iodide.
This coupling reaction is more effective for 2-bromopyridine than for 3-bromopyridine.
90
Jackson and co-workers have developed a related methodology to prepare various
unnatural amino acids via palladium-catalysed cross coupling reactions on iodoalanine 41.
91
The use of Rieke zinc has been reported to give the best results for the zincation step.
92 When
applied to tetrabromo N4Py (3), this methodology could enable the direct introduction of amino
acids into the N4Py ligand system. This zinc coupling methodology was thus applied to the
direct cross coupling of bromopyridines 14 and 43 to iodoalanine 41 via 42 to furnish the
pyridinylalanine derivatives 44 and 45 (Scheme 4.16).
54,92
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Scheme 4.16. The direct coupling of iodoalanine 41 to bromopyridines 14 and 43.
Other cross coupling reactions on bromopyridines that could in principle be considered include
the palladium-catalysed carbonylation of bromopyridines with carbon monoxide and
phenylboronic acid to phenyl pyridinyl ketones.
42b Also, the Pd(PPh3)4-mediated cyanation of
bromopyridines has been described using tributyltin cyanide.
93 Alternatively, a reaction with
Zn(CN)2 in DMF catalysed by Pd2(dba)3 with 1,1’-bis(diphenylphosphino)ferrocene (dppf) as
ligand was reported.
94 The latter procedure allowed the successful preparation of nitrile 47
during the development of a synthetic pathway of a tetrasubstituted N4Py ligand (Chapter 3).
After refluxing for one night, the bromide 46 was almost fully converted into the nitrile 47,
which was isolated in 40% yield after column chromatography.
N
OTBDMS
NC N
OTBDMS
Br
Pd2(dba)3, dppf
DMF, H2O
Zn(CN)2
∆
46 47 (40%)
Scheme 4.17. The palladium-catalysed preparation of nitrile 47 from bromide 46.
Pioneering work was undertaken by Knochel and colleagues
95 on the palladium- or iron-
catalysed
96 functionalisation of halopyridines by cross coupling reactions that employ aryl-
magnesium reagents and copper cyanide as a co-catalyst. These Grignard reagents are100
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generally obtained via a halide-magnesium exchange reaction utilising isopropylmagnesium
bromide. Under these conditions reagents can be used that incorporate a variety of functional
groups.
97 Related to this type of cross coupling is the metal-catalysed reaction of
alkylmagnesium halides with bromopyridines.
18,98
By using the metal-catalysed cross coupling reactions not only C–C bonds can be created,
but also C–N bonds.
99 Various metal-phosphine complexes have been found to be capable of
catalysing this C–N bond formation in aromatic heteroatom coupling reactions.
49,100 For
instance, the palladium-
99,101,102 or nickel-catalysed
103 aminations of monohalopyridines, or a
regioselective palladium(II)-catalysed amination of dichloropyridines
104 to secondary and tertiary
amines, were achieved in good yields. Furthermore, intermolecular C–N bond formation
between aryl bromides, iodides, and triflates and amides has been mediated by a palladium
105
or copper
106 catalyst,
  although the use of halopyridines has not as yet been reported by
researchers.
4.5  Functionalisation of tetrabromo N4Py
From the test reactions performed on 3-bromopyridines described in the previous sections it is
clear that bromopyridines are most susceptible to the Suzuki reactions. These cross coupling
reactions provide the resulting arylpyridine products in excellent yields after purification. An
additional advantage is that a wide range of organoboronic acids are commercially available,
which might facilitate the preparation of various derivatives of the tetrabromide N4Py ligand 3.
Although the Stille reaction proved to be equally efficient in the model cross coupling reactions,
the troublesome removal of the residual tin salts from the reaction product disfavoured its
application in the functionalisation of 3.
The reaction of tetrabromo N4Py (3) with four equivalents of phenylboronic acid (15) and
4 mol% Pd(PPh3)4 as the catalyst (equivalent to 1 mol% of palladium catalyst per bromide) in a
refluxing mixture of toluene and aqueous sodium carbonate could not be driven to
completion.
54 By the addition of more phenylboronic acid and catalyst, up to ten equivalents of
15 and 12 mol% Pd(PPh3)4, a complete conversion of the starting material to a single
compound was obtained after a week under reflux conditions, but unfortunately not to the
desired tetraphenyl N4Py derivative 48. NMR analysis clearly indicated that the resonance
signals, characteristic for N4Py molecules, were significantly shifted. Typically, the doubly
benzylic proton of a N4Py ligand is observed at approximately 5.2 ppm and the other benzylic
methylene protons of the N4Py core around 3.9 ppm. Both signals were absent in the NMR
spectrum obtained for the crude product of this Suzuki reaction, and a new signal at 4.4 ppm
was observed. This presumably can be attributed to a degradation product formed due to the
prolonged reaction time. In addition, the protons at the 6-positions of the pyridine rings in
tetrasubstituted N4Py ligands are always observed as a set of two singlets at 8.2 to 8.4 ppm, due
to the dissymmetry between the upper and lower half of the molecule. The 
1H NMR spectrum of
this degradation product, however, presented only one signal in this region.
Therefore, the reaction was repeated in toluene with ten equivalents phenylboronic acid
(15) and 12 mol% Pd(PPh3)4, which afforded product 48 after one night at reflux and
subsequent workup in 80% yield (Scheme 4.18). The 
1H NMR spectrum showed the
characteristic signals that can be expected for tetrafunctionalised N4Py ligands as described101
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above. The molecular ion of 48 and its expected fragmentations were detected by mass
spectroscopy and confirmed that indeed the tetrasubstituted cross-coupled was obtained. No
detectable amounts of mono-, di- or trisubstituted products were present. These products from
incomplete reactions, if present, should be detectable by NMR, as the electronic effect of the
phenyl groups on the N4Py ligand is substantially different from that of the bromides. A trace of
the previously observed side-product was also present. The identity of this compound has not
yet been elucidated.
48
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Scheme 4.18. The successful tetrafunctionalisation of tetrabromo N4Py (3) by the
Suzuki reaction with phenylboronic acid (15).
In the test reactions on several bromopyridines, it was shown that THF as the solvent generally
gave rise to superior efficiencies over toluene in Suzuki cross coupling reactions. Therefore, the
Suzuki reaction of 3 with phenylboronic acid (15) was also performed in THF. After one hour at
reflux a full conversion of the starting material 3 was already observed. Unfortunately, this was
not the desired product. Again, an unidentified product was observed by NMR analysis,
indicating that in THF a species is formed that is presumably very reactive and results in the
formation of the unwanted product. Even when samples were taken after a few minutes and
analysed by NMR, only the unidentified compound could be observed without any trace of the
desired product 48.
In order to test the susceptibility of tetrabromo N4Py (3) towards halogen-metal exchange
and subsequent quenching with electrophiles, 3 was treated at room temperature with 4.5
equivalents of isopropylmagnesium bromide as a solution in THF (Scheme 4.19). Mass analysis
of a sample that was quenched with water, however, only showed the dibromide N4Py
derivative 49a. Addition of more isopropylmagnesium bromide did not result in a complete
magnesium-bromide exchange, even after heating at reflux temperature. When a sample was
quenched with D2O, mass analysis revealed the incorporation of three deuterium atoms which
suggested the formation of 49b. Not only does this indicates that magnesium-bromide exchange
occurs at two of the four sites, but also that the doubly benzylic position in 3 is deprotonated.
The addition of DMF to the reaction mixture afforded the dialdehyde N4Py derivative 49c,
which has been characterised by NOESY NMR experiments. The doubly benzylic position
apparently does not react with DMF, and is therefore reprotonated during workup. These
findings indicate that the lower half of 3 is not susceptible towards a metal-halogen exchange,
possibly due to the delocalisation of the negative charge over the two adjacent pyridine rings.102
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Scheme 4.19. Regioselective magnesium-bromide exchange of tetrabromo N4Py.
4.6  Discussion and conclusions
Within the fascinating field of cross coupling methodologies new contributions to metal-
catalysed reactions are continuously being reported as replacements for long-established
chemical procedures, or as simplifications of complicated bond formations and structure
modifications. It is therefore likely that for reactions that have until now been accompanied by
poor results, or even proven to be non-susceptible to their metal-mediated versions, a cross
coupling variation will be invented. In light of the recent progressions in this field so far, it is only
a question of time before the current procedures are superseded by even more refined versions.
From the investigated cross coupling reactions in this chapter it has become evident that the
Suzuki reaction is the most effective and practical method for the modification of
bromopyridines. Fortunately, this reaction applied to tetrabromo N4Py (3), which entails four
palladium-mediated functionalisations on a single molecule, proceeded efficiently to furnish the
cross-coupled product tetraphenyl N4Py (48) in an excellent yield of 80% with no detectable
amounts of products from incomplete cross coupling reactions on 3. These findings seem to
indicate that other high yielding cross coupling reactions on a bromopyridine can also be
applied to provide the corresponding tetrasubstituted N4Py derivatives.
The synthesis of the tetrabromide N4Py derivative 3 could be accomplished by taking
advantage of the reported change in regioselectivity in the lithiation of 2,5-dibromopyridine by
substituting a co-ordinating solvent by a non-co-ordinating solvent.
4 This enabled the
construction of the N4Py core while preserving the remaining bromide on the pyridine ring for
further functionalisation of the final ligand 3. The developed synthetic pathway to tetrabromo
N4Py (3) still requires further optimisation, for instance in the formation of bispyridinyl ketone 8.
The troublesome dialkylation of bispyridinyl methylamine 10 is a well-known problem in the
preparation of many N4Py derivatives, which can sometimes lead to disappointing results.
4.7  Experimentals
General information
For general remarks on instrumentation, methods, and chemicals, see the Experimental Section
in Chapter 3. The NMR spectra of compounds 44 and 45 were recorded on a Bruker 250
spectrometer (
1H NMR at 250 MHz, 
13C NMR at 62.8 MHz). 5-Bromo-2-picoline
21 and
2-methoxy-4,4,5,5-tetramethyl-1,2,3-dioxaborolane
107 were prepared according to literature
procedures and all the spectroscopic data were in good agreement with the literature.103
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5-Bromo-2-pyridinecarbaldehyde
4 (7)
To a suspension of 2,5-dibromopyridine (9.47 g, 39.2 mmol) in dry toluene (500 mL) at –80°C
was slowly added n-BuLi (29 mL, 46 mmol, 1.2 equiv) under a nitrogen atmosphere. After
stirring the mixture at –80°C for 2 h neat DMF (3.9 mL, 50 mmol, 1.3 equiv) was added. The
reaction mixture was allowed to warm to room temperature after an additional hour. Dilute HCl
(1 M, 100 mL) was added and the mixture was stirred for 15 min. After separation the water
layer was extracted with diethyl ether (2x50 mL). The organic layer was washed with brine (50
mL) and dried over Na2SO4. Concentration by rotary evaporation afforded 7 as a light brown
solid (6.66 g, 91%).
108
1H NMR (CDCl3, 300 MHz) δ 7.80 (d, J = 8.1 Hz, 1H), 7.98 (dd, J = 8.1, 2.2 Hz, 1H), 8.80 (d,
J = 1.8 Hz, 1H), 9.99 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ 122.4 (d), 125.9 (s), 139.6 (d),
150.9 (s), 151.3 (d), 192.0 (d). HRMS calcd for C6H4NOBr 184.948, found 184.947.
Bis(5-bromo-2-pyridinyl)methanone (8)
Method A: The same procedure as described for 7, using 2,5-dibromopyridine (8.62 g, 35.6
mmol) and n-BuLi (27 mL, 43 mmol, 1.2 equiv). Quenching the reaction mixture with a solution
of aldehyde 7 (6.64 g, 35 mmol) in dry toluene (175 mL) furnished after workup a residual brown
oil that was taken up in CH2Cl2 (300 mL). Activated MnO2 (12.8 g, 133 mmol, 3.8 equiv) was
added in portions over 8 h to the suspension at reflux. The solvent was evaporated, the residue
filtered through Celite and washed with ethyl acetate. After evaporation of the solvent 8 was
precipitated from diethyl ether as a brown solid (3.07 g, 26%).
109
Method B: The same procedure as described for 7, employing 2,5-dibromopyridine (10.7 g,
44.3 mmol) in dry toluene (1 L) and n-BuLi (29 mL, 46 mmol, 1.05 equiv). After 2 h at –80°C
the reaction was quenched with freshly distilled diethyl carbonate (2.7 mL, 22 mmol, 0.5 equiv).
After further workup and extractions using ethyl acetate, removal of the solvent furnished a dark
brown oil, which solidified on standing. By triturating the crude product with diethyl ether pure
8 was obtained as a light brown solid (2.77 g, 37%). Recrystallisation from diethyl ether
afforded the analytically pure product.
mp 191.8–192.7°C. 
1H NMR (CDCl3, 300 MHz) δ 7.98 (d, J = 8.2 Hz, 2H), 8.03 (dd, J = 8.2,
2.0 Hz, 2H), 8.77 (d, J = 2.0 Hz, 2H). 
13C NMR (CDCl3, 50.3 MHz) δ 124.7 (s), 126.3 (d),
139.4 (d), 150.3 (d), 152.1 (s), 191.0 (s). HRMS calcd for C11H6N2OBr2 339.885, found
339.885. Anal. calcd for C11H6N2OBr2: C 38.60; H 1.80; N 8.20; Br 46.70. Found: C 38.33; H
1.80; N 8.01; Br 47.04.
Bis(5-bromo-2-pyridinyl)methanone oxime (9)
A mixture of 8 (2.77 g, 8.10 mmol), hydroxylammonium chloride (3.0 g, 42 mmol, 5 equiv),
and pyridine (3.4 mL, 42 mmol, 5 equiv) in ethanol (60 mL) was refluxed for 1.5 h and
subsequently cooled to room temperature. The mixture was poured into ice water and stirred in
an ice bath for 1 h. The solids were collected by filtration and washed with cold dilute ethanol
(50%). After drying in air the product was obtained as a light brown solid (2.63 g, 91%).
Recrystallisation from ethanol/water afforded analytically pure 9 as fine, lilac/grey needles.
mp 191.1–191.7°C. 
1H NMR (CDCl3, 300 MHz) δ 7.63 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.4
Hz, 1H), 7.92 (dd, J = 8.4, 1.8 Hz, 1H), 7.99 (dd, J = 8.4, 1.8 Hz, 1H), 8.65 (d, J = 1.8 Hz,
1H), 8.70 (d, J = 1.8 Hz, 1H). 
1H NMR (CD3OD, 300 MHz) δ 7.56 (d, J = 8.4 Hz, 1H), 7.83104
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(d, J = 8.4 Hz, 1H), 8.01 (dd, J = 8.4, 2.2 Hz, 1H), 8.10 (dd, J = 8.4, 2.2 Hz, 1H), 8.50 (d, J
= 2.2 Hz, 1H), 8.68 (d, J = 2.2 Hz, 1H). 
13C NMR (CDCl3, 50.3 MHz) δ 119.8 (s), 120.3 (s),
122.8 (d), 127.0 (d), 138.7 (d), 139.4 (d), 149.5 (d), 150.0 (d), 150.6 (s), 153.0 (s), 153.9 (s).
HRMS calcd for C11H7N3OBr2 354.895, found 354.896. Anal. calcd for C11H7N3OBr2: C 37.00;
H 2.00; N 11.80; Br 44.80. Found: C 36.58; H 2.06; N 11.41; Br 44.58.
Bis(5-bromo-2-pyridinyl)methylamine (10)
Zinc dust (1.1 g, 17 mmol, 3.4 equiv) was carefully added in small portions over 5 min to a
suspension of 9 (1.79 g, 5.01 mmol) in acetic acid (30 mL) and water (15 mL). The mixture was
stirred at room temperature for 30 min, filtered over Celite and washed with water. After
evaporation of the solvent the residue was neutralised with concentrated ammonia (25 mL,
25% v/v) and extracted with CH2Cl2 (3x20 mL). The organic layer was washed with brine (15
mL), dried over Na2SO4, and concentrated in vacuo to furnish pure 10 as a brown viscous oil
that solidified on standing (1.62 g, 94%).
1H NMR (CDCl3, 300 MHz) δ 2.38 (br. s, 2H), 5.24 (s, 1H), 7.29 (d, J = 8.4 Hz, 2H), 7.72 (dd,
J = 8.4, 1.8 Hz, 2H), 8.55 (d, J = 1.8 Hz, 2H). 
13C NMR (CDCl3, 75.5 MHz) δ 61.1 (d), 119.1
(q), 123.0 (d), 139.2 (d), 150.1 (d), 160.6 (q). HRMS calcd for C11H9N3Br2 340.916, found
340.916.
5-Bromo-2-picoline N-oxide (12)
21b
A mixture of 5-bromo-2-picoline (11.7 g, 68.0 mmol) and mCPBA (20.9 g, 97.0 mmol, 1.4
equiv) in CH2Cl2 (300 mL) was stirred at room temperature overnight. Saturated Na2CO3 (300
mL) was added and after stirring for 30 min the layers were separated. The water layer was
extracted with CH2Cl2 (6x50 mL), and the combined organic layers were washed with brine (50
mL) and dried over Na2SO4. Evaporation of the solvent yielded 12 as a light yellow solid that
was recrystallised from diethyl ether (12.5 g, 98%).
mp 119.3–120.4ºC (lit.
110 117–118°C). 
1H NMR (CDCl3, 300 MHz) δ 2.43 (s, 3H), 7.11 (d, J =
8.4 Hz, 1H), 7.29 (dd, J = 8.4, 1.1 Hz, 1H), 8.38 (d, J = 1.1 Hz, 1H). 
13C NMR (CDCl3, 75.5
MHz) δ 17.2 (q), 117.1 (s), 126.3 (d), 128.2 (d), 140.5 (d), 147.9 (s). HRMS calcd for
C6H6BrNO 186.963, found 186.963.
5-Bromo-2-(chloromethyl)pyridine (13)
Protected from moisture TFAA (10 mL, 71 mmol, 5 equiv) was carefully and slowly added to 12
(2.63 g, 14.0 mmol). After the vigorous thermal reaction had ceased, the orange mixture was
stirred at room temperature for 30 min, and then refluxed for 30 min. Saturated NaHCO3 was
carefully added after cooling to room temperature until pH 8 was reached. The resulting red
solution was stirred at room temperature under nitrogen overnight. The mixture was extracted
with CH2Cl2 (6x25 mL), and the combined organic layers were washed with brine (25 mL) and
dried over Na2SO4. Evaporation of the solvent yielded 13 as a dark brown oil (2.15 g, 81%),
which was used without any further purification.
21b
1H NMR (CDCl3, 300 MHz) δ 3.41 (br. s, 1H), 4.72 (s, 2H), 7.20 (d, J = 8.3 Hz, 1H), 7.81 (dd,
J = 8.3, 2.2 Hz, 1H), 8.60 (d, J = 2.2 Hz, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ 63.9 (t), 118.8
(s), 121.9 (d), 139.3 (d), 149.3 (d), 158.5 (s). HRMS calcd for C6H6NOBr 186.963, found
186.965.105
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Thionyl chloride (0.89 mL, 12 mmol, 1.5 equiv) was slowly added to a solution of crude
5-bromo-2-(hydroxymethyl)pyridine (1.51 g, 8.03 mmol) in CH2Cl2 (30 mL) at 0°C, protected
from moisture. After being allowed to warm to room temperature the reaction mixture was
stirred overnight. Saturated NaHCO3 (20 mL) was added and the layers were separated. The
water layer was extracted with CH2Cl2 (3x10 mL). The combined organic layers were washed
with brine (10 mL) and dried over Na2SO4. Concentration by rotary evaporation furnished 13
as a dark brown oil (1.63 g, 97%) that was used without further purification. The product can be
stored at –20ºC under nitrogen for many months without any detectable signs of degradation.
1H NMR (CDCl3, 300 MHz) δ 4.61 (s, 2H), 7.37 (d, J = 8.4 Hz, 1H), 7.84 (dd, J = 8.4, 2.2 Hz,
1H), 8.62 (d, J = 2.2 Hz, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ 45.8 (t), 120.0 (s), 124.0 (d),
139.5 (d), 150.3 (d), 155.0 (s). HRMS calcd for C6H6NClBr 204.929, found 204.929.
N-[Bis(5-bromo-2-pyridinyl)methyl]-N,N-bis[(5-bromo-2-pyridinyl)methyl]amine (3)
A mixture of 10 (0.72 g, 2.1 mmol), 13 (1.8 g, 8.7 mmol, 4 equiv), DIEA (7.2 mL, 41 mmol, 20
equiv), and dry acetonitrile (1.5 mL) was heated at 80°C under a nitrogen atmosphere for 2
days. After evaporation of the solvent the residue was taken up in CH2Cl2 (10 mL), washed with
water (3x5 mL), brine (10 mL), and dried over Na2SO4. Concentration by rotary evaporation
afforded a dark brown, viscous oil that solidified on standing. After purification by flash
chromatography over alumina using a gradient of hexane/ethyl acetate/TEA (40:9:1 to 30:9:1)
and evaporation of the solvents, the residue was precipitated from diethyl ether to furnish 3 as a
white solid (0.83 g, 58%). Recrystallisation from CH2Cl2/diethyl ether afforded pure 3 as white
needles.
mp 151.6–152.2°C. 
1H NMR (CDCl3, 300 MHz) δ 3.84 (s, 4H), 5.21 (s, 1H), 7.40 (d, J = 8.4
Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.72 (dd, J = 8.4, 2.2 Hz, 1H), 7.78 (dd, J = 8.4, 2.2 Hz,
1H), 8.56 (d, J = 2.2 Hz, 1H), 8.59 (d, J = 2.2 Hz, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ 56.3
(t), 70.7 (d), 119.0 (s), 119.5 (s), 124.4 (d), 125.2 (d), 138.9 (d), 139.0 (d), 150.1 (d), 150.3
(d), 157.7 (s). MS CI [M+H]
+ calcd for C23H18Br4N5 m/z 679.8, found 679.9. Anal. calcd for
C23H17Br4N5: C 40.44; H 2.51; N 10.25; Br 46.79. Found: C 39.54; H 2.39; N 9.96; Br 45.60.
3-Phenylpyridine (17)
Method A: A mixture of 3-bromopyridine (0.31 g, 2.0 mmol), phenylboronic acid (0.27 g, 2.2
mmol, 1.1 equiv), Pd(PPh3)4 (69.3 mg, 60 µmol, 3 mol%), aqueous Na2CO3 (2 M, 6 mL), and 4
droplets of ethylene glycol was heated to reflux in THF (12 mL) under a nitrogen atmosphere
overnight. The layers were separated and the organic layer was washed with aqueous Na2CO3
(2 M, 3x5 mL), brine (10 mL), and dried over Na2SO4. Evaporation of the solvent afforded a
yellow oil that was purified by flash column chromatography over silica using hexane/ethyl
acetate/triethylamine (30:9:1) as the eluent to furnish 17 as a colourless oil (0.27 g, 87%). Rf =
0.33 (SiO2, hexane/ethyl acetate=3:1).
Method B: A mixture of tributyl(phenyl)stannane (33) (0.37 g, 1.0 mmol), 3-bromopyridine (14)
(0.16 g, 1.0 mmol), and Pd(PPh3)4 (16 mg, 14 µmol, 1.4 mol%) in dry THF (10 mL) was
heated to reflux under a nitrogen atmosphere for 3 days. Dilute HCl (30 mL, 2 M) was added to
the reaction mixture and the phases separated after stirring for 15 min. The aqueous phase was
washed with CH2Cl2 (3x25 mL) and neutralised with concentrated ammonia (25% v/v). The
resulting suspension was extracted with CH2Cl2 (7x25 mL). The organic phase was washed with106
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brine (25 mL) and dried over Na2SO4. After evaporation of the solvent the crude product was
purified by column chromatography over silica using hexane/ethyl acetate (3:1) to afford 17 as
a colourless oil (50 mg, 32%).
111
1H NMR (300 MHz, CDCl3) δ 7.35 (dd, J = 8.1, 4.6 Hz, 1H), 7.40 (dt, J = 7.0, 2.2 Hz, 1H),
7.47 (dd, J = 7.2, 7.0 Hz, 2H), 7.57 (dt, J = 7.2, 2.2 Hz, 2H), 7.86 (dt, J = 8.1, 1.7 Hz, 1H),
8.58 (d, J = 4.6 Hz, 1H), 8.84 (d, J = 1.7 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3) δ 123.4 (d),
127.0 (d), 127.9 (d), 128.9 (d), 134.1 (d), 136.4 (s), 137.6 (s), 148.1 (d), 148.3 (d). HRMS
calcd for C11H9N 155.074, found 155.073.
2-Methyl-5-phenylpyridine (18)
Following the procedure for 17, compound 18 was obtained as a colourless oil (0.32 g, 95%)
from 5-bromo-2-picoline (0.34 g, 2.0 mmol) after workup and flash column chromatography
over silica using hexane/ethyl acetate/triethylamine (30:9:1) as the eluent. Rf = 0.44 (SiO2,
hexane/ethyl acetate=3:1).
1H NMR (300 MHz, CDCl3) δ 2.56 (s, 3H), 7.15 (d, J = 8.1 Hz, 1H), 7.33 (t, J = 7.0 Hz, 1H),
7.41 (dd, J = 7.5, 7.0 Hz, 2H), 7.51 (d, J = 7.5 Hz, 2H), 7.71 (dd, J = 8.1, 2.4 Hz, 1H), 8.70
(d, J = 2.4 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3) δ 23.9 (q), 123.0 (d), 126.8 (d), 127.6 (d),
128.8 (d), 133.5 (s), 134.5 (d), 137.7 (s), 147.3 (d), 157.0 (s). HRMS calcd for C12H11N
169.089, found 169.089.
3-(3-Pyridinyl)aniline (19)
Following the procedure for 17, compound 19 was obtained as a colourless viscous oil (68 mg,
95%) from 3-bromopyridine (66 mg, 0.42 mmol) and 16 (78 mg, 0.42 mmol) after workup and
flash column chromatography over alumina using hexane/ethyl acetate/triethylamine (9:30:1) as
the eluent. Rf = 0.42 (SiO2, hexane/ethyl acetate=3:1).
1H NMR (200 MHz, CDCl3) δ 3.77 (br. s, 2H), 6.71 (ddd, J = 8.0, 2.1, 1.0 Hz, 1H), 6.86 (dd, J
= 2.1, 1.7 Hz, 1H), 6.94 (ddd, J = 7.7, 1.7, 1.0 Hz, 1H), 7.24 (dd, J = 8.0, 7.7 Hz, 1H), 7.32
(ddd, J = 8.0, 4.7, 0.8 Hz, 1H), 7.82 (ddd, J = 8.0, 2.1, 1.6 Hz, 1H), 8.55 (dd, J = 4.7, 1.6
Hz, 1H), 8.80 (d, J = 2.1 Hz, 1H). 
13C NMR (50.3 MHz, CDCl3) δ 114.9 (d), 116.1 (d), 119.1
(d), 124.8 (d), 131.3 (d), 135.6 (d), 138.3 (s), 140.2 (s), 148.5 (s), 149.6 (d), 149.7 (d). HRMS
calcd for C11H10N2 170.084, found 170.084.
3-(6-Methyl-3-pyridinyl)aniline (20)
Following the procedure for 17, compound 20 was obtained as a light yellow solid (0.14 g,
90%) from 5-bromo-2-picoline (0.14 g, 0.84 mmol) and 16 (0.78 mg, 0.42 mmol) after workup
and flash column chromatography over silica using hexane/ethyl acetate/triethylamine (10:20:1)
as the eluent. Rf = 0.42 (SiO2, hexane/ethyl acetate=3:1).
mp 105.2–106.8°C. 
1H NMR (300 MHz, CDCl3) δ 2.57 (s, 3H), 3.77 (br. s, 2H), 6.68 (dd, J =
7.9, 2.0 Hz, 1H), 6.84 (t, J = 2.0 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 7,17 (d, J = 8.0 Hz, 1H),
7.22 (dd, J = 7.9, 7.6 Hz, 1H), 7.71 (dd, J = 8.0, 2.3 Hz, 1H), 8.67 (d, J = 2.3 Hz, 1H). 
13C
NMR (75.5 MHz, CDCl3) δ 24.1 (q), 113.4 (d), 114.5 (d), 117.3 (d), 123.0 (d), 129.9 (d), 133.8
(s), 134.6 (d), 139.1 (s), 147.0 (s), 147.5 (d), 157.1 (s). HRMS calcd for C12H12N2 184.100,
found 184.099.107
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2-Bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (21)
The same procedure as described for 7, using 2,5-dibromopyridine (1.0 g, 4.2 mmol), n-BuLi
(2.7 mL, 4.4 mmol, 1.04 equiv) in dry diethyl ether (50 mL), followed by quenching with
2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
107 (0.72 g, 4.6 mmol, 1.1 equiv) afforded
after a neutral workup the product as a light yellow solid (0.69 g, 57%).
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1H NMR (300 MHz, CDCl3) δ 1.35 (s, 12H), 7.49 (d, J = 8.1 Hz, 1H), 7.89 (dd, J = 8.1, 1.8
Hz, 1H), 8.69 (d, J = 1.8 Hz, 1H). MS EI [M]
+ calcd for C11H15BBrNO2 m/z 283.0, found 283,
285; [M–CH3]
+ 268, 270. MS CI [M+H]
+ calcd for C11H16BBrNO2 m/z 284.0, found 284, 286;
[M+NH4]
+ 301, 303; [M–Br]
+ 206.
N-(3-Iodophenyl)phthalimide (26)
A mixture of 3-iodoaniline (2.5 g, 11.4 mmol) and phthalic anhydride (1.69 g, 11.4 mmol) was
heated to reflux in acetic acid (50 mL) for 3 h. After cooling to room temperature the
suspension was filtered over Celite and washed with cold ethanol. The residue was taken up in
CH2Cl2 and filtered. Evaporation of the solvent afforded the product as a white powder (3.8 g,
94%), which could be recrystallised from toluene (3.0 g, 76%).
mp 194.5–194.7°C. 
1H NMR (300 MHz, CDCl3) δ 7.22 (t, J = 8.1 Hz, 1H), 7.43 (ddd, J = 8.1,
1.1, 0.7 Hz, 1H), 7.72 (ddd, J = 8.1, 1.5, 1.1 Hz, 1H), 7.79 (dd, J = 5.5, 2.9 Hz, 2H), 7.82
(dd, J = 1.5, 0.7 Hz, 1H), 7.94 (dd, J = 5.5, 2.9 Hz, 2H). 
13C NMR (50.3 MHz, CDCl3) δ 93.7
(s), 123.9 (d), 125.8 (d), 130.4 (d), 131.5 (s), 133.4 (s), 134.6 (d), 135.2 (d), 137.0 (d), 167.1
(s). MS EI [M]
+ calcd for C14H8INO2 m/z 349.0, found  349.
2-Bromo-5-(tributylstannyl)pyridine (30)
To a solution of 2,5-dibromopyridine (10.0 g, 41.4 mmol) in dry diethyl ether (500 mL) at –80°C
under a nitrogen atmosphere was slowly added n-BuLi (27.0 mL, 43.2 mmol, 1.04 equiv). After
60 min at –80°C tributyltin chloride (12.3 mL, 45.2 mmol, 1.1 equiv) was added to the red
solution. After 1 h at –80°C the reaction mixture was allowed to warm to room temperature. A
saturated ammonium chloride solution (125 mL) was added and the layers were separated. The
water layer was extracted with diethyl ether (3x100 mL). The combined organic layers were
washed with brine (50 mL) and dried over Na2SO4. Concentration by rotary evaporation
afforded a light yellow oil, which was purified by flash column chromatography over silica using
hexane/ethyl acetate (30:1) as the eluent to furnish 30 as a colourless oil (18.3 g, 99%). Rf =
0.36 (SiO2, hexane/ethyl acetate=30:1).
1H NMR (300 MHz, CDCl3) δ 0.84–1.62 (m, 27 H), 7.40 (d, J = 7.7 Hz, 1H), 7.56 (dd, J =
7.7, 1.8 Hz, 1H), 8.30 (s, 1H). 
13C NMR (50.3 MHz, CDCl3) δ 9.5 (t), 13.4 (q), 27.0 (t), 28.3 (t),
127.9 (d), 133.4 (s), 134.1 (s), 145.9 (d), 155.9 (d). MS EI [M]
+ calcd for C17H30BrNSn m/z
447.0, found 447; [M–C4H9]
+ 390; [M–2C4H9]
+ 334; [M–3C4H9]
+ 278. MS CI [M+H]
+ calcd
for C17H31BrNSn m/z 448.0, found 448.
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3-(Tributylstannyl)pyridine (31)
The same procedure as described for 30, using 3-bromopyridine (1.49 g, 9.4 mmol), n-BuLi
(6.2 mL, 9.9 mmol, 1.04 equiv) in dry diethyl ether (100 mL), and quenched with tributyltin
chloride (2.8 mL, 10.3 mmol, 1.1 equiv) to furnish a residual yellow oil after workup.
Purification by flash column chromatography over silica using a gradient of hexane/ethyl acetate108
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(30:1 to 3:1) furnished 31 as a colourless oil (3.3 g, 93%). Rf  = 0.29 (SiO2, hexane/ethyl
acetate=30:1).
1H NMR (300 MHz, CDCl3) δ 0.75–1.68 (m, 27H), 7.20 (dd, J = 7.3, 4.6 Hz, 1H), 7.72 (ddd, J
= 7.3, 1.8, 1.5 Hz, 1H), 8.49 (dd, J = 4.6, 1.5 Hz, 1H), 8.58 (s, 1H).
N-(3-(3-Pyridinyl)phenyl)phthalimide (29)
Following the procedure for 17 (Method B), using a mixture of stannane 31 (0.50 g, 1.4 mmol),
iodide 26 (0.47 g, 1.4 mmol), and Pd(PPh3)4 (31 mg, 27 µmol, 2 mol%) in dry THF (10 mL).
Workup and purification afforded 29 as a light brown solid (20 mg, 5%).
111
1H NMR (300 MHz, CDCl3) δ 7.36 (dd, J = 8.0, 4.7 Hz, 1H), 7.49 (m, 1H), 7.61 (m, 2H), 7.66
(s, 1H), 7.80 (dd, J = 5.5, 3.1 Hz, 2H), 7.89 (d, J = 8.0 Hz, 1H), 7.97 (dd, J = 5.5, 3.1 Hz,
2H), 8.60 (d, J = 4.7 Hz, 1H), 8.86 (s, 1H).
N-(3-(6-Bromo-3-pyridinyl)phenyl)phthalimide (32)
The same procedure as described for 29, using stannane 30 (0.67 g, 1.5 mmol). Workup and
purification afforded 32 as a yellow solid (30 mg, 5%).
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1H NMR (300 MHz, CDCl3) δ 7.50–7.64 (m, 5H), 7.75 (dd, J = 8.4, 2.6 Hz, 1H), 7.81 (dd, J =
5.5, 3.3 Hz, 2H), 7.97 (dd, J = 5.5, 3.3 Hz, 2H), 8.60 (d, J = 2.6 Hz, 1H). MS CI [M+H]
+
calcd for C19H11N2BrO2 m/z 379.0, found 379, 381 (396, 398 [M+NH4]
+, 301 [M–Br]
+, 156
[M–Pht–Br]
+).
Tributyl(phenyl)stannane (33)
The same procedure as described for 30, using bromobenzene (0.50 mL, 4.8 mmol), n-BuLi
(3.0 mL, 4.8 mmol) in dry THF (25 mL), and quenched with tributyltin chloride (1.4 mL, 5.3
mmol, 1.1 equiv) to furnish a residual colourless oil after workup. Purification by flash column
chromatography over alumina using hexane/ethyl acetate (30:1) as the eluent furnished 33 as a
colourless oil (1.3 g, 73%). Rf = 0.80 (SiO2, hexane/ethyl acetate=30:1).
1H NMR (200 MHz, CDCl3) δ 0.84–1.56 (m, 27H), 7.23–7.34 (m, 2H), 7.43–7.48 (m, 3H).
13C NMR (50.3 MHz, CDCl3) δ 9.4 (t), 13.6 (q), 27.3 (t), 29.0 (t), 127.8 (d), 136.4 (d), 141.5 (s).
MS EI [M]
+ calcd for C18H32Sn  m/z 368.2, found 367; [M–C4H9]
+ 311; [M–2C4H9]
+ 255;
[M–3C4H9]
+ 197.
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4-(3-Pyridinyl)-3-butyn-1-ol (36)
A mixture of 3-bromopyridine (0.48 mL, 5.0 mmol), freshly distilled 3-butyn-1-ol (0.57 mL, 7.5
mmol, 1.5 equiv), PdCl2(PPh3)2 (35 mg, 50 µmol, 1 mol%), and CuI (4.8 mg, 25 µmol, 0.5
mol%) in dry TEA was stirred at room temperature for 3 days under a nitrogen atmosphere.
The solvent was evaporated in vacuo and the residue was partitioned between CH2Cl2 (10 mL)
and water (10 mL). After separation of the layers the aqueous layer was extracted with CH2Cl2
(5x10 mL). The combined organic layers were washed with water (2x10 mL), brine (10 mL),
and dried over Na2SO4. Evaporation of the solvent afforded an orange oil (0.99 g) that was
purified by flash column chromatography over silica using hexane/ethyl acetate/triethylamine
(20:20:1) as the eluent to furnish 36 as a colourless oil (0.45 g, 62%).
1H NMR (300 MHz, CDCl3) δ 2.58 (t, J = 6.5 Hz, 2H), 3.72 (t, J = 6.5 Hz, 2H), 4.73 (br. s,
1H), 7.08 (dd, J = 8.0, 4.8 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 4.8 Hz, 1H), 8.47109
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(d, J = 1.1 Hz). 
13C NMR (50.3 MHz, CDCl3) δ 23.6 (t), 60.3 (t), 78.0 (s), 91.2 (s), 120.8 (s),
122.9 (d), 138.7 (d), 147.4 (d), 151.7 (d). HRMS calcd for C9H9NO 147.068, found 147.069.
4-(3-Pyridinyl)-3-butynyl acetate (37)
Following the procedure for 36, compound 37 was obtained as a light yellow oil (0.44 g, 47%)
from 14 (0.48 mL, 5.0 mmol) and 35 (0.72 g, 7.5 mmol, 1.5 equiv) after workup and flash
column chromatography over alumina using hexane/ethyl acetate (9:1) as the eluent.
1H NMR (300 MHz, CDCl3) δ 2.07 (s, 3H), 2.74 (dd, J = 7.0, 6.6 Hz, 2H), 4.23 (dd, J = 7.0,
6.6 Hz, 2H), 7.19 (dd, J = 7.7, 4.9 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 8.47 (d, J = 4.9 Hz,
1H), 8.61 (s, 1H). 
13C NMR (75.5MHz, CDCl3) δ 19.9 (q), 20.8 (t), 62.1 (t), 78.8 (s), 89.1 (s),
122.9 (s), 138.5 (d), 148.3 (d), 151.0 (d), 152.4 (d), 169.1 (s). MS CI [M+H]
+ calcd for
C11H12NO2 m/z 190.1, found 190.
3-Pyridinylalanine derivative 44
Zinc dust (0.13 g, 2.0 mmol, 2 equiv) was activated by heating under vacuum in the presence of
iodine (15 mg, 60 µmol). After cooling under a nitrogen atmosphere, a solution of iodoalanine
41 (0.33 g, 1.0 mmol) in dry DMF (0.30 mL) was added at 0°C and stirred for 3 h. PdCl2(PPh3)2
(38 mg, 54 µmol, 5.4 mol%) and 3-bromopyridine (0.21 g, 1.3 mmol, 1.3 equiv) were added
and the mixture was stirred at 40°C for 4 h. Water (10 mL) and ethyl acetate (10 mL) were
added and the layers were separated. After extracting the aqueous layer with ethyl acetate
(3x10 mL), the combined organic layers were washed with water (3x10 mL) and dried over
MgSO4. Evaporation of the solvent afforded a yellow oil (0.45 g), which was purified by column
chromatography over silica using a gradient of petroleum ether (40-60)/ethyl acetate (2:1 to 1:1) to
afford pure 44 as a light yellow oil (0.08 g, 29%). Rf = 0.29 (SiO2, hexane/ethyl acetate=30:1).
1H NMR (250 MHz, CDCl3) δ 1.38 (s, 9H), 2.98 (dd, J = 14.0, 6.4 Hz, 1H), 3.12 (dd, J = 14.0,
5.5 Hz, 1H), 3.68 (s, 3H), 4.53 (ddd, J = 7.6, 6.4, 5.5 Hz, 1H), 5.74 (d, J = 7.6 Hz, 1H), 7.17
(dd, J = 7.9, 4.7 Hz, 1H), 7.44 (dt, J = 7.9, 1.4 Hz, 1H), 8.28 (s, 1H), 8.44 (dd, J = 4.7, 1.4
Hz, 1H). 
13C NMR (62.8 MHz, CDCl3) δ 28.1 (q), 35.5 (t), 52.3 (q), 54.0 (d), 80.0 (s), 123.3 (d),
131.7 (s), 136. 7 (d), 148.3 (d), 150.4 (d), 154.8 (s), 171.7 (s).
2-Pyridinylalanine derivative 45
The same procedure as described for 44, using 2-bromopyridine (0.21 g, 1.3 mmol, 1.3 equiv)
to afford after workup and column chromatography pure 45 as a light yellow oil (0.11 g, 39%).
Rf = 0.46 (SiO2, hexane/ethyl acetate=30:1).
1H NMR (250 MHz, CDCl3) δ 1.37 (s, 9H), 3.20 (dd, J = 14.6, 5.3 Hz, 1H), 3.28 (dd, J = 14.6,
5.5 Hz, 1H), 3.65 (s, 3H), 4.64 (ddd, J = 8.3, 5.5, 5.3 Hz, 1H), 5.87 (d, J = 8.3 Hz, 1H), 7.03
(m, 2H), 7.50 (dt, J = 7.6, 1.8 Hz, 1H), 8.40 (dd, J = 4.0, 1.8 Hz, 1H). 
13C NMR (62.8 MHz,
CDCl3) δ 28.20 (q), 39.20 (t), 52.15 (q), 52.90 (d), 79.61 (s), 121.72 (d), 123.61 (d), 136.45
(d), 149.10 (d), 155.42 (s), 157.06 (s), 172.35 (s).
2-Cyano-5-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine (47)
114
A mixture of bromide 41
115 (3.0 g, 10 mmol), Zn(CN)2 (0.70 g, 6.0 mmol), dppf (8.4 mg, 15
µmol, 0.15 mol%), and Pd2(dba)3 (5.9 mg, 6.4 µmol, 0.064 mol%) was heated in DMF (5 mL)
and water (50 µL) under nitrogen at 110°C overnight. After the addition of water (10 mL) and110
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diethyl ether (25 mL) the layers were separated. The organic layer was washed with water (4x5
mL), brine (5 mL), and dried over Na2SO4. Evaporation of the solvent furnished a black residue
that was purified by flash column chromatography over silica using a gradient of hexane/diethyl
ether (5:1 to 3:1). The product was obtained as a light brown oil (0.98 g, 40%). Rf = 0.43
(SiO2, hexane/diethyl ether=3:1).
1H NMR (CDCl3, 300 MHz) δ 0.11 (s, 6H), 0.93 (s, 9H), 4.81 (s, 2H), 7.66 (d, J = 8.1 Hz, 1H),
7.80 (dd, J = 8.1, 1.1 Hz, 1H), 8.64 (s, 1H). 
13C NMR (CDCl3, 75.5 MHz) δ –5.4 (q), 18.1 (s),
25.7 (q), 62.0 (t), 117.3 (s), 128.0 (d), 132.1 (s), 134.2 (d), 140.9 (s), 148.9 (d). HRMS calcd
for C13H20N2OSi 248.134, found 248.135.
N-[Bis(5-phenyl-2-pyridinyl)methyl]-N,N-bis[(5-phenyl-2-pyridinyl)methyl]amine (48)
A mixture of tetrabromo N4Py (3) (0.20 g, 0.30 mmol), phenylboronic acid (0.36 g, 3.0 mmol,
10 equiv), Pd(PPh3)4 (40 mg, 34 µmol, 12 mol%), aqueous Na2CO3 (2 M, 2 mL), and 4
droplets of ethylene glycol was heated at reflux in toluene (4 mL) under a nitrogen atmosphere
overnight. The layers were separated and the aqueous phase was extracted with CH2Cl2 (3x10
mL). The combined organic layers were washed with aqueous Na2CO3 (2 M, 3x5 mL), brine
(10 mL), and dried over Na2SO4. Evaporation of the solvent afforded the product as a dark
yellow oil that solidified upon standing (0.16 g, 80%).
1H NMR (300 MHz, CDCl3) δ 4.10 (s, 4H), 5.50 (s, 2H), 7.30–7.90 (m, 28H), 8.72 (d, J = 2.2
Hz, 2H), 8.82 (s, 1H). 
13C NMR (50.3 MHz, CDCl3) δ 57.3 (t), 72.4 (d), 115.6 (d), 119.0 (d),
123.0 (d), 123.8 (d), 126.8 (d), 126.9 (d), 127.8 (d), 128.2 (d), 128.4 (d), 128.8 (d), 131.8 (d),
132.0 (d),134.6 (d), 134.7 (s), 134.9 (s), 137.5 (d), 147.2 (d), 147.6 (d), 158.3 (s), 158.6 (s).
MS CI [M+H]
+ calcd for C47H38N5 m/z 672.3, found 672; Fragmentations m/z 352, 323, 170.
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6-({[bis(5-bromo-2-pyridinyl)methyl][(5-formyl-2-pyridinyl)methyl]amino}methyl)-
nicotinaldehyde (49c)
To 3 was added isopropylmagnesium bromide (4.5 equiv, 2 M in THF) and the mixture was
stirred at room temperature for 1 h. A sample was quenched with water and analysed by ESI-MS
to reveal the mass of 49a. More isopropylmagnesium bromide (4 equiv) was added and the
reaction mixture was heated to reflux for 1 h. Dry DMF (15 equiv) was added. The mixture was
washed with water, brine, and dried over Na2SO4. Evaporation of the solvent afforded a brown oil.
 
1H NMR (300 MHz, CDCl3) δ 4.03 (s, 4H), 5.27 (s, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.71 (d, J =
8.2 Hz, 2H), 7.76 (dd, J = 8.2, 1.8 Hz, 2H), 8.07 (dd, J = 8.2, 1.8 Hz, 2H), 8.58 (d, J = 1.8
Hz, 2H), 8.93 (d, J = 1.8 Hz, 2H), 10.04 (s, 2H). 
13C NMR (50.3 MHz, CDCl3) δ 58.0 (t), 71.8
(d), 120.5 (s), 124.1 (d), 126.0 (d), 130.9 (s), 136.9 (d), 139.8 (d), 150.2 (d), 152.4 (d), 158.2
(s), 166.2 (s), 191.1 (d).
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N4Py iron complexes
5.1  Introduction
Several tetrasubstituted N4Py derivatives have been described in earlier chapters.
1 The synthesis
of such pentadentate ligands was centred on the construction of a tetrafunctionalised N4Py
derivative that would facilitate the covalent attachment of four peptide chains (Chapter 3).
During the development of a synthetic pathway to this type of template, some N4Py derivatives
were prepared enabling the spectroscopic features and the oxidation behaviour of their iron
complexes to be examined. These experimental results will be presented and discussed in this
chapter. Furthermore, the peroxidase activity of a N4PyFe-peptide complex will be described,
as well as the stability of the sulphur linker that has been used to couple the peptides to the
ligand.
5.2  Iron(II) complexes of tetrasubstituted N4Py ligands
The iron(II) complex 2a of N4Py (1a) has previously been fully characterised and has shown to
be a good functional mimic of the non-haem glycopeptide iron bleomycin (Fe–BLM).
2 A
catalytic cycle was proposed for N4PyFe (summarised in Chapter 2),
2 which could also be
applicable to Fe–BLM.
Several structural variations on 2a have been carried out to ascertain the correlation
between the composition of the iron(II) complex and its oxidation behaviour.
2b These changes
involved altering the oxidation state of the metal ion, the nature of axial ligand, and the N4Py
ligand itself. Various mono- and disubstituted derivatives of 1a and their iron complexes have
been prepared and characterised as low-spin iron(II) complexes.
2 The complex 2a will be
referred to here only as a reference for the newly developed tetrasubstituted N4Py complexes
2b–f.
2,3118
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Scheme 5.1. The iron(II) complexes of N4Py (1a) and tetrasubstituted N4Py
derivatives 1b–f (peptide=Ac–CGLHELLKG–NH2, coupled via the cysteine residue).
4
Upon the addition of iron(II) perchlorate to the pentadentate ligands 1a–f in acetonitrile the iron
complexes  2a–f were obtained (Scheme 5.1). The synthesis and characterisation of these
tetrasubstituted N4Py derivatives 1b–f have been described in earlier chapters. The
corresponding iron complexes have not yet been discussed with the exception of 2e and 2f,
which were described in Chapter 3.
5
The 
1H NMR spectra of 2b–d in CD3CN revealed signals in the diamagnetic range of 0–10
ppm, which is distinctive for low-spin iron(II) complexes of N4Py ligands.
2 The UV-Vis
absorption bands of 2b–f (Table 5.2 p. 123, Figure 5.5 p. 122) also correlate well with those of
the previously prepared iron(II) complexes of N4Py derivatives with maximum absorptions
typically around 380 and 460 nm as expected.
2b,5 In addition, the electrospray ionisation mass
analyses (ESI-MS) were in accordance with the postulated composition of the complexes 2b–d.
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m/z (amu)
Figure 5.1. The 
1H NMR spectrum of 2b in CD3CN (left), and the observed and calculated
isotope distribution patterns for [2b–(ClO4)
––(MeCN)]
+ (top and bottom right,
respectively).
The solvent not only has an effect on the λmax and the extinction coefficient (vide infra), but also
on the stability of the iron(II) complexes of N4Py and its derivatives. In solvents such as acetone,
methanol, or water the stability is limited to approximately one day, presumably due to the
exchange of the axial ligand.
2b Therefore, it is not surprising that these complexes are most
stable in acetonitrile, for at least several weeks, as verified by UV-Vis spectroscopy.119
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The characteristic UV-Vis absorption bands for [(N4Py4Br)Fe(MeCN)](ClO4)2 ( 2b) in
methanol were found to be extremely temperature-dependent. The individual absorption bands
for 2b around 380 and 460 nm could not be detected at 20°C, although these bands became
more distinct as the temperature was lowered, which was accompanied by an increase in
absorption (Figure 5.2). The extinction coefficient of 2b at –10°C, however, is still significantly
lower than that observed for 2a under similar conditions (2a: λmax 453 nm, ε 42 x 10
2 M
–1cm
–1;
2b: λmax 455 nm, ε 26 x 10
2 M
–1cm
–1).
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Figure 5.2. UV-Vis spectra of 2b: increase in absorption in methanol as the
temperature is lowered from 20°C to 5, 0, –5, –10, and –15°C, respectively.
Figure 5.3. Temperature-dependent 
1H NMR spectra of 2b in CD3OD.120
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A plausible explanation for this temperature-dependent UV-Vis absorption of 2b in methanol
might be the initial formation of a high-spin Fe
IIIOMe complex at room temperature. This
species has previously also been described for 2a,
2b although it is not as readily formed as that
of 2b. As the temperature is then lowered, this species becomes a low-spin iron(II) complex. The
spin transition was confirmed by temperature-dependent 
1H NMR analysis (Figure 5.3), which
revealed a paramagnetic spectrum with very broad signals in the range of 0 to 100 ppm at 10°C
and higher temperatures. At –10°C a diamagnetic spectrum was observed with well defined,
although broadened signals from 0 to 10 ppm. The exact composition of this low-spin species
and the process involved still need to be ascertained.
Crystals of the iron(II) complexes 2b and 2c suitable for X-ray analysis were obtained by
the slow diffusion of ethyl acetate into their solutions in acetonitrile (Figure 5.4). Five
co-ordination sites to the iron centre are occupied by the chelating ligand and a solvent derived
acetonitrile molecule functions as an axial ligand. This mode of co-ordination to the metal ion is
analogous to that observed for N4Py (1a).
3 As can be seen in Figure 5.4, the bromine atoms of
1b and the side chains in 1c are directed away from the iron centre in the complex. The same
spatial arrangement can, therefore, also be predicted for other tetrasubstituted N4Py ligands
with functional groups in the same positions as in 1b and 1c.
Although the iron-nitrogen bond lengths of 2b and 2c are comparable to those found for
N4PyFe (2a), all of the bonds between the pyridine nitrogens and the iron centre (Fe–Npy) are
shorter than was found for 2a (Table 5.1). In contrast to 2a, the bond lengths of the iron centre
to the acetonitrile nitrogen (Fe–NMeCN) in 2b and 2c are slightly elongated, whereas the bond
lengths of the tertiary amine to the metal centre (Fe–Namine) are comparable in all three
complexes. Another difference is the distance of the iron centre above the mean plane that is
constructed by the four equatorial pyridine nitrogen atoms (Fe–Npy–mean plane), which are identical
in 2a and 2b but is shorter in 2c. Electronic effects alone are, in our opinion, insufficient to
explain these observations. Therefore, these minor differences in bond lengths in 2a, 2b and 2c
are most likely due to the differences in temperature during the X-ray analysis (See footnote in
Table 5.1).
Table 5.1. Selected bond distances for 2b and 2c. The standard deviations are given in
parentheses (2a is included for comparison).
a
Bond (Å) 2a
3 2b
6 2c
Fe–Namine N1 1.961(3) 1.965(3) 1.958(3)
Fe–Npy N2 1.976(3) 1.965(3) 1.957(3)
N3 1.967(3) 1.956(3) 1.960(3)
N4 1.968(3) 1.962(3) 1.960(3)
N5 1.975(3) 1.970(3) 1.967(3)
Fe–NMeCN N6 1.915(3) 1.927(4) 1.928(3)
Fe–Npy–mean plane 0.2071(5) 0.207(1) 0.197(1)
a) X-ray diffraction of 2a was performed at 130 K, 2b at 90 K, and 2c at 100 K.121
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Figure 5.4. Pluto representation of 2b (top) and 2c (bottom). Hydrogen atoms and
counterions are omitted for clarity.122
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5.3  Iron(III) hydroperoxo species
Upon the addition of excess hydrogen peroxide to 2a–f the iron complexes are converted to the
corresponding iron(III) hydroperoxo species 3a–f (Scheme 5.2). The nature of this species was
previously elucidated for N4PyFe (2a),
2 and the mechanism of its formation and further reaction
is also considered to be applicable to other N4Py derivatives. In acetone the conversion to the
hydroperoxide species (Fe
IIIOOH) is fast and complete, and can be monitored by UV-Vis
spectroscopy (depicted in Figure 5.5 for 2a–d). The complex 2e can also be converted into its
Fe
IIIOOH species 3e, although this was considerably less stable, was prepared as a model for
peptide-bound N4PyFe complexes like 2f to study the stability of the complex and its sulphur
linker towards the applied oxidative conditions (vide infra).
acid
base H2O2
3a-f
(L)FeII(MeCN)
2a-f 4
OH
O (L)FeIII
(L)FeIII 
O
O
+ 2+ 2+
Scheme 5.2. Formation of the purple end-on Fe
IIIOOH species 3a–f from the
corresponding iron(II) complexes 2a–f, and the reversible conversion of 3a to the blue
Fe
IIIO2 species 4.
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Figure 5.5. UV-Vis spectra of the iron(II) complexes 2a–d (solid lines) and the
corresponding Fe
IIIOOH species 3a–d (dashed lines) in acetone at 20°C.
The spectroscopic data for the iron(II) complexes 2a–d and their iron(III) hydroperoxo species
3a–d are summarised in Table 5.2 where acetone or acetonitrile was employed as the solvent.
The purple intermediates 3b and 3c exhibit absorptions around 540 nm with extinction
coefficients of 1000–1200 M
–1cm
–1, which are characteristic for low-spin end-on Fe
IIIOOH
species.
2,7 The lower extinction coefficients of 3d and 3e were attributed to the rapid
decomposition of the intermediate, which is thought to occur during the conversion of the123
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iron(II) complex to the hydroperoxide species. The degradation of 3d was also accompanied by
a substantial amount of catalase activity, which involves the decomposition of hydrogen
peroxide to dioxygen and water.
Similar to the complexes 2a–d, the characteristics and the stability of the Fe
IIIOOH
intermediate was also found to be solvent-dependent. The general trend comprises of a small
red shift for the iron(II) complexes on the exchange of acetonitrile as the solvent for acetone,
which becomes more distinct for the corresponding Fe
IIIOOH species. In addition, the
complexes 2a–d generally exhibit a higher extinction coefficient in acetonitrile, in contrast to
their corresponding Fe
IIIOOH species 3a–d. This is considered to be caused by the unfavourable
exchange of the axial ligand in acetonitrile, which results in a slow and incomplete formation of
the peroxide species 3a–d, and consequently leads to a lower absorption intensity for these
intermediates.
2
Table 5.2. Spectroscopic data of the Fe
II and Fe
IIIOOH complexes of N4Py and its derivatives in
acetone at room temperature.
a
[(L)Fe
II(MeCN)](ClO4)2 [(L)Fe
IIIOOH](ClO4)2
Entry Ligand (L) λmax (nm) ε (x 10
2 M
–1cm
–1) λmax (nm) ε (x 10
2 M
–1cm
–1)
1 1a 457 (455) 53 (48) 539 (520) 11 (7.2)
2 1b 464 (460) 70 (88) 553 (544) 11 (8.9)
3 1c 461 (457) 41 (59) 538 (522) 10 (7.8)
4 1d 457 (454) 33 (46) 531 (517) 8.2 (6.4)
5 1e
b 456 (n.d.) 37 (n.d.) 525 (n.d.) 3.4 (n.d.)
a) The results in parentheses refer to acetonitrile as solvent. n.d.=not determined.
b) At 0°C, λmax,2e 457 nm, ε 26 x 10
2 M
–1cm
–1; λmax,3e 531 nm, ε 3.7 x 10
2 M
–1cm
–1.
It is known that a more electron-withdrawing ligand will be a weaker σ bond donor and a
stronger π acceptor.
7 Consequently, the electron density on the metal centre will be decreased,
thus resulting in a higher redox potential of the corresponding complex.
2b,7 The decrease in the
energy of the ligand-to-metal charge transfer band for the Fe
IIIOOH species will be accompanied
by an increase in the λmax.
2b,7 Substituents at the 5-position of the pyridine rings in disubstituted
N4Py ligands were previously found to have only a minor electronic effect on the metal ion.
2b
However, the redox potential of the tetrabromide N4PyFe derivative 2b was found to be
substantially higher than that of N4PyFe 2a (E½=1010 mV vs. SCE)
2 and a dibromo N4PyFe
derivative
8 (E½=1100 mV vs. SCE).
2b The cyclic voltammetry measurements for 2b displayed a
reversible oxidation wave with a redox potential for the Fe
II/Fe
III couple of 1198 mV vs. SCE
and an observed peak-to-peak separation of 105 mV (Figure 5.6). Forward and reverse
differential pulse voltammetry at a scan rate of 10 mVs
–1 confirmed this process to be reversible
with a redox potential for the Fe
II/Fe
III couple of 1196 mV vs. SCE.
The general trend infers that the introduction of a greater number of electron-withdrawing
groups into the N4Py ligand results in an increase in the redox potential of the corresponding124
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Figure 5.6. Cyclic voltammogram of 2b in acetonitrile at 22°C (scan rate 100 mVs
–1).
iron(II) complex. This in turn gives rise to the observed relatively large red shift for the Fe
IIIOOH
species 3b (Table 5.2, entries 1 and 2). The electronic effect of the methoxymethyl groups or
the alkyl spacers in 3c and 3d influence the absorption maxima only to a minor extent.
Unfortunately, as the redox potentials for 2c and 2d have not yet been determined, conclusive
evidence cannot be provided for the relationship between the redox potential of N4PyFe
complexes and the absorption maximum of their iron(III) hydroperoxo species.
The Fe
IIIOOH species of 2e could not be detected by a stepwise titration of the iron(II)
complex with hydrogen peroxide in acetone at room temperature. However, when a single
aliquot of excess hydrogen peroxide was added to 2e the intermediate 3e could be observed for
a limited period. Its lifetime was significantly extended to approximately fifteen minutes by
reducing the temperature of the solution to 0°C. The pH appeared to have only a minor effect
on the extinction coefficient of 2e (λmax 452 nm, εpH 4 35 x 10
2 M
–1cm
–1, εpH 7 38 x 10
2 M
–1cm
–1,
εpH 10 33 x 10
2 M
–1cm
–1) at room temperature. The intermediate 3e could not be detected even
under these conditions. A fine light yellow solid was always observed in the cuvette subsequent
to these UV-Vis experiments. Unfortunately, the identity of this material could not be established
by mass analysis. Nevertheless, it was hypothesised that this residue could be the product from
the oxidative degradation of the ligand. Similar observations were made when employing the
dipeptide-bound N4PyFe complex described in Chapter 2.
9
In an attempt to oxidise 1,2,4,5-tetramethoxybenzene (Scheme 5.5C, p. 130) by 2e the
oxidation reaction was monitored by ESI-MS at room temperature. It was verified that a rapid
decomposition of the catalyst occurred in the absence of any detectable oxidation of the
substrate (Figure 5.7). Although the intensities of the peaks cannot be quantified, it is clear that
the disappearance of 2e (m/2z 646.0 amu for [M–2(ClO4)
––(MeCN)]
2+) is accompanied by the
formation of a new, related species, possibly from the oxidation of the sulphur atoms in ligand 1e.
One suggestion for the assignment of the peak at 654.6 amu is the introduction of one
oxygen atom in the doubly-charged species from 2e. The mass of 670.4 amu could originate
from the complex 2e after the oxidation of three sulphur atoms to the corresponding
sulphoxides. If so, it still remains a mystery as to why no further oxidation of the sulphur linkers
was observed. The visual observations during the UV-Vis experiments, however, did confirm
that the catalyst had decomposed under the employed oxidative conditions (vide supra). The125
Characterisation and application of tetrasubstituted N4Py iron complexes
600 650 700
0
20
40
60
80
100
7
0
7
.
5
6
4
6
.
0
R
e
l
a
t
i
v
e
 
I
n
t
e
n
s
i
t
y
 
(
%
)
m/z (amu)
600 650 700
6
7
8
.
4
7
0
1
.
5
6
9
0
.
6
6
7
0
.
4
6
5
4
.
6
6
4
6
.
1
6
1
9
.
4
m/z (amu)
600 650 700
6
7
0
.
4
6
4
1
.
3
6
1
9
.
4
m/z (amu)
Figure 5.7. ESI-MS analysis for the oxidation of 1,2,4,5-tetramethoxybenzene by 2e
(m/2z 646.0 amu) at room temperature by hydrogen peroxide at t=0 (A), t=1 min
(B), and t=20 min (C).
masses at m/z 619.4 and 641.3 were assigned to singly-charged species, although their exact
identity still remains unknown, as is the structure of the doubly-charged species at m/z 690.6
and 701.5. These observed masses, however, also cannot be assigned to the corresponding
Fe
IIIOOH intermediate.
The iron(III) hydroperoxo species 3a (λmax 548 nm, ε 12 x 10
2 M
–1cm
–1) can be deprotonated
reversibly to the conjugate base 4 (λmax 690 nm, ε 440 M
–1cm
–1) in methanol at –10°C (Scheme
5.2). UV-Vis, EPR, and resonance Raman spectroscopy as well as ESI-MS analysis established
the nature of this high-spin Fe
III–η
2–O2 species 4.
10 It can be assumed that this interconversion
will also be applicable to the iron(II) complexes of N4Py derivatives in general.
Although the purple intermediate 3b can be generated readily in acetone and acetonitrile at
20°C, in methanol this conversion is by no means complete (λmax 557 nm, ε 3.5 x 10
2 M
–1cm
–1).
Surprisingly, no significant formation of 3b was observed at –10°C in methanol. Instead a new
small absorption at 509 nm was detected (Figure 5.8). Presumably, the axial methoxy ligand in
the Fe
IIIOMe species that is formed in situ is bound too strongly to the metal ion, and thus
prevents a facile conversion to the purple intermediate 3b. The addition of base resulted in the
immediate disappearance of the absorption bands for the observed intermediate, but did not
lead to the formation of a Fe
III–η
2–O2 species as found for 3a. This was surprising as it was
assumed that the electron-withdrawing bromides in the Fe
IIIOOH species 3b would promote its
deprotonation. However, if the Fe
IIIOOH species is not formed due to the strongly bound
methoxy ligand, then this would explain the absence of the corresponding blue species.
A BC126
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Figure 5.8. UV-Vis spectra of 2a and 2b in methanol at –10°C (thin solid lines), after
the addition of 5 equiv H2O2 (dashed lines), and 5 equiv NH4OH (dotted lines)
(#=3b+5 equiv NH4OH).
5.4  Oxidation of organic substrates
As previously observed for 2a, its Fe
IIIOOH species is capable of oxidising a variety of organic
substrates such as benzene, styrene, benzyl alcohol, cyclohexene and cyclohexane.
11 The
proposed mechanism for the oxidation of alkanes was discussed and summarised in Chapter
2.
2b,11b
3a
[(N4Py)FeIIIOO H ] 2+ + [(N4Py)FeIV =O]2+ OH
homolytic
cleavage
OH H2O
OH]2+ [(N4Py)FeIII
products RH R
[(N4Py)FeIV =O]2+
Scheme 5.3. Proposed mechanism for substrate (R–H) oxidation by 3a.
2b
The influence of the substituents in the ligands 1b–d towards the oxidation behaviour of the
corresponding iron(II) complexes 2b–d was examined using the substrates cyclohexene (5) and
cyclohexane (9) (Scheme 5.4). These substrates were selected due to their high turnover
(expressed in TON, mol product per mol catalyst) in oxidation reactions catalysed by 2a and
thereby provided a suitable basis on which to assess the catalytic activity of 2b–d.127
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H2O2
2a-d
++
56 7 8
(A)
11 10 9
+
2a-c
H2O2
O OH
(B)
Scheme 5.4. The anticipated products for the oxidation of cyclohexene (A) and
cyclohexane (B).
The catalytic oxidation reactions were carried out in acetone or acetonitrile at 20°C under a
nitrogen atmosphere in the presence of an excess of substrate (substrate/H2O2/catalyst=
1000:100:1). The catalysts 2a–d were used as a stock solution in acetonitrile. The oxidation
was initiated by the addition of a single aliquot of hydrogen peroxide. Within the examined
time-span a blank reaction by hydrogen peroxide could not be detected, even in the presence of
an equal catalytic quantity of iron perchlorate. Therefore, the observed oxidation of the
substrates was solely attributed to the catalytic activity of 2a–d. The conversions of 5 and 9 over
time employing acetone as the solvent are shown in Figure 5.9 and Figure 5.10, respectively.
Table 5.3 summarises the TONs of the catalysts when subjected to a reaction time of one hour.
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Figure 5.9. Catalytic oxidation of cyclohexene to cyclohexenol (solid) and
cyclohexenone (open) by hydrogen peroxide in acetone at 20°C (2a: ––,–□–;
2b: ––,–◊–; 2c: ––,–Δ– ; 2d: –○–,––).
The iron(II) complex 2a is clearly the most active catalyst of all the complexes 2a–d for the
oxidation of cyclohexene. The final TON of 21.3 for 2a (Table 5.3, entry 1) was comparable to
the previously reported TON of 23.1.
11b Although the purple colour of the Fe
IIIOOH128
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intermediates 3a–c disappeared after approximately 15 minutes, the oxidation reaction ceased
after a further 15 minutes for 2a and 2b, as can be seen in Figure 5.9 and Figure 5.10. This
observation was not attributed to a complete deactivation of the catalyst, as the addition of
further hydrogen peroxide caused the reaction to recommence. The same was also applicable to
2b, which, although less active than 2a, displayed a similar oxidation behaviour over time.
Within the timeframe of one hour the reactivity of the catalyst 2c towards cyclohexene was
not only lower than that of 2a or 2b, it was also almost linear as opposed to the exponential
curves as observed for 2a and 2b. In addition, the dissipation of the curves for 2c in Figure 5.9
indicates an increased product selectivity over time. The catalyst 2d seemed to be deactivated
almost immediately and consequently did not yield more than two turnovers (Table 5.3). In all
the above cases, the oxidation product cyclohexene oxide (8) was only formed in minute
quantities, if at all.
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Figure 5.10. Catalytic oxidation of cyclohexane to cyclohexanol (solid) and
cyclohexanone (open) by hydrogen peroxide in acetone at 20°C (2b: ––,–◊–;
2c: ––,–Δ–).
In the oxidation of cyclohexane the behaviour of the catalysts 2b and 2c was comparable to
that shown in Figure 5.9. As before, the iron(II) complex 2b was found to be less reactive than
2a (Table 5.3, entry 2) and the conversion ceased after approximately thirty minutes. In
addition to this, the activity of 2c proceeded beyond the allocated reaction time of one hour,
which was accompanied by an increased selectivity over time. Due to the previously observed
deactivation of the catalyst 2d, this iron(II) complex was not examined for the oxidation of
cyclohexane.
In order to determine the maximum number of turnovers for each catalyst, an excess of
hydrogen peroxide was slowly administered to the reaction mixture over one hour. The results
in Table 5.3 (in brackets) not only illustrated that a higher turnover can be obtained, but also
that the selectivity of the reaction is inverted when cyclohexene is employed as the substrate.
This selectivity is best expressed as the ratio of alcohol over ketone product (A/K). The ratios in
Table 5.4 indicate that this selectivity is virtually unaffected using the substrate cyclohexane,
which suggests that the mechanism involved is also unaffected. In general, an A/K ratio of one129
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Table 5.3. Turnover numbers of the iron(II) complexes of N4Py and its derivatives for the
catalytic oxidation reactions in acetone after one hour at room temperature.
a
Entry Substrates Products 2a 2b
b 2c 2d
1 cyclohexene 6 21 (24) 16 (17) 13 (14) 2 (2)
7 7 (5) 5 (27) 5 (31) 2 (4)
8 – (13) 0.1 (3) 2 (8) 1 (2)
2 cyclohexane 10 17
c 11 (16) 9 (16) n.d.
11 7
c 5( 9 ) 4( 6 ) n . d .
a) Results in parentheses refer to a slow addition of 2000 equiv H2O2 over one hour.
b) TONs in acetonitrile as the solvent:  6: 8,  7: 5, 8: –.
(Compared to N4PyFe:
c 6: 28, 7: 7, 8: 1)
c)  Taken from the Ph. D. thesis of Gerard Roelfes.
2,11b
will be obtained if free radical intermediates are involved in the reaction,
12 which can react, for
instance, with dioxygen to propagate a radical chain auto-oxidation process. This ratio is only
observed for the oxidation of cyclohexene by 2d. In light of the calculated A/K ratio and the
catalase activity during the UV-Vis experiments (vide supra), the decomposition of 2d is
attributed to the formation of free radicals during the oxidation reaction.
Table 5.4. The ratios of alcohol (A) over ketone (K) product formation in acetone at 20°C.
a
Entry Catalyst A/K (cyclohexene) A/K (cyclohexane)
1 2a 3.0 (0.4) 2.6 (n.d.)
b
2 2b 3.4 (0.6) 2.1 (1.7)
3 2c 2.4 (0.5) 2.2 (2.6)
4 2d 1.1 (0.5) n.d.
a)  Results in parentheses refer to a slow addition of 2000 equiv H2O2 over 1 h.
b)  Taken from the Ph. D. thesis by Gerard Roelfes.
2
The Fe
IIIOOH intermediate in the presence of hydrogen peroxide is capable of oxidising
alcohols like cyclohexanol to the corresponding ketone.
11b However, the observed A/K<1 for
cyclohexene upon the slow addition of excess hydrogen peroxide is not due to the in situ
oxidation of the alcohol to the ketone, as the A/K ratios were found to be relatively constant for
2b and 2c during and after the addition of hydrogen peroxide. It was previously established that
slow addition of 100 equivalents of hydrogen peroxide leads to an increase in the A/K ratio.
11b
Presumably, the addition of 2000 instead of 100 equivalents of hydrogen peroxide with respect
to the catalyst has affected the rate-determining step of the reaction, or altered the mechanism.
However, at the present time no conclusive evidence can be provided to either support or
disprove this conjecture. A full kinetic study will have to be undertaken to provide such130
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evidence. The higher hydrogen peroxide concentration can also give rise to more
decomposition by catalase. The produced dioxygen in turn can react with free radicals present
to propagate the radical chain process,
12 but this would result in A/K ratios of one as opposed to
the observed values of less than one.
5.5  Assays for screening peroxidase activity
Peroxidases catalyse the oxidation of a wide range
of substrates using hydrogen peroxide as the
terminal oxidant.
13 Their huge structures, however,
make it difficult to study or determine the factors
that govern their function and behaviour.
Therefore, microperoxidases (right) are commonly
used as models for these haemoproteins.
14,15,16
These small haem-peptide fragments can be
obtained by the proteolytic digestion of
cytochromes  c, and contain a small peptide
fragment that is covalently linked to the haem via
two cysteine residues.
Substrates that are used to investigate the peroxidase activity of newly developed
peroxidases or their mimics are usually probes that enable their conversion to be monitored by
UV-Vis spectroscopy.
17 A typical reaction to test for peroxidase activity involves the oxidation of
o-methoxyphenol (12) to compound 13,
18 which is sometimes referred to as tetraguaiacol
(Scheme 5.5A).
14b,19,20 When subjected to the oxidising conditions the substrate 2,2’-azinobis-(3-
ethyl-benzothiazoline-6-sulphonic acid) (ABTS, Scheme 5.5B) is converted into a radical cation
(vide infra).
15,21 Even though these probes can be readily applied as assays for peroxidase
activity, they do not enable the selectivity of the catalyst to be monitored. The probe
tetramethoxybenzene
22 (14) creates an opportunity to determine the product selectivity of the
16
(C)
(B)
(A)
ABTS+
+
O
O
OMe
MeO
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MeO
OMe OMe
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Scheme 5.5. Assays for screening peroxidase activity.131
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peroxidation reaction that is catalysed by the (artificial) enzyme or mimic (Scheme 5.5C).
23 A
drawback for this assay, however, is that it necessitates the need for a standardised HPLC
method to quantify the product distribution.
5.6  Oxidation of ABTS by non-haem catalysts
The peroxidase activity and the pH-dependency of N4PyFe (2a) and the peptide complex 2f
were determined by monitoring spectrophotometrically the formation of the emerald green
ABTS
+• radical cation over time at 660 nm (ε 1.47 x 10
4 M
–1cm
–1).
16b This probe had also been
used to establish the peroxidase activity of the dipeptide-bound N4PyFe catalyst presented in
Chapter 2.
24
N
S
N
N
S
N
HO3S
SO3H
Figure 5.11. The ABTS radical cation.
It has been established that the rate limiting step for microperoxidases and other peroxidase
enzymes is the formation of the reactive intermediate.
14a,15b,16,19d This process obeys pseudo-first-
order kinetics at low concentrations. Under the same conditions these kinetics could also apply
to the peroxidation of ABTS using the non-haem catalysts 2a or 2f. However, a full kinetic
study has not yet been undertaken to establish the kinetics for this reaction. The following
discussion is purely speculative with regards to the observed formation of ABTS
+• and the
factors that could influence the peroxidation reaction.
By employing an ABTS/H2O2/catalyst ratio of 500:1000:1 the concentration of the substrate
and the oxidant can be considered to have little or no effect on the rate of the reaction. The
reactions were initiated by the addition of hydrogen peroxide to a thermostatically controlled
and buffered (AcOH/NaOAc) solution of the substrate and the catalyst. The previously
established optimal pH range of 3.0 to 4.5 was employed to study the catalytic activity of 2a
during the peroxidation of ABTS.
24
The highest initial rate for the peroxidation by 2a was observed at pH 3.5 (Figure 5.12A).
The observed curvatures in the formation of ABTS
+• (Figure 5.12) were attributed to the
deactivation of the catalyst. Similar oxidative degradation of the catalyst is also common for
microperoxidases and haem oxygenases.
14a,15b,16,25 The catalyst is completely deactivated within
approximately 100–400 seconds, depending on the applied pH. The continued formation of
ABTS
+• originates from the non-catalysed peroxidation of ABTS by hydrogen peroxide. This is
the main disadvantage of using ABTS as a probe for peroxidation activity. As a result, the
experimental data for the peroxidation of ABTS catalysed by iron perchlorate, N4PyFe (2a),
and the peptide-bound complex 2f has to be corrected for this background reaction, which
accentuates the deactivation of the catalyst over time (Figure 5.12B).
When compared to N4PyFe, the N4PyFe-peptide complex 2f displayed a substantially
lower activity for the peroxidation of ABTS under identical conditions (Figure 5.12B). This result132
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Figure 5.12. Formation of the ABTS
+• radical cation over time at 20°C, expressed in
turnover numbers (TON). (A) pH-dependency of 2a; (B) background corrected
oxidation of ABTS by 2a, 2f, and iron(II) perchlorate at pH 3.5, and by 2a in the
presence of the radical scavenger 2,4,6-tri-tert-butylphenol (TBP); (C) effect of
TEMPO on the catalytic activity of 2a at pH 3.5 (–○– background reaction by H2O2;
–– H 2O2 and 2a; –– TEMPO; –– TEMPO and H2O2; –– H 2O2 and 2a in the
presence of 0.3 equiv TEMPO with respect to H2O2; –Δ– H2O2 and 2a in the presence
of 1 equiv TEMPO with respect to H2O2).
A
B
C
–– pH 3.0
–– pH 3.5
–– pH 4.0
–– pH 4.5
–– 2f
–– Fe(ClO4)2
–– 2a
–– 2a + 0.67 eq.
TBP
–Δ– 2a + 1.3 eq. 
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is attributed to the steric interactions between the peptide chains of the catalyst and the ABTS
substrate. However, these peptides appear to prolong the lifetime of the catalyst from
approximately 150 to almost 400 seconds. It was already established that a reduction in
temperature extends the lifetime of the Fe
IIIOOH intermediate 3f (vide supra). Therefore, by
lowering the temperature and changing the solvent to acetone for example, the oxidative
decomposition of the complex by the hydroxyl radicals might be reduced. The use of another,
smaller substrate molecule like 1,2,4,5-tetramethoxybenzene (14) might also improve the
catalytic turnover by reducing the steric interactions.
The turnover towards the end of the reaction period is also far too low to support the
reduced reaction rate of ABTS
+• formation due to a complete consumption of hydrogen
peroxide. This observation was further validated upon the addition of more hydrogen peroxide,
which did not appear to affect the reaction. The addition of a new batch of catalyst 2a,
however, was able to induce a small and brief increase in the reaction rate. An initial increase in
the catalyst loading also led to an enhanced reaction rate.
It has been suggested that hydroxyl radicals are involved in the catalytic oxidation of
alkanes by N4PyFe (2a).
2b The oxidation of ABTS to ABTS
+• can also be accomplished
efficiently by hydroxyl radicals only.
26 Furthermore, these strongly oxidising species, as well as
hydrogen peroxide itself, could be the source of the catalyst’s degradation.
If the rate-determining step of the peroxidation by 2a involves the formation of the
Fe
IIIOOH intermediate, then the addition of a hydroxyl radical scavenger should not have any
effect on the initial reaction rate but only on the lifetime of the catalyst. However, the addition of
tri-tert-butylphenol, an efficient radical scavenger,
16b not only gave rise to an increased lifetime
of the catalyst, but also to a reduction in the reaction rate (Figure 5.12B). These observations
imply that the rate determining step does not in fact involve the formation of the transient
Fe
IIIOOH intermediate, but rather the reaction of the reactive species with the substrate ABTS.
Trapping these hydroxyl radicals and/or the proposed one-electron oxidation species
[(N4Py)Fe
IV(O)]
2+ (Scheme 5.3) with the scavenger will consequently result in the observed
drop in the reaction rate. In addition, these findings strongly support the suggestion that
hydroxyl radicals are involved in the catalytic cycle of 2a.
2b,11b
A drop in the rate of ABTS
+• formation was also observed when the free radical 2,2,6,6-
tetramethylpiperidin-1-oxyl (17, TEMPO) was used for the reaction catalysed by 2a (Figure
5.12C). The addition of 2,2,6,6-tetramethylpiperidine (TEMP) had a similar, but less
pronounced, negative effect on the reaction rate (not shown). However, the use of either of
these reagents did not lead to an extended lifetime for the catalyst. The effect of TEMPO and
TEMP was dependent upon the amount that was added to the reaction mixture. Although
ABTS has also been applied as a scavenger of free radicals like hydroxyl and bromine radicals,
as well as ferryl porphyrins,
27 TEMPO itself was not able to oxidise efficiently ABTS to the
ABTS
+• radical cation (Figure 5.12C). In fact, the reaction of TEMPO with ABTS was
substantially slower than that observed for hydrogen peroxide, even in the presence of 2a (not
shown). The combination of hydrogen peroxide and TEMPO resulted only in a minor increase
in the rate of the background reaction (Figure 5.12C).
From these observations it can be concluded that TEMPO reacts with the Fe
IIIOOH
intermediate and interferes with the homolytic O–O bond dissociation. Consequently, the
formation of the hydroxyl radicals and the one-electron [(N4Py)Fe
IV(O)]
2+ species is hampered134
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(Scheme 5.3). The mechanism involved could be related to the suggested mechanism for the
oxidation of alcohols using TEMPO.
28 The oxoammonium salt 18, formed by a
disproportionation of TEMPO (17), can react with the Fe
IIIOOH species 3a, as shown in Scheme
5.6. The equilibrium between 18 and 20 subsequently can result in the slow release of 3a, and
therefore in a slower formation of the hydroxyl radicals and [(N4Py)Fe
IV(O)]
2+, which leads to
the reduced rate of the ABTS peroxidation and the catalyst degradation. Although highly
speculative, this conjecture can account for the observations shown in Figure 5.12.
3a
+ 2
(N4Py)FeIIIOOH
N
HO O
O
FeIII(N4Py)
N
O
17
N
O
18
N
OH
19
20
+ H
- H
Scheme 5.6. Proposed mechanism for trapping the Fe
IIIOOH intermediate by TEMPO.
UV-Vis experiments in acetone at room temperature independently established that the addition
of TEMPO and TEMP to the purple Fe
IIIOOH intermediate resulted in the immediate
disappearance of its absorption band. If TEMPO was added before the addition of hydrogen
peroxide, the formation of Fe
IIIOOH was substantially slower and incomplete. The interaction
between TEMP and Fe
IIIOOH might be due to a simple acid/base reaction. Under these
conditions the anticipated blue [(N4Py)Fe
III–η
2–(OO)]
+ species 4 was indeed detected by
means of a very low and broad absorption band (λmax 705 nm). The low stability was attributed
to the employed solvent and temperature.
5.7  Discussion and conclusions
The introduction of four substituents at the 5-position of the pyridine rings in the N4Py ligand
was found to influence the characteristic absorption maxima and the extinction coefficients of
the corresponding iron(II) complexes only to minor extent. These results, therefore, infer that the
proposed mechanism for the Fe
IIIOOH formation from N4PyFe (2a) also applies to a broader
range of N4Py derivatives. However, the exact nature of the substituent determines the stability
and reactivity of the Fe
IIIOOH intermediate, either by altering the redox potential of the iron
complex, as in the case of 2b, or by (presumably) the intramolecular oxidative degradation of
the catalyst, as observed for 2d.135
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The tetrasubstituted N4PyFe derivatives 2b and 2c proved to be active catalysts for the
oxidation of cyclohexene and cyclohexane. Although reduced, the longer lasting reactivity of 2c
indicates that by tuning the substituents on the N4Py ligand the lifetime of the catalyst can also
be prolonged.
The peroxidase activity of N4PyFe (2a) was found to be strongly pH-dependent, which
might be due to a pH-controlled destruction of the catalyst, as a higher activity leads to a more
rapid degradation of the catalyst. The synthesised N4PyFe-peptide complex 2f also displayed
peroxidase activity as demonstrated by the oxidation of chromogen ABTS. Although the
observed activity is substantially lower than that of 2a, a significantly higher activity compared
to the background reaction by hydrogen peroxide was observed. Furthermore, the lifetime of
catalyst  2f was longer than that of 2a. Mass spectrometry analysis during the oxidation of
1,2,4,5-tetramethoxybenzene by the tetracysteine derived N4PyFe complex 2e indicated that
oxygen atoms were introduced into the ligand system. Under the applied conditions oxidation
of the substrate could not be detected. Nevertheless, before 2e can be ruled out as an active
oxidation catalyst, it is suggested that optimised reaction conditions are first established.
5.8  Experimentals
General information
For general information about chemicals and instrumentation, see Chapter 3. N4PyFe (2a) was
prepared as described previously.
2a,3,11a For the preparation and analysis of ligand 2b, see
Chapter 4. For the preparation and analysis of ligands 1c–f and iron(II) complexes 2e and 2f,
see Chapter 3. GC analyses were performed on an Agilent 6890 Series GC System, equipped
with a HP-1 methyl siloxane capillary column (30.0 m x 250 µm x 0.25 µm). The injection port
and FID detector were set at 300°C. The temperature profile for the cyclohexene oxidation
started at 50°C for 3 min, then was raised to 70°C at 3°C/min and maintained at that
temperature for 8 min, followed by a temperature increase of 10°C/min to 100°C, and then to
250°C at 30°C/min. For the cyclohexane oxidation the initial temperature was set to 40°C for
15 min, followed by 10°C/min to 180°C and maintained at that temperature for 3 min.
Calibration curves for the oxidation products shown in Scheme 5.4 have been determined using
bromobenzene as internal standard.
[(N4Py4Br)Fe(MeCN)](ClO4)2 (2b)
To a suspension of N4Py4Br (93 mg, 0.14 mmol) in methanol (3 mL) was added
Fe(ClO4)2⋅6H 2O (56 mg, 0.15 mmol, 1.1 equiv) in acetonitrile (1.5 mL). The resulting clear dark
red/brown solution was stirred at room temperature for 15 min. Slow diffusion of ethyl acetate
into this solution furnished 2b as red crystals (115 mg, 87%).
1H NMR (CD3CN, 300 MHz) δ 4.31 (dd, JAB = 51.8, 18.5 Hz, 4H), 6.32 (s, 1H), 7.00 (d, J =
8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.88 (dd, J = 8.4, 1.8 Hz, 2H), 8.10 (dd, J = 8.4, 1.8
Hz, 2H), 9.01 (d, J = 1.8 Hz, 2H), 9.10 (d, J = 1.8 Hz, 2H). ESI-MS [M–(ClO4)
––(MeCN)]
+
calcd for C23H17Br4ClFeN5O4  m/z 833.7, found 833.6. [M–2(ClO4)
––(MeCN)]
2+ calcd for
C23H17Br4FeN5 m/z 367.4, found 367.8. Anal. calcd for C25H20Br4Cl2FeN6O8 C 30.68; H 2.07; N
8.59. Found: C 30.48; H 2.27; N 8.36.136
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[(N4Py(CH2OMe)4)Fe(MeCN)](ClO4)2 (2c)
To a solution of 1c (32 mg, 0.059 mmol) in acetonitrile (1.5 mL) was added Fe(ClO4)2⋅H2O (17
mg, 0.066 mmol, 1.1 equiv). The deep red solution was placed in a sealed container and ethyl
acetate was allowed to diffuse slowly into the solution. A dark red oil was formed after a week.
The solution was removed and the oil dissolved in acetonitrile. A fine red powder was formed,
which was isolated and redissolved in acetonitrile. Slow diffusion of ethyl acetate provided 2c as
red crystals after two weeks (9 mg, 18%).
1H NMR (CDCl3, 300 MHz) δ 3.29 (s, 6H), 3.34 (s, 6H), 4.32 (dd, JAB = 27.9, 8.1 Hz, 4H), 4.38
(s, 4H), 4.47 (s, 4H), 6.31 (s, 1H), 7.04 (d, J = 8.1 Hz, 2H), 7.63 (d, J = 7.7 Hz, 2H), 7.85 (m,
4H), 8.82 (s, 2H), 8.92 (s, 2H). ESI-MS [M–(ClO4)
––(MeCN)]
+ calcd for C31H38ClFeN5O8 m/z
698.2, found 698.0. [M – 2(ClO4)
–]
2+ calcd for C33H40FeN6O4  m/z 320.1, found 320.3.
[M–2(ClO4)
––(MeCN)]
2+ calcd for C31H37FeN5O4 m/z 299.6, found 300.0.
[(N4Py(CH2CH2CH2OMe)4)Fe(MeCN)](ClO4)2 (2d)
To a solution of 1d (35 mg, 0.054 mmol) in acetonitrile (1.5 mL) was added Fe(ClO4)2⋅6H 2O
(22 mg, 0.060 mmol, 1.1 equiv). The deep red solution was placed in a sealed container and
ethyl acetate was allowed to slowly diffuse into the solution. A dark red oil was formed after a
week. Repeated attempts failed to yield crystals and 2d was obtained as a dark red/brown oil
(41 mg, 84%).
1H NMR (CDCl3, 300 MHz) δ 1.85 (m, 8H), 2.80 (m, 8H), 3.25 (s, 6H), 3.32–3.48 (m, 8H),
3.39 (s, 6H), 4.36 (dd, JAB = 31.7, 18.1 Hz, 4H), 6.32 (s, 1H), 7.07 (d, J = 8.1 Hz, 2H), 7.61
(d, J = 7.7 Hz, 2H), 7.86 (s, 4H), 8.83 (s, 2H), 8.94 (s, 2H). ESI-MS [M – (ClO4)
– – (MeCN)]
+
calcd for C39H53ClFeN5O8 m/z 810.3, found 810.3. [M–2(ClO4)
–]
2+ calcd for C41H56FeN6O4 m/z
376.2, found 376.4. [M–2(ClO4)
––(MeCN)]
2+ calcd for C39H53FeN5O4 m/z 355.7, found 355.9.
Cyclic voltammetry of 2b
The cyclic voltammetry measurements were performed by dr. Scott Killeen at Unilever
Research, Vlaardingen, The Netherlands, on a three-electrode electrochemical cell interfaced to
a Princeton Applied Research potentiostat (Model 273A). The electrodes used (Working: 5 mm
diameter glassy carbon, Counter: Pt wire, Reference: Ag/AgCl (3 M KCl)) were freshly cleaned
by standard techniques prior to each measurement. The supporting electrolyte was 0.1 M
tetrabutylammonium perchlorate (puriss, Fluka) in acetonitrile (analytical grade, Mallinckrodt
Baker BV). The sample for analysis was prepared by dissolving 2b (3 mg) in the electrolyte (10
mL). All measurements were carried out at 22ºC and degassed with argon prior to
measurement. For CV experiments the scan rate was 100 mVs
–1 with an increment of 5 mV.
The differential pulse voltammetry experiments were conducted at a scan rate of 10mVs
–1 with
an increment of 2 mV.
X-ray crystallography
29
The selected crystal was mounted on a glass fibre and aligned on a Bruker
30 SMART APEX
CCD diffractometer (Platform with full three-circle goniometer) equipped with a 4K CCD
detector and a Bruker  KRYOFLEX low-temperature device. Intensity measurements were
performed using graphite monochromatic Mo–Kα  radiation from a sealed ceramic diffraction137
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tube (50 kV/40 mA). All calculations for refinement and graphics were performed on a Pentium
III (Debian-Linux) computer at the University of Groningen with the program packages
SHELXL
31 (least-square refinements), a locally modified version of the program PLUTO
32
(preparation of illustrations) and the PLATON
33 package (checking the final results for missed
symmetry with the MISSYM option, solvent accessible voids with the SOLV option, and
calculation of geometric data).
Structure analysis of 2b. Crystallisation from acetonitrile/ethyl acetate initially afforded 2b as
red square platelets, with a monoclinic unit cell with a P21/n space group, as well as a
disordered and fractional occupation with the solvent molecules. Recrystallisation furnished red
octahedral-shaped crystals. Dimensions of the crystal used for analysis: 0.40 x 0.32 x 0.22 mm.
The final unit cell was elucidated from the xyz centroids of 7444 reflections after refinement
and integration using the programs SMART and SAINT. In total 1800 frames were collected
with an exposure time of 10 s per frame. Intensity data was corrected for Lorentz and
polarisation effects, as well as for decay and absorption: a semi-empirical absorption correction
was applied, based on the intensities of symmetry-related reflections measured at different
angular settings (SADABS),
34 and reduced to Fo
2. The program suite SHELXTL was used for
space group determination (XPREP).
31 The structure was solved by automated Patterson
methods using the program DIRDIF.
35 The positional and (an)isotropic displacement parameters
for the non-hydrogen atoms were refined on F
2 using full-matrix least-squares procedures.
The asymmetric unit cell contains eleven moieties: two iron complexes (cations) and four
perchlorate anions, one ethyl acetate and four acetonitrile solvent molecules with no atom
setting at a special position. The triclinic unit cell contains twenty-two discrete units separated by
normal van der Waals distances.
Crystal data. ([C25H20Br4FeN6]
2+)2.(ClO4
–)4.C4H8O2.(C2H3N)4; M = 2209.9 gmol
–1; triclinic; space
group P–1 with a = 16.8760(8), b = 16.9697(8), c = 17.1403(8) Å; α = 64.758(1)°, β =
63.885(1)°, γ = 77.286(1)°; V = 3983.5(3) Å
3; Z = 2; Dx = 1.842 gcm
–3; λ = 0.71073 Å; µ =
45.86 cm
–1; F(000) = 2176; T = 90 K; GooF = 1.030; wR(F
2) = 0.1105 for 20152 reflections
and 974 parameters; R(F) = 0.0423 for 15627 reflections obeying the Fo ≥ 4.0 σ(Fo) criterion of
observability.
Structure analysis of 2c. Red coloured triangular/block-shaped crystals were obtained after a
troublesome crystallisation from acetonitrile by slow diffusion of ethyl acetate. Most of the
crystals were joined together, which hampered the X-ray structure determination, however a
small suitable specimen was found. Dimensions of the crystal used for analysis: 0.10 x 0.10 x
0.10 mm.
The final unit cell was obtained from the xyz centroids of 6038 reflections after refinement
and integration using the programs SMART and SAINT. A total of 1800 frames were collected
with an exposure time of 30 s per frame. Intensity data was corrected for Lorentz and
polarisation effects, scale variation, and for decay and absorption. A multi-scan absorption
correction was applied, based on the intensities of symmetry-related reflections measured at
different angular settings (SADABS),
34 and reduced to Fo
2. The program suite SHELXTL was
used for space group determination (XPREP).
31 The E-statistics of the triclinic unit cell were
indicative of a centrosymmetric space group. The structure was solved by direct methods using138
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SIR-97.
36 The positional and anisotropic displacement parameters for the non-hydrogen atoms
were refined. Refinement was complicated by a disorder problem: from the solution it was clear
that one of the two perchlorate anions was highly disordered. The electron density of the atoms
appeared to be diffuse, indicating transformational disorder. A disorder model with bond
restraints and two different orientations were also introduced into the subsequent refinement.
The site-occupation factor of the major fraction of the disordered perchlorate anions was refined
to a value of 0.519(5).
The asymmetric unit consists of four moieties: a cationic iron complex, two perchlorate
anions, one of which is highly disordered, and one acetonitrile solvent molecule. Reduced cell
calculations did not indicate any higher metric lattice symmetry and examination of the final
atomic co-ordinates of the structure did not yield any additional metric symmetry elements.
Crystal data. [C33H40FeN6O4]
2+.(ClO4
–)2.C2H3N; Mr = 880.52 gmol
–1; triclinic; space group P–1
with a = 10.2381(6), b = 13.1842(7), c = 16.4591(9) Å; α = 67.046(1)°, β = 77.949(1)°, γ =
75.701(1)°; V = 1966.57(19) Å
3; Z = 2; Dx = 1.487 gcm
–3; λ = 0.71073 Å; µ = 5.90 cm
–1;
F(000) = 916; T = 100 K; GooF = 1.028; wR(F
2) = 0.1485 for 8855 reflections and 567
parameters, 8 restraints; R(F) = 0.0584 for 6275 reflections obeying the Fo ≥ 4.0 σ(Fo) criterion
of observability.
Catalytic oxidation of cyclohexene and cyclohexane
A 3.50 mM stock solution of the catalyst was prepared in acetonitrile. For the experiment a 1.0
mL aliquot was transferred into the reaction flask and the solvent evaporated in vacuo. A stock
solution of the substrate (43.75 mmol) and bromobenzene (4.37 mmol) as an internal standard
was prepared in the appropriate solvent (50.00 mL). A 4.0 mL aliquot of stock solution was
added to the catalyst under a nitrogen atmosphere. Samples were taken at designated intervals,
filtered over a small amount of silica gel, washed with diethyl ether/methanol (9:1, 1 mL), and
analysed by gas chromatography. Duplicate experiments were performed to calculate the
average number of turnovers (margin of error ∼1 turnover).
Procedure A: The oxidation was initiated by injection of H2O2 (35 µL, 10 M, 30% in water) to
the reaction mixture (catalyst/H2O2/substrate=1:100:1000) at 20°C. Samples (200 µL) were
taken at intervals of 5, 10, 20, 30, 45, and 60 min.
Procedure B: The H2O2 (0.75 mL, 10 M, 30% in water) was administered to the reaction
mixture (catalyst/H2O2/substrate=1:2000:1000) by a syringe pump over 1 h at 20°C. Samples
(200 µL) were taken at intervals of 30, 60, and 90 min.
ABTS oxidation
All ABTS oxidation experiments were performed in 0.1 M acetate buffers at pH 3.0, 3.5, 4.0,
and 4.5 using a magnetically stirred, thermostatically controlled quartz cuvette at 20°C. The
increase in absorption due to the ABTS
+• radical cation formation was monitored by a UV-Vis
spectrophotometer at 660 nm (ε 1.47 x 10
4 M
–1cm
–1)
15b at intervals of 1 s for 400 s with an
incremental cycle time of 10% after an initial time of 60 s. The experimental conditions were
identical to those described previously by Dr. C. T. Choma.
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6  Conclusions and future prospects
6.1  Introduction
Over the past decades numerous structure-stability and structure-function studies have been
performed on native proteins and designed peptide structures. Today, this knowledge is applied
to the construction of proteins with enhanced or modified enzymatic activities,
1 as well as
relatively small peptide-based catalysts or architectures.
2 The examples illustrated and discussed
in Chapter 1 of de novo designed four-helix bundle motifs clearly demonstrate that considerable
progress has been made towards the design and synthesis of artificial proteins and enzyme
mimics in recent years.
3
Several of the reported four-helix bundles have successfully been provided with a catalytic
function, often via the introduction of a prosthetic group like a haem or porphyrin moiety,
2c or
by a specific spatial arrangement of certain α-amino acids.
4 Although the catalytic activity of the
designed structures is often inferior to that of the natural systems, the results appear to be quite
promising to anticipate native-like behaviour of these synthetic enzymes analogues in the near
future. Examples of artificial non-haem oxidising enzymes based on the four-helix bundle motif
have yet to be reported to the best of our knowledge.
6.2  From natural enzyme to enzyme mimic
The iron(II) complex of the pentadentate ligand N4Py,
5,6 which was developed within our
research group, was previously found to be an active catalyst for the oxidation of various
organic substrates.
7 Mechanistic studies have led to a proposed catalytic cycle for the oxidation
of alkanes by N4PyFe.
8 The characterised reaction intermediates have proved that this non-
haem oxidation catalyst can also function as an effective model for the natural glycopeptide iron
bleomycin.
The research presented in this thesis explored and developed synthetic procedures by which
four functionalities could be introduced into the N4Py scaffold and thereafter enabled the
coupling of four peptide chains. Previously in our group, Choma et al. successfully established142
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the preparation of a dipeptide-bound N4PyFe catalyst, which also displayed peroxidase
activity.
9 The peptides were coupled via a cysteine residue to two chloromethylene substituents
at the periphery of the N4Py ligand. This methodology, however, could not be applied to the
construction of the corresponding tetrapeptide derivative, as the required N4Py template 4 (R=Cl)
was found to be intrinsically unstable.
The four pyridine rings that are tethered to the central nitrogen atom in the N4Py ligand
were subsequently functionalised to facilitate the covalent attachment of four peptide chains via
a C3-spacer (Scheme 6.1). The resulting peptide-bound iron complexes were then obtained via
the nucleophilic substitution of a cysteine thiolate in the peptide sequence, and subsequent
inclusion of an iron(II) metal ion. Purification by reversed-phase HPLC furnished the target
structure as a single product, which was validated by MALDI spectrometry.
This methodology could eventually enable the introduction of the N4PyFe complex into a
four-helix bundle to examine the effect of the peptide environment on the catalytic activity of
the iron complex. Conversely, the N4PyFe complex could also provide these peptide bundles
with a catalytic function.
(Pep = Ac-CGGGGDYKDDDDK-NH2)  2b
NC H 3
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NN
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NN
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Scheme 6.1. The N4PyFe-peptide complexes 2a and 2b, prepared from the
tetrafunctionalised N4Py derivative 1.
10
The peroxidase activity of the peptide-bound N4PyFe catalyst 2a was examined for the
oxidation of the chromogen ABTS (Chapter 5). Although the catalytic activity observed was
substantially lower than that of N4PyFe, the lifetime of 2a appeared to be extended compared
to that of N4PyFe. These findings are still only considered to be a preliminary conclusion, as the
results were obtained using a single substrate and peptide complex combination. By examining
the stability of the related tetracysteine N4PyFe catalyst towards oxidation at room temperature,
a rapid decomposition of the catalyst was observed, presumably initiated by the oxidation of the
sulphide linker.
6.3  Alternatives for peptide coupling
Although peptides have been successfully coupled to the N4Py scaffold via a C3-spacer,
modelling studies using different peptide sequences have revealed that the resulting four-helix
bundle structure will be more compact employing a C1-spaced N4PyFe catalyst.
11 This
necessitates the development of an alternative means of attaching peptides to the C1-spaced143
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N4Py ligand 3, as the tetrachloro N4Py derivative 4 (R=Cl) was found to be far too unstable
for this application. Some of the model reactions carried out to elucidate the origin of this
instability could provide better solutions to overcome this problem.
The terminal hydroxyl functionalities in 3 can be deprotonated by sodium hydride in DMF
and in principle allowed to react with N-bromoacylated peptides (Table 6.1, entry 1).
Alternatively, the hydroxyl groups can be oxidised to aldehydes or carboxylic groups, and
subsequently coupled to peptides via the N-termini or lysine residues in the sequence to form
imine or amide bonds, respectively (Table 6.1, entries 4 and 5). However, attempts to form an
amide bond between an amine and a carboxy derivatised N4Py ligand have so far been
unsuccessful.
12 In Scheme 3.12 a procedure was described in which the benzylic hydroxyl group
3
N
HO
N
OH
N
N
HO
N
OH
4
N
R
N
R
N
N
R
N
R
Table 6.1. A number of methods for peptide coupling after transforming the hydroxyl
functionalities in 3.
Entry R Peptide terminus Linkage Ref.
1O H
peptide N
O
Br ether 13
2S H
peptide N
O
Br sulphide 14,15
3S H HS peptide disulphide 16
4C H O peptide H2N imine
a 17
5C O 2H peptide H2N amide 18
6N H 2 N
O
H
peptide
H
imine
a 19
7N H 2
O
HO
peptide amide 18
a)  Subsequent reduction of the imine provides a much more stable amine linkage.144
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of 3-(hydroxymethyl)pyridine was converted into a thiol under acidic conditions. As it was
previously established that the tetrachloromethylene N4Py derivative 4 (R=Cl) was only stable
as its hydrochloride salt, this procedure could facilitate the preparation of the corresponding
tetrasulphide N4Py derivative 4 (R=SH). This can subsequently be allowed to react with
N-bromoacylated peptides or a cysteine residue to form a thioether or a disulphide linkage,
respectively (Table 6.1, entries 2 and 3). The tetrafunctionalised N4Py derivative with amine
groups at the periphery (4, R=NH2) might be obtained from 3 via the introduction of an
appropriate linker that contains a (protected) amine functionality. However, as the
corresponding model reactions, described in Chapter 3, were unsuccessful, this does not prove
to be a viable option. As an alternative, the tetrabromide N4Py derivative 5 could enable these
compounds to be prepared via metal-catalysed cross coupling reactions (Scheme 4.2), as
presented in Chapter 4. These amine groups can subsequently be allowed to react with a
carboxyl group in the peptide chain to form an amide bond (Table 6.1, entry 7). Alternatively,
these amine functionalities can be used to couple peptides via an imine bond, which can then
be reduced to afford a more stable amine bond (Table 6.1, entry 6).
By employing selectively removable protecting groups for lysine and cysteine (Table 6.2),
the presence of more than one of these residues in a peptide chain can still enable a site-specific
introduction of an appropriately functionalised N4PyFe catalyst. However, the stability of the
peptide-bound N4Py ligand towards the applied deprotection conditions after coupling the
peptides has yet to be ascertained.
Table 6.2. Some examples of selectively removable protecting groups for lysine and cysteine.
Entry Residue Protecting group
5 Deprotection method Ref.
1L y s i n e A l l o c P d C l 2(PPh3)2/Bu3SnH/AcOH 14,20
2L y s i n e B o c T F A 2 1
3 Lysine Z TMSOTf/TFA 21
4L y s i n e D d e H 2NNH2 20,22
5 Cysteine Trt TFA/DTT 14,22
6 Cysteine Acm Hg(OAc)2, pH 4 14,22
7 Cysteine tert-butyl DTT 22
8 Cysteine Acm AgOTf/TFA 23
6.4  Tetrabromo N4Py as a versatile building block
The developed convergent synthetic route to the N4PyFe-peptide catalysts involves numerous
reaction steps. The encountered dead-end after the lengthy synthetic pathway to the C1-spaced
N4Py derivative 4 (R=Cl) was quite unfortunate. In the development of a total synthesis to
complex natural compounds these unwanted terminations are often also encountered.
24 These
natural compounds are generally far more complex, which might “justify” these dead-ends,
although this does not imply that these can be identified earlier for more concise synthetic
routes.145
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By modification of the synthetic route the corresponding C3-spaced derivative could be
obtained. In order to avoid an iterative ligand construction of N4Py derivatives from their initial
building blocks, N4Py4Br (5) was developed. This ligand can in principle enable a divergent
synthesis of various N4Py ligand structures using cross coupling methodologies (Scheme 4.2).
After the construction of the N4Py scaffold this ligand was functionalised by subsequent
reactions at the bromide sites in the molecule, and thereby functioned as a building block. This
procedure has already been successfully applied to the preparation of tetraphenyl N4Py (6a,
R’=H) via the Suzuki reaction of 5 with phenylboronic acid. The examined test reactions on
bromopyridines have indicated that other types of cross coupling reactions and reagents could
also prove to be potential candidates for synthesising a wide range of N4Py derivatives.
n
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Scheme 6.2. A selection of potential N4Py ligands that can be envisaged from
N4Py4Br (5) by, for instance, cross coupling (6a–d) or lithiation reactions (6e–f).
The iron complexes of the N4Py derivatives obtained from 5 could have interesting catalytic
properties in oxidation reactions and also could enable the redox potential of the iron centre to
be tuned to our advantage.
25 Furthermore, the introduction of appropriate tethers at the
periphery of the N4Py ligand might also improve the stability of the catalyst. In Chapter 5 it was
already demonstrated that the oxidation behaviour of tetrafunctionalised N4PyFe complexes is
substantially different from the iron(II) complex of N4Py. In addition to this, the redox potential
of [(N4Py4Br)Fe(MeCN)](ClO4)2 was found to be almost 200 mV higher than that of N4PyFe
(1196 mV vs. 1010 mV).
6.5  Conclusions
The challenge presented in the original research proposal, which outlined the construction of an
artificial peroxidase, has so far not entirely been met. The work described in this thesis presents
an overview of the synthetic difficulties encountered during the preparation of a N4Py ligand
with four covalently bound peptide chains. Unfortunately, due to the considerable amount of
time that was invested in the development of a synthetic pathway to peptide-bound N4PyFe146
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catalysts and the accompanied complications during the HPLC purifications, the introduction of
the N4PyFe catalyst inside a four-helix bundle has as yet not been accomplished. A peptide
coupling with a sequence that was designed to fold into a four-helix bundle, although
attempted,
26 proved to be unsuccessful.
In order to obtain an artificial enzyme, four peptide sequences will need to be attached to
the ligand that will not only fold into a four-helix bundle, but eventually also discriminate
between different substrate molecules (specificity) and/or possible reaction products (selectivity).
This necessitates a design that will implement a certain synergy between the chemistry of the
N4PyFe catalyst and the ability of the peptides surrounding it to provide a selective binding site
that may discriminate between different substrates.
Further optimisation of the reaction conditions using model peptide-bound N4PyFe
catalysts, for instance by substrate screening and investigating the pH- and temperature-
dependence, could provide a better insight into the feasibility of employing the N4PyFe catalyst
as a catalytic centre within a designed four-helix bundle. The peptide sequences introduced into
the peptide-bound N4PyFe catalyst 2a so far were not designed to fold into a four-helix bundle,
and thus lacked a well-defined structure that could affect or control the oxidation process.
Depending on which sequences are selected for the peptide coupling, the catalyst can be
positioned either in the core of the bundle or as a tethering moiety. If the catalyst is to be
located in the core, a cavity will have to be created to host the N4PyFe complex without
disrupting the stability of the four-helix bundle. Such a cavity will not have to be incorporated
into the design if the peptides are linked to the catalyst via their termini. However, such a design
will not enable an optimal interaction of these peptides with the catalyst to modulate its activity.
The oxidation experiments in Chapter 5 have revealed that the sulphide linkage in the
N4PyFe-peptide catalyst is prone to oxidation under the applied conditions. The bare N4PyFe
catalyst, however, is also deactivated by oxidative degradation. If the results from the oxidation
experiments of the examined tetracysteine N4PyFe derivative are ignored, then the N4Py ligand
can be considered to be no more than a potential template for the construction of four-helix
bundles with a non-haem iron-catalyst in the hydrophobic core. However, for the peptide
complex to function properly as an artificial peroxidase a more stable linker, for instance an
ether or amide bond, will be required. Preliminary results have already indicated that a
disulphide linkage between a pyridine thiol and a cysteine residue in a peptide sequence can be
readily obtained.
11 Furthermore, this disulphide linkage was found to be stable towards
oxidation in the presence of hydrogen peroxide and N4PyFe.
11
During the catalytic cycle of N4PyFe hydroxyl radicals are formed. The stability of the
peptide chains towards these hydroxyl radicals could be quite low, although peptides have been
reported to increase the stability of microperoxidases towards oxidative degradation.
27 However,
it is important to remember that the catalytic cycle of N4PyFe
IIIOOH most likely also involves a
non-radical pathway via a more selective, iron centred oxidising intermediate, presumably
[(N4Py)Fe
IVO]
2+.
8d Therefore, suppressing the radical pathway will not only extend the lifetime
of the catalyst by reducing, or even preventing, its oxidative degradation, but possibly also
enhancing its selectivity during the oxidation reaction.
Although the only attempted Suzuki reaction on N4Py4Br (5) involved the synthesis of 6a
(R’ = H), the outcome of this reaction and that of the performed model reactions in Chapter 4
seem to be encouraging for other related substrates. The exploration of the potential cross147
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coupling reactions and conditions has opened up a promising new domain to more readily
accessible N4Py derivatives, whose preparation could unfortunately not be attempted due to a
lack of time.
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Appendix 1: Abbreviations
ABTS 2,2’-azinobis-(3-ethyl-benzothiazoline-6-sulphonic acid)
Acm acetamidomethyl
Alloc allyloxycarbonyl
9-BBN 9-borabicyclo[3.3.1]nonane
BLM bleomycin
Boc tert-butoxycarbonyl
dba dibenzylideneacetone
Dde 2-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl
DIEA N,N-diisopropylethylamine
DMF N,N-dimethylformamide
dppe 1,2-bis(diphenylphosphino)ethane
dppf 1,1’-bis(diphenylphosphino)ferrocene
DTT dithiothreitol
EPR electron paramagnetic resonance
ESI-MS electrospray ionisation mass spectrometry
Fmoc 9-fluorenylmethoxycarbonyl
HMPA hexamethylphosphoramide
mCPBA meta-chloroperoxybenzoic acid
N3Py N-[di(2-pyridinyl)methyl]-N-(2-pyridinylmethyl)amine
N4Py N-[di(2-pyridinyl)methyl]-N,N-bis(2-pyridinylmethyl)amine
N4PyFe [(N4Py)Fe(MeCN)](ClO4)2
NMR nuclear magnetic resonance
Pht phthalimide
Py5 2,6-bis{methoxy[di(2-pyridinyl)]methyl}pyridine
SCE saturated calomel electrode
TBDMS tert-butyldimethylsilyl
TEA triethylamine
TEMP 2,2,6,6-tetramethylpiperidine
TEMPO 2,2,6,6-tetramethylpiperidin-1-oxyl
Tf trifluoromethanesulphonyl or triflate
TFA trifluoroacetic acid
TFAA trifluoroacetic acid anhydride
THF tetrahydrofuran
TMEDA N,N,N’,N’-tetramethylethylenediamine
TMS trimethylsilyl
TON turnover number
TPA tris(2-pyridinylmethyl)amine
Trt triphenylmethyl or trityl
Ts  p-toluenesulphonyl (tosyl)
Z  benzyloxycarbonyl151
Appendix 2: α-amino acids; structures and abbreviations
Name, three and one letter abbreviations Side chain (R)
Alanine Ala A    
CH3
Arginine Arg R
H
NN H 2
NH
Asparagine Asn N
O
NH2
Aspartic acid Asp D
O
OH
Cysteine Cys C SH
Glutamic acid Glu E
OH
O
Glutamine Gln Q
NH2
O
Glycine Gly G     H
Histidine His H N
N H
Isoleucine Ile I
R
CO2H H2N
H152
Name, three and one letter abbreviations Side chain (R)
Leucine Leu L
Lysine Lys K
NH2
Methionine Met M
S
Phenylalanine Phe F
Proline Pro P N CO2H
H
H
Serine Ser S OH
Threonine Thr T
OH
Tryptophan Trp W
N
H
Tyrosine Tyr Y
OH
Valine Val V153
Samenvatting
Van natuurlijk enzym naar functionele modellen
Enzymen zijn zeer complexe en, op moleculaire schaal, meestal zeer grote structuren die
betrokken zijn bij veel chemische processen in levende organismen. De rol die zij kunnen
vervullen is niet alleen het bewerkstelligen van het transporteren of opslaan van stoffen in het
lichaam, maar ook die van biokatalysator in stofwisselingsreacties. Als katalysator maakt het
enzym het mogelijk om de activeringsenergie van een reactie te verlagen, waardoor
substraatmoleculen sneller omgezet kunnen worden tot specifieke producten bij lage
(lichaams)temperaturen. Deze enzymen, ook wel proteïnen of eiwitten genoemd, zijn natuurlijke
polymeren, die opgebouwd zijn uit een specifieke selectie aminozuren in een door de evolutie
bepaalde volgorde. Deze aminozuurvolgorde bepaalt vervolgens de manier waarop de
peptidenketen zich tot een karakteristieke driedimensionale structuur opvouwt en welke functie
de proteïne vervult. Die functie gaat verloren bij het verstoren of ontvouwen (denatureren) van
de compacte 3D structuur. Echter, de proteïnen zijn in staat om hun natuurlijke toestand weer
terug te vinden via een complex opvouwmechanisme, waarvan de ‘bouwtekening’ verborgen zit
in de specifieke selectie van de betrokken aminozuren. Andersom kan een analoge 3D structuur
van enzymen tot stand komen, terwijl de aminozuursamenstelling verschillend is.
De samenstelling en functie die enzymen nu hebben, is het gevolg van het evolutieproces
tijdens de afgelopen miljarden jaren. In een hoog tempo echter wordt er de laatste decennia
door vele onderzoekers gewerkt aan het ontrafelen van de exacte samenstelling van de vele
enzymen en hun werkingsmechanisme. Bovendien wordt veel tijd en moeite gestopt in het
vinden van de ‘gebruiksaanwijzing’ die kan vertellen welke selectie en volgorde van aminozuren
nodig is om een gewenste enzymstructuur te verkrijgen. Op dit deelgebied van het
biochemische onderzoek speelt zich onder andere het zogenaamde “de novo proteïne design”
af. De afgelopen twee decennia is er al veel kennis verzameld over de gecompliceerde
vouwprocessen die zich afspelen in het traject van peptidenketen tot driedimensionale structuur.
Men is er nu zelfs in geslaagd om kleine, compacte peptidenstructuren te maken die een
enzymfunctie kunnen nabootsen.
In hoofdstuk 1 is een overzicht gegeven van een groot aantal peptidenstructuren die
gebaseerd zijn op het zogenaamde vier-helix bundel motief. Dit is een compacte
organisatiestructuur, waarin vier α-helices geassocieerd kunnen zijn als vier individuele
peptidenketens met elk een α-helix vorm (Figuur 1), als een dimeer van twee aan elkaar
gekoppelde α-helices, of als een enkele keten met daarin vier α-helix domeinen, die zich kan
opvouwen tot een vier-helix bundel. Om de stabiliteit van deze structuren te vergroten, of om154
eventueel de helix bundel een functie te geven, worden deze peptidenketens ook wel aan een
‘template’ molecuul gebonden (Figuur 1).
Figuur 1. Een vier-helix bundel als tetrameer van vier individuele α-helices (links) of
verbonden aan een cyclische peptide als ‘template’ (rechts).
De drijvende kracht achter de associatie van de peptidenketens tot een vier-helix bundel is een
soort schizofrenie in de individuele α-helices; één zijde bestaat uit waterminnende (hydrofiel)
aminozuren, terwijl de andere zijde uit watermijdende (hydrofoob) aminozuren bestaat. In water
zullen daarom de helices zich groeperen, waarbij de hydrofobe zijden zich naar elkaar zullen
richten om het contact met de watermoleculen te minimaliseren.
Aan de hand van deze relatief eenvoudige peptidenstructuren hebben proteïne designers
enkele processen kunnen bestuderen die betrokken zijn bij het vormen van de 3D structuur van
een enzym, uitgaande van de primaire structuur van de eiwitketen. Hun toegeëigende kennis is
vervolgens vaak met succes toegepast in het ontwerpen van een grote verscheidenheid aan vier-
helix bundels, met of zonder katalytische functie. Echter, de activiteit van het kunstmatige
enzym is meestal onderschikt aan die van de natuurlijke proteïne. Door de reeds gemaakte
vorderingen in dit nog relatief prille onderzoeksgebied kunnen verbeteringen tot meer
natuurlijke enzymen in de nabije toekomst verwacht worden.
Een niet-eitwitcomponent (een co-factor of prosthetische groep, zoals een heem molecule)
is meestal vereist voor de werking van het enzym. Deze bevindt zich dan veelal in het actieve
centrum waar de katalyse zich afspeelt. Het streven van sommige onderzoeksgroepen is dan ook
om kleine moleculen of metaalcomplexen te ontwerpen die dezelfde hoge activiteit en
selectiviteit hebben als de natuurlijke macromoleculen, met zo mogelijk zelfs een andere
substraat voorkeur. In deze enzymmodellen is vaak, maar lang niet altijd, de ruimtelijke
ordening van functionele groepen rond het katalytisch centrum in het eiwit gekopieerd. Echter,
de efficiëntie van de natuurlijke biokatalysatoren blijkt zeer moeilijk bewerkstelligd te kunnen
worden.
Verder bieden deze enzymmodellen de mogelijkheid om nog onbekende reactie-
mechanismen van proteïnen te ontrafelen. Dat betekent overigens niet, dat een vereenvoudigd
enzymmodel vanzelfsprekend tot een gemakkelijke benadering leidt en een snelle ontrafeling
van het reactiemechanisme van een enzym geeft. Hiervoor moet ten eerste vastgesteld worden,
dat het model een goed werkend en correct model is voor het enzym in kwestie. Het chemische155
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gedrag en de analytische data moet daarvoor overeenkomen met dat van het enzym. Verder
moet het mechanisme van dit model natuurlijk nog opgehelderd worden, wil het inzicht kunnen
verschaffen in de werking van het natuurlijke proteïne.
Van functionerend model naar kunstmatig enzym
In de onderzoeksgroep van prof. dr. B. L. Feringa is een katalysator ontwikkeld op basis van
een niet-heem molecule, genaamd N4Py, waarvan het ijzercomplex N4PyFe als model fungeert
voor ijzer-bleomycine (Figuur 2). Dit natuurlijke glycopeptide wordt als antibioticum toegepast
in anti-tumor behandelingen. Het verbruikt hiervoor moleculair zuurstof om DNA te ‘knippen’
op specifieke posities in de DNA-keten. Daarnaast is deze geactiveerde vorm van bleomycine
ook in staat om verschillende organische verbindingen te oxideren. De werkelijke samenstelling
van geactiveerd bleomycine en het mechanisme van de oxidatieve werking zijn nog niet geheel
opgehelderd. Wanneer dit wel achterhaald zou kunnen worden, zou het bijvoorbeeld mogelijk
worden om varianten van bleomycine te maken, die effectiever werken of ook voor andere
medicinale toepassingen gebruikt zouden kunnen worden.
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Figuur 2. Het N4Py ligand, het overeenkomstige niet-heem ijzercomplex N4PyFe en
het reactieve intermediair N4PyFeOOH.
In het recente verleden zijn belangrijke vorderingen gemaakt in het ontrafelen van het
oxidatiemechanisme van N4PyFe, en mede daardoor dat van ijzer-bleomycine. In hoofdstuk 2
is een beknopt overzicht gegeven van het resultaten die behaald zijn in onze onderzoeksgroep
tijdens het promotieonderzoek van Gerard Roelfes. Net als ijzer-bleomycine bleek het reactieve
intermediair N4PyFeOOH, gevormd door de reactie van N4PyFe met waterstofperoxide, niet
alleen in staat te zijn om verscheidene organische verbindingen te kunnen oxideren, maar ook
DNA te kunnen ‘knippen’. Hoewel enkele belangrijke intermediairen in de katalytische cyclus
van N4PyFe geïdentificeerd en gekarakteriseerd zijn, blijven enkele vragen nog onbeantwoord.
Het doel van dit onderzoek was om het N4Py ligand dusdanig aan te passen, dat er vier
peptidenketens aan gekoppeld kunnen worden. Hierdoor zou het uiteindelijk mogelijk worden
om N4Py toe te passen als een functionele ‘template’ in de vorming van een vier-helix bundel
(Figuur 3). Een functie kan zo verkregen worden in de peptidenbundel, doordat het
overeenkomstige ijzercomplex in staat is substraatmoleculen te oxideren. Door het samenspel
van de katalytische werking van het N4PyFe-complex en zijn peptidenomgeving te
optimaliseren, wordt het wellicht mogelijk om een kunstmatige peroxidase te ontwerpen.156
Figuur 3. De kristalstructuur van N4PyFe supergepositioneerd over dat van een
dimere vier-helix bundel (links: bovenaanzicht, rechts: zijaanzicht).
In onze onderzoeksgroep zijn we er eerder in geslaagd om twee chloromethyleen groepen in het
N4Py ligand aan te brengen. Hierdoor konden twee peptiden via een cysteine aminozuur in de
sequentie aan het ligand gekoppeld worden door middel van een nucleofiele substitutie reactie.
Het overeenkomstige ijzer(II)complex vertoonde peroxidase activiteit, en gaf daarmee aan, dat
het mogelijk moet zijn om het N4PyFe-complex in een vier-helix bundel in te bouwen met
behoud van een oxidatieve werking. De kracht van het gebruik van cysteine om peptiden aan
het ligand te koppelen is, dat het thiolaat anion een goede nucleofiel is. Bovendien maakt deze
strategie het mogelijk om het N4PyFe-complex overal in de vier-helix bundel te plaatsen,
afhankelijk van de positie van de cysteine in de peptidensequentie.
In hoofdstuk 3 wordt een syntheseroute besproken, die het in principe mogelijk maakt om
een groot aantal N4Py derivaten met vier functionele groepen te synthetiseren (4). Hierbij
worden eerst de benodigde zijketens in 2,5-dibroompyridine (1) geïntroduceerd, waarna het
ligand zelf opgebouwd wordt (Schema 1). Door deze convergente syntheseroute zijn we er
uiteindelijk in geslaagd om vier peptidenketens via deze zijketens aan het N4Py ligand te
koppelen. Als eerste werden één-koolstof (C1) zijketens geïntroduceerd, zoals die in het eerder
gesynthetiseerde dipeptide-N4PyFe-complex waren gebruikt. Echter, het overeenkomstige
tetragesubstitueerde N4Py ligand bleek niet stabiel genoeg te zijn om verder te kunnen
functionaliseren. Na vele testreacties om de oorzaak van deze instabiliteit te achterhalen, is
besloten om een langere (C3) zijketen te gebruiken. Het hiermee verkregen N4Py derivaat bleek
gelukkig wel stabiel genoeg om vier peptidenketens aan te koppelen.
Het nadeel van deze convergente syntheseroute is, dat voor elke gewenste verandering in
de zijketens de gehele synthese opnieuw doorlopen moet worden. Dit omvat ongeveer dertien
reactiestappen, afhankelijk van de geïntroduceerde zijketens. Daar komt nog bij, dat succes met
de uiteindelijk verkregen verbinding niet gegarandeerd kan worden, wat kan leiden tot de
noodzaak van het synthetiseren van een andere derivaat. Het zou daarom gunstiger zijn om
eerst een N4Py ligand te maken, die het vervolgens mogelijk maakt om vrijwel elke gewenste
zijketen te kunnen introduceren, direct of na enkele functionaliseringsreacties. Deze divergente
synthese wordt besproken in hoofdstuk 4, waarbij het N4Py derivaat 3 (Schema 1)
gefunctionaliseerd kan worden door middel van metaal-gekatalyseerde cross koppelingreacties.
De uitgevoerde testreacties op broompyridine verbindingen waren vaak zeer succesvol en
vertegenwoordigen daarmee enkele veelbelovende functionaliseringsreacties om op 3 toe te157
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passen. Eén cross koppelingreactie, die al met succes is uitgevoerd, is de Suzuki reactie tussen 3
en fenylboorzuur, waardoor een tetrafenyl N4Py derivaat werd verkregen.
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Schema 1. Convergente versus divergente synthese van tetragesubstitueerde N4Py
liganden (FG = functionele groep).
De laatste decennia is ontzettend veel onderzoek verricht aan deze cross koppelingreacties,
waardoor het vaak mogelijk is geworden om vele lang bekende of moeilijke syntheses te
vervangen door een metaal-gekatalyseerde reactie onder redelijk milde omstandigheden. Door
het snel stijgende aantal publicaties in dit onderzoeksgebied met daarnaast een toenemend
aantal commercieel verkrijgbare reagentia voor deze cross koppelingreacties zou het mogelijk
kunnen worden om een groot aantal N4Py derivaten te verkrijgen. De overeenkomstige
ijzer(II)complexen zullen waarschijnlijk een verschillend gedrag gaan vertonen als katalysator in
oxidatiereacties, waardoor het misschien mogelijk wordt om de N4PyFe-katalysator af te stellen
op de gewenste eigenschappen.
Enkele tetragesubstitueerde N4Py liganden die in hoofdstuk 3 en 4 zijn besproken, zijn
onderzocht op hun katalytische activiteit in de oxidatie van cyclohexeen en cyclohexaan
(hoofdstuk 5). Hierbij werd duidelijk, dat er grote onderlinge verschillen ontstaan door de
aangebrachte zijketens, niet alleen in de verhouding van de uiteindelijk verkregen producten,
maar ook in het gedrag van de katalysatoren als die in de tijd gevolgd wordt. Verder worden in
dit hoofdstuk de spectroscopische data van deze ijzercomplexen besproken en vergeleken.
Bovendien worden de kristalstructuren van twee tetragesubstitueerde N4PyFe-complexen
gepresenteerd.
Eén van de gesynthetiseerde N4Py-peptide-ijzercomplexen is onderzocht naar de
katalytische activiteit die het vertoont in de peroxidatie van ABTS, een substraat waarvan de
omzetting spectrofotometrisch gevolgd kan worden. De besproken resultaten in hoofdstuk 5
geven aan, dat dit peptidencomplex wel degelijk peroxidase activiteit vertoont, echter met een
veel lagere katalytische ‘turnover’ dan N4PyFe zelf. Frappant genoeg lijkt het peptidencomplex158
wel een langere levensduur te hebben dan N4PyFe, die beide onder de oxidatieve
omstandigheden gedegradeerd worden. Massaspectrometrie-analyse tijdens oxidatie reacties
met een tetracysteine N4PyFe-derivaat hebben aangetoond, dat zeer waarschijnlijk de
sulfidebinding tussen het ligand en de peptidenketen geoxideerd wordt, wat dan vervolgens zal
leiden tot de waargenomen degradatie. Het is verder duidelijk geworden, dat de temperatuur en
de pH een duidelijk effect hebben op de activiteit en de levensduur van de N4PyFe-katalysator,
en daarmee ook op de overeenkomstige N4PyFe-peptide-complexen.
Tot slot kan gesteld worden, dat er nog veel onderzoek gedaan moet worden naar het
ontwerpen van een stabiele vier-helix bundel die het mogelijk moet maken om de N4PyFe-
katalysator te kunnen huisvesten. Wel heeft dit onderzoek geleid tot twee verschillende
syntheseroutes, die het mogelijk maken om de benodigde, en andere, N4Py derivaten te
bereiden. Hoewel enkele synthesestrategieën voor de peptidenkoppeling aan het N4Py ligand
zijn geprobeerd, met en zonder succes, zijn er nog vele andere mogelijkheden over die
onderzocht kunnen worden. Hiervoor is echter niet alleen behoorlijk wat materiaal nodig, maar
met de betrokken pyridinechemie vaak ook veel geduld en doorzettingsvermogen.